



BIDDING DOCUMENT
TO CONCLUDE THE FRAMEWORK CONTRACT
FOR SUPPLY OF MEDICINES / DRUGS
INCLUDING MEDICAL DEVICES
FOR ALL
PESSI HOSPITALS / DIRECTORATES
THROUGH PESSI PRE-QUALIFIED FIRMS
FOR THE YEAR 2023-24

**PUNJAB EMPLOYEES SOCIAL SECURITY INSTITUTION, (HEAD OFFICE),
3/A, GULBERG-V, LAHORE. Ph. No.042-99263122**



THE PUNJAB EMPLOYEES' SOCIAL SECURITY INSTITUTION
(HEAD OFFICE)
3/A, Gulberg-V, Lahore

Tender Enquiry # SSP(510)/2023/Vol-XIV

**FRAMEWORK CONTRACT FOR THE SUPPLY OF MEDICINES/DRUGS
 INCLUDING MEDICAL DEVICES FOR ALL PESSI HOSPITALS/DIRECTORATES
 FOR THE YEAR 2023-24**

The Punjab Employees Social Security Institution, Head Office Lahore invites sealed bids from PESSI Pre-qualified Pharmaceutical Manufacturers / Sole Agents of Foreign Principals to conclude the Framework Contract for supply of Medicines/Drugs including Medical Devices for all PESSI Hospitals/ Directorates for the year 2023-24 on FOR Basis at Central Medical Store Depot (CMSD) Lahore and consignee's end (*PESSI Hospitals and Directorates*).

Interested bidders may get the bidding document along with detailed specifications from the office of the undersigned from the date of publication of tender on submission of written request on original letter head along with payment of non-refundable tender fee of Rs. 2,000/- (*Rupees two thousand only*). The bidding document can also be downloaded from PPRA Website www.ppra.punjab.gov.pk & PESSI Website www.pessi.gop.pk.

Bidding shall be conducted through Single Stage – Two Envelopes Bidding Procedure, as per Rule 38(2)(a) of Punjab Procurement Rules, 2014. The envelopes shall be marked as "*FINANCIAL PROPOSAL*" and "*TECHNICAL PROPOSAL*" in bold and legible letters in separate envelopes.

The Technical Bids shall accompany 3% Bid Security of the estimated price in the form of Bank Guarantee / CDR. Interested bidders may submit their bids by 06.06.2023 till 11:00 A.M in the office of the undersigned which shall be opened on the same day i.e 06.06.2023 at 11:30 A.M in presence of the representatives of the participating firms.

Procurement shall be governed under Punjab Procurement Rules 2014 (amended). The tender can be cancelled at any stage as per Rule 35 of PPRA Rules 2014.

DIRECTOR (PURCHASE)
For COMMISSIONER PESSI
The Punjab Employees Social Security Institution Head Office
3-A Gulberg-V Lahore 042-99263122



THE PUNJAB EMPLOYEES' SOCIAL SECURITY INSTITUTION
(HEAD OFFICE)
3/A, Gulberg-V, Lahore

Tender Enquiry NO.SSP(510)/2023/Vol-XIV/

| | |
|------------------------------|------------------------------------|
| TENDER FEE: | Rs. 2000/- (Non-refundable) |
| LAST DATE OF RECEIPT: | 06.06.2023 (11.00 A.M.) |
| DATE OF OPENING: | 06.06.2023 (11.30 A.M.) |

SUBJECT: FRAMEWORK CONTRACT FOR THE SUPPLY OF MEDICINES/DRUGS INCLUDING MEDICAL DEVICES FOR ALL PESSI HOSPITALS/ DIRECTORATES FOR THE YEAR 2023-24 FROM PESSI PRE-QUALIFIED FIRMS

Technical specifications, Evaluation Criteria and Check List for the Framework Contract for the supply of medicines including medical devices for the year 2023-24 are enclosed herewith.

Detail of Instructions to the bidders, General Conditions of contract, special conditions of Contract & schedule of requirements are mentioned in the bidding document which is available at PPRA Web Site www.ppra.punjab.gov.pk and PESSI website www.pessi.gop.pk.

NO. SSP(510)/2023/Vol-XIV/

Dated Lahore, the _____.2023

M/s. _____

DIRECTOR (PURCHASE)

This is certified that the item quoted against PESSI No. _____ with brand name of _____ is readily available at following leading chain pharmacies having 5 branches in any one major city of Punjab:-

| Sr.# | NAME OF PHARMACY | VERIFIED BY THE AUTHORIZED OFFICER/OFFICIAL OF RESPECTIVE PHARMACY WITH NAME, DESIGNATION & STAMP. |
|------|------------------|----------------------------------------------------------------------------------------------------|
| 1. | | |
| 2. | | |
| 3. | | |
| 4. | | |
| 5. | | |

Summary of Invoices shall be provided which could be verified accordingly. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant document should not be part of bid.

I, Mr/Miss _____

Designation _____ on the behalf of my firm hereby undertake that if above said information is left unattended or proved to be wrong on checking, the department reserves the right to reject the offer which is not challengeable in any court of law.

Signature of Authorized Person. _____
 Name of Authorized Person: _____
 Designation of Authorized Person: _____
 Participating Firm Name: _____
 Phone No. _____
 Stamp: _____

PRICE SCHEDULE 2023-24

Must be attached (*duly signed and stamped*) with Financial Bid.

Tender No. _____ **Due on** _____

Manufactured by _____

Address. _____

Manufacturing license No. _____ **Validity** _____

| ITEM #. | PESSI # | NAME AS IN PESSI LIST | BRAND NAME OF THE OFFERED ITEM | QTY. REQUIRED | DRUG REGD . NO. | PACKING OFFERED | MRP FIXED BY DRAP | T.P. OF THE DRUG | PRICE OFFERED <i>(inclusive of all taxes)</i> | | Total Amount |
|---------|---------|-----------------------|--------------------------------|---------------|-----------------|-----------------|-------------------|------------------|--------------------------------------------------|----------|--------------|
| | | | | | | | | | In figures | In words | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

Note:

1. Quoted price should not exceed the Trade Price.
2. In the financial bids the arithmetical errors shall be rectified on the following basis.
 - a. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected.
 - b. If there is a discrepancy between words and figures, the amount in words shall prevail
3. Furthermore, the firm is liable to furnish an affidavit to the effect that the quoted prices are not more than the prices quoted in any Government Institution.

Signature of Authorized Person. _____

Name of Authorized Person: _____

Designation of Authorized Person: _____

Participating Firm Name: _____

Phone No. _____

Stamp: _____

Bid Reference No:

Check List (Mandatory) for Documentary Evidence

| S. # | Required Documentation |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Original Tender Purchase Receipt (F-6) |
| 2. | Original 3% Bid Security of the estimated prices is attached with the Technical Bid |
| 3. | Drug Specification proforma duly completed |
| 4. | Copy of valid Drug Registration Certificates issued by the DRAP |
| 5. | Summary of Invoices shall be provided which could be verified accordingly. Any false claim shall be considered as fraudulent practice. Unnecessary / irrelevant document should not be part of bid. |
| 6. | Valid Letter of Authorization from manufacturers / Sole Agency Agreement |
| 7. | FDA/WHO/EMA/MDD approved quality certificates and other certificates as required in Evaluation Criteria |
| 8. | Copy of valid GMP and other Certificate as required. In case of imported product, valid GMP certificate issued by the regulatory authority of manufacturer's country will be considered. |
| 9. | Copy of NTN Certificate |
| 10. | Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that None of the batch of quoted medicine has been declared Spurious / Adulterated by DTLs of the Punjab / NIH Islamabad or any competent Lab of Pakistan during last one years. |
| 11. | Proof of Active Tax Payer |
| 12. | Copy of General Sales Tax Registration |
| 13. | Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that i. Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP. Non-conviction from any court of law and black listing. |
| 14. | Thermo-log data and cold chain maintenance record must be provided by the bidders for Biological Products and Heat Sensitive Products |
| 15. | Affidavit on E-Stamp Paper worth Rs. 100/- to the effect that the prices quoted in PESSI are neither more than the Trade Price nor more than the prices quoted in any Government Institution / Semi Government / Autonomous Body. |
| 16. | Valid printed original price list of relevant tender period. |
| 17. | In case of poly pack of Small Volume Parenterals and Large Volume Parenterals the firm shall submit Undertaking on Rs,100 legally notarized E-stamp paper to the effect that latex and plastic used in manufacturing is of pharmaceutical grade and free from DEHP or other hazardous plasticizer and source is not re-used/ crushed material. |
| 18. | In case of Disposable, Auto-Disable syringes, I.V Cannula and IV set Undertaking on Rs, 100 legally notarized E-Stamp paper to the effect that they are manufactured from material of transparent medical grade. |
| 19. | Two Samples of each medicine in Commercial Packs Note: Specifications quoted in the Technical Offer will be verified from the samples provided with the bids alongwith two lists of submitted sample for verification / acknowledgement and no bid shall be acceptable without samples. |

**BIDS EVALUATION CRITERION FOR DRUGS / MEDICINES INCLUDING
MEDICAL DEVICES FOR MANUFACTURER**

Failure to comply with any compulsory parameter / knockout clauses will result in “non-responsiveness of the bidder for quoted item”. Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

- i. Original F-6 regarding payment of tender fees.
- ii. The bidder must possess valid Drug Manufacturing License issued by DRAP (Manufacturers).
- iii. Pre-qualification of the firm with PESSI regarding quoted section / dosage form.
- iv. The bidder will provide valid Drug Registration Certificate of the quoted product. The product having minimum two years’ experience will be eligible.
- v. Valid GMP Certificate issued by the DRAP.
- vi. Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfill the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.
- vii. Undertaking on E-stamp paper worth Rs. 100/- regarding “Non Declaration of Spurious/ Adulterated Batch” by any notified Drug Testing Laboratory of quoted item within last one year.
- viii. Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non-conviction from any court of law and black listing.
- ix. Two commercial packs as samples of quoted medicines for evaluation by the technical committee

MARKING CRITERIA

Technical Evaluation Criteria for Manufacturers

| Sr. # | Description | Category Points |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 1 | Source of API of Quoted Item | 15 |
| i) | Original Source /Research Molecule (Affidavit on firm's letter head) | 15 |
| ii) | Source Licensed by Original or accredited by FDA/WHO/EMA (Certificate) <i>(The bidder must provide Import record of one year (from Jul. 2021 to onwards) i.e. copy of GD/LC of quoted raw material source)</i> | 10 |
| iii) | Others Source of Raw Material with Certificate of Analysis (Jul. 2021 to onwards) | 08 |
| 2 | Bio Equivalence /Bio-similarity Study (if applicable) of Quoted Product in finished form (affidavit on Rs:100 e-stamp paper in case of research molecule) | 15 |
| i) | Original Manufacturer will be awarded full marks. | 15 |
| ii) | Bio equivalence/Bio-similarity Study from any of the below mentioned labs: <ul style="list-style-type: none"> • WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. <i>(The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).</i> | 10 |

| | | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3 | EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS | 20 |
| | Past performance of quoted product with major Government Sector/ Semi Government / Autonomous Body / PESSI during last two financial years | |
| i) | Supply of the quoted product Higher than the advertised quantity | 20 |
| ii) | Supply of the quoted product Equivalent to the advertised quantity | 15 |
| iii) | Supply of the quoted product at least 60% of advertised quantity | 10 |
| | The bidder shall provide verifiable documentary evidences like commercial sales summary / supply order of the quoted product. | |
| 4. | Availability of quoted product at major chain pharmacies (02 marks for each pharmacy) | 10 |
| i) | Supply of quoted product at 5 or more chain pharmacies | 10 |
| ii) | Supply of quoted product at upto 4 chain pharmacies | 08 |
| iii) | Supply of quoted product at upto 3 chain pharmacies | 06 |
| iv) | Supply of quoted product upto 02 chain pharmacies | 04 |
| | The bidder shall provide verifiable documentary evidence (invoices) regarding availability of quoted items. Pharmacy chain will be any company operating at least 5 pharmacies in any one major city of Punjab. | |
| | Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 10 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. | |
| 5. | Production Capacity of the quoted product during last one year | 10 |
| i) | 06 to 08 Batches of the quoted item | 10 |
| ii) | 02 to 05 Batches of the quoted item | 07 |
| | The bidder shall provide documentary proof regarding batch history of the quoted product | |
| 6. | Quality Product | 05 |
| i) | If samples of quoted product declared sub-standard by DTL are less than 1% during last Financial year | 05 |
| ii) | If samples of quoted product declared sub-standard by DTL are 1-2% during last Financial year | 03 |
| iii) | If samples of quoted declared sub-standard by DTL are 2-3% during last Financial year | 01 |
| | The bidder will provide undertaking on Rs. 100/- notarized e-stamp paper. Data of substandard batches may be verified from Drug Testing Laboratories. | |
| | Total | 75 |

NOTE: For product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 65%.

QUALIFYING MARKS: 49 OUT OF 75 (65%)

1. Financial bids of only "Technically Qualifying Bidders" will be opened.

BIDS EVALUATION CRITERION FOR SOLE AGENTS (DRUG / MEDICINES)

Failure to comply with any compulsory parameter / knockout clauses will result in “non-responsiveness of the bidder for quoted item”. Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

- i. Original F-6 regarding payment of tender fees.
- ii. The bidder must possess valid Drug sale License (in case of importers).
- iii. Pre-qualification of the firm as Sole Agents and respective Foreign Principal with PESSI.
- iv. The bidder will provide valid Drug Registration Certificate of the quoted product with DRAP. The product having minimum two years’ experience will be eligible.
- v. Valid GMP Certificate from country of manufacturer.
- vi. Valid letter of authorization from manufacturer / sole agency agreement.
- vii. Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfil the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.
- viii. Undertaking on E-stamp paper worth Rs. 100/- regarding “Non Declaration of Spurious/Adulterated Batch” by any notified Drug Testing Laboratory of quoted item within last one year.
- ix. Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non-conviction from any court of law and black listing.
- x. Two commercial packs as samples of quoted medicines for evaluation by the technical committee.

MARKING CRITERIA

TECHNICAL EVALUATION CRITERIA FOR SOLE AGENT

| Sr. # | Description | Category Points |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 1 | Source of API of Quoted Item | 10 |
| i) | Original Source /Research Molecule (Affidavit on firm's letter head) | 10 |
| ii) | Source Licensed by Original or accredited by FDA/WHO/EMA (Certificate) <i>(The bidder must provide Import record of one year (from July 2021 to onward) i.e. copy of GD/LC of quoted raw material source)</i> | 08 |
| iii) | Others Source of Raw Material with Certificate of Analysis(July 2021 to onwards) | 05 |
| 2 | Bio Equivalence / Bio-similarity Study (if applicable) of Quoted Product (affidavit on Rs:100 E-stamp paper in case of research molecule)* | 15 |
| i) | Original Manufacturer will be awarded full marks. | 15 |
| ii) | Bio equivalence/Bio-similarity Study from any of the below mentioned labs: <ul style="list-style-type: none"> • WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. <i>(The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).</i> | 10 |
| 3 | EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS | 20 |

| | | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | Past performance of quoted product with major Government Sector/ Semi Government / Autonomous Body / PESSI during last two financial years | |
| i) | Supply of the quoted product Higher than the advertised quantity | 20 |
| ii) | Supply of the quoted product Equivalent to the advertised quantity | 15 |
| iii) | Supply of the quoted product at least 60% of advertised quantity | 10 |
| | The bidder shall provide verifiable documentary evidences like commercial sales summary / supply order of the quoted product. | |
| 4. | Availability of quoted product at major chain pharmacies (02 marks for each pharmacy) | 10 |
| i) | Supply of quoted product at 5 or more chain pharmacies | 10 |
| ii) | Supply of quoted product at upto 4 chain pharmacies | 08 |
| iii) | Supply of quoted product at upto 3 chain pharmacies | 06 |
| iv) | Supply of quoted product upto 02 chain pharmacies | 04 |
| | The bidder shall provide verifiable documentary evidence (invoices) regarding availability of quoted items. Pharmacy chain will be any company operating at least 5 pharmacies in any one major city of Punjab. | |
| | Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 10 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. | |
| 6. | Local Market Business | 10 |
| | How many years the quoted product is being marketed in Pakistan. | |
| i) | 2-3 years | 03 |
| ii) | 4-5 years | 05 |
| iii) | 6 years and above | 10 |
| 8. | Drug Testing | 05 |
| | Reports of WHO/FDA Accredited International Labs performed on the product | |
| i) | 1-2 Labs | 05 |
| ii) | Testing by national Labs | 03 |
| 9. | Quality Product | 05 |
| i) | If samples of quoted product declared sub-standard by DTL are less than 1% during last Financial year | 05 |
| ii) | If samples of quoted product declared sub-standard by DTL are 1-2% during last Financial year | 03 |
| iii) | If samples of quoted declared sub-standard by DTL are 2-3% during last Financial year | 01 |
| | The bidder will provide undertaking on Rs. 100/- notarized E-stamp paper. Data of substandard batches may be verified from Drug Testing Laboratories. | |
| | TOTAL MARKS | 75 |

NOTE: For product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 65%.

QUALIFYING MARKS: 49 OUT OF 75 (65%)

1. Financial bids of only “Technically Qualifying Bidders” will be opened.



THE PUNJAB EMPLOYEES' SOCIAL SECURITY INSTITUTION
(HEAD OFFICE)
3/A, Gulberg-V, Lahore

SPECIFICATIONS OF MEDICINES YEAR 2023-24

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|----|-------------|-------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| | | (A) ANTACIDS: | | | | |
| 1 | P-0001 | Susp. Alu Hydroxide 215mg, Mag. Hydroxide 80mg, Simethicone 25mg/5ml | 120ml | 45 | 228497 | 10282365 |
| | | Susp. Alu Hydroxide 200mg, Magnesium Oxide 100mg, Simethicone 20mg, dicyclomine HCL 2.5mg | 60ml | 110 | 3000 | 330000 |
| | | Drops Simethicone 40mg/ml | 30ml | 45 | 306 | 13770 |
| | | Susp. Simethicone 40mg/ml | 120ml | 73 | 0 | 0 |
| 2 | P-0002 | Susp.Sucralfate 1gm/5ml | 60ml | 78.2 | 2314 | 180954.8 |
| 3 | P-0003 | Cap.Omeprazole 20mg Pellets | 100 | 162 | 73450 | 11898900 |
| | | Cap.Omeprazole 40mg Pellets | 14 | 45.5 | 0 | 0 |
| 4 | P-0004 | Tab. Mag. Trisilicate 500mg + Dried Alu Hydroxide250mg. | 500 | 425 | 126 | 53550 |
| 5 | P-0005 | Infusion Omeprazole Sodium 42.6mg equivalent to Omeprazole 40mg (Lyophilized) | 1 | 36 | 153740 | 5534640 |
| 6 | P-0006 | Tab. Famotidine 20mg | 20 | 27 | 32500 | 877500 |
| | | Tab. Famotidine 40mg | 10 | 15.7 | 13260 | 208182 |
| 7 | P-0007 | Tab.Sodamint (Sodium Bicarbonate 300mg) | 1000 | 105 | 661 | 69405 |
| 8 | P-0008 | Tab. Sucralfate 250mg + Calcium Carbonate 100mg | 32 | 120 | 0 | 0 |
| 9 | P-0009 | Cap. / Tab. Pantoprazole 20mg | 14 | 56 | 15670 | 877520 |
| | | Cap. / Tab. Pantoprazole 40mg | 14 | 299 | 900 | 269100 |
| 10 | P-0010 | Inj. Pantoprazole 40mg | 1 | 100 | 880 | 88000 |
| 11 | P-0011 | Tab. Salazopyrin 500mg | 10 | 112 | 46 | 5152 |
| 12 | P-0012 | Tab/Cap. Esomperazole 20mg | 14 | 35.84 | 8200 | 293888 |
| | | Tab/Cap. Esomperazole 40mg | 14 | 48.86 | 1350 | 65961 |
| 13 | P-0013 | Inj. Cimetidine 200mg | 1 | 34 | 2000 | 68000 |
| | | (B) ANTISPASMODIC/ANTICHOLINER GIC: | | | 0 | 0 |
| 14 | P-0014 | Inj. Atropine Sulphate 1mg/ml (1ml Amp). | 100 | 239 | 41 | 9799 |
| 15 | P-0015 | Tab. / Cap. Mebevirine 135mg. | 30 | 94 | 11242 | 1056748 |
| 16 | P-0016 | Tab. Mesalazine 400mg. | 30 | 500 | 1000 | 500000 |
| 17 | P-0017 | Inj.Neostigmine 2.5mg/5ml | 10 | 330 | 14 | 4620 |
| 18 | P-0018 | Tab.Pyridostigmine Bromide 60mg | 20 | 51 | 6 | 306 |
| 19 | P-0019 | Tab. Chlordiazepoxide 5mg + Clidinium Bromide 2.5mg. | 50 | 157.11 | 200 | 31422 |
| 20 | P-0020 | Tab.Hydrated Phloroglucinol 80mg equivalent to anhydrous Phloroglucinol | 30 | 163 | 4600 | 749800 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|----|-------------|--------------------------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| | | 62.233mg, trimethylphloroglucinol 80mg | | | | |
| 21 | P-0021 | Tab.Hyoscine-N-butylbromide10mg,Paracetamol500mg. | 100 | 476.76 | 8848 | 4218372.48 |
| 22 | P-0022 | Inj.Hydrated Phloroglucinol 40mg,trimethylphloroglucinol 0.04mg | 6 | 149 | 10422 | 1552878 |
| 23 | P-0023 | Inj.Hyoscine-N-butyl bromide 20mg/1ml | 30 | 160 | 260 | 41600 |
| 24 | P-0024 | Inj.Glycopyrrolate 0.2mg/ml | 10 | 281 | 5 | 1405 |
| 25 | P-0025 | Syp.Hyoscine 5mg/5ml | 60ml | 129.85 | 970 | 125954.5 |
| | | (C) ANTI-DIARRHOEALS: | | | 0 | 0 |
| 26 | P-0026 | Tab. Attapulgit 500mg | 100 | 206 | 2501 | 515206 |
| 27 | P-0027 | Susp. Furazolidone 25mg / 5ml, Kaolin Pectin | 1 | 10 | 4100 | 41000 |
| 28 | P-0028 | O.R.S.(WHO formulation) sachet contains:NaCl 2.6gm, Sod.Citrate 2.9gm, KCL1.5gm, Dextrose Anhydrous 13.5gm. | 20 | 198.2 | 19275 | 3820305 |
| 29 | P-0029 | Diocahedral Smectite 3gm Powder. | 30 | 210 | 1902 | 399420 |
| 30 | P-0030 | Saccharomyces Boulardii 250mg Powder | 10 | 423.58 | 90 | 38122.2 |
| 31 | P-0031 | Susp. Activated Attapulgit 1000mg/10ml. | 1 | 30 | 200 | 6000 |
| 32 | P-0032 | Susp.Zinc Sulphate Monohydrate 10mg equivalent to 3.64mg Elemental Zinc | 60ml | 35.59 | 9950 | 354120.5 |
| 33 | P-0033 | Sachet Racecadotril 10mg | 16 | 480 | 10 | 4800 |
| | | Sachet Racecadotril 30mg | 10 | 450 | 0 | 0 |
| 34 | P-0034 | Suspension Bacillus Clausii | 10x5ml | 1750 | 10 | 17500 |
| | | (D) ANTI-AMOEBICS: | | | 0 | 0 |
| 35 | P-0035 | Tab.Metronidazole 200mg | 200 | 200 | 200 | 40000 |
| | | Tab.Metronidazole 400mg | 100 | 176.66 | 20690 | 3655095.4 |
| 36 | P-0036 | Inj. Metronidazole 500mg/100ml. | 1 | 31.38 | 143051 | 4488940.38 |
| 37 | P-0037 | Susp. Metronidazole 200mg/5ml. | 90ml | 57.26 | 61060 | 3496295.6 |
| 38 | P-0038 | Susp. Metronidazole 75mg+ Furazolidine 25mg. | 1 | 42 | 8000 | 336000 |
| 39 | P-0039 | Tab. Diloxanide Furoate 500mg + Metronidazole 400mg. | 15 | 96.62 | 1425 | 137683.5 |
| 40 | P-0040 | Syp. Diloxanide Furoate 250mg+Metronidazole Benzoate 320mg equivalent to metranidazole 200mg/10ml | 90ml | 66.16 | 10870 | 719159.2 |
| | | (E) ANTHELMENTICS. | | | 0 | 0 |
| 41 | P-0041 | Tab.Albendazole 200mg. | 2 | 24.35 | 15250 | 371337.5 |
| | | Tab.Albendazole 400mg. | 1 | 70 | 140 | 9800 |
| 42 | P-0042 | Tab.Mebendazole 100mg | 60 | 22 | 100 | 2200 |
| | | Tab.Mebendazole 500mg | 12 | 50 | 0 | 0 |
| 43 | P-0043 | Susp. Albendazole 100mg/5ml. | 1 | 20 | 17470 | 349400 |
| | | Susp. Albendazole 200mg/5ml. | 1 | 35 | 410 | 14350 |
| 44 | P-0044 | Susp. Mebendazole 100mg/5ml. | 30ml | 40 | 3050 | 122000 |
| | | (F) LAXATIVES/PURGATIVES/LUBRICANTS: | | | 0 | 0 |
| 45 | P-0045 | Tab. Bisacodyl 5mg. | 100 | 30 | 2827 | 84810 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|----|-------------|----------------------------------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 46 | P-0046 | Bisacodyl Suppository 0.01gm | 30 | 150 | 0 | 0 |
| | | Glycerine Suppository. | 25 | 150 | 172 | 25800 |
| 47 | P-0047 | Sodium Biphosphate 19.2gm, sodium phosphate 7.2gm, sodium contents in 120ml 4.5gm (Enema Liquid) | 1 | 36 | 5620 | 202320 |
| 48 | P-0048 | Sod. Picosulphate 7.5mg/ml Drops. | 15ml | 35 | 15740 | 550900 |
| 49 | P-0049 | Liq.Lactulose 3.35gm/5ml | 120ml | 135 | 40090 | 5412150 |
| 50 | P-0050 | Susp. Magnesium Hydroxide 70% V/V + Liq. Paraffin 25% V/V. | 120ml | 50.53 | 44800 | 2263744 |
| | | (G) DRUGS ACTING ON LIVER: | | | 0 | 0 |
| 51 | P-0051 | Infusion Ornithine Aspartate 5g/10ml. | 10ml | 284 | 1740 | 494160 |
| 52 | P-0052 | Syp. Ornithine Aspartate 60mg, Nicotinamide 4.8mg, Riboflavin-5mg, Phosphate Sod. 0.153mg/ml | 120ml | 250 | 7350 | 1837500 |
| 53 | P-0053 | Tab. Pancreatin 210 P.U. + Bromelain 35,000 PU, Dimethylpolysiloxan 50mg+ Sodium Dehydrocholate 20mg + Metoclopramide 6mg. | 30 | 100 | 0 | 0 |
| 54 | P-0054 | Tab. Silymarin 200mg | 20 | 110 | 1300 | 143000 |
| 55 | P-0055 | Syp. Silymarin 105mg/5ml | 120ml | 91.23 | 3150 | 287374.5 |
| 56 | P-0056 | Sachet Ornithine Aspartate 3gm | 5 | 495 | 0 | 0 |
| 57 | P-0057 | Tab. Sofosbuvir 400mg (alongwith Cap. / Tab. Ribavirin 400mg) | | | 0 | 0 |
| 58 | P-0058 | Tab. Daclatasvir 60mg | | | 0 | 0 |
| 59 | P-0059 | Inj. Pegylated Interferon alongwith Cap. / Tab. Ribavirin 400mg | Vial | 2599 | 0 | 0 |
| 60 | P-0060 | Tab. Velpatasvir 100mg + Sofosbuvir 400mg | | | 0 | 0 |
| 61 | P-0061 | Tab. Ledipasvir 90mg + Sofosbuvir 400mg | | | 0 | 0 |
| | | (H) ANTI-EMETIC/ANTI-NAUSEANTS: | | | 0 | 0 |
| 62 | P-0062 | Tab. Metoclopramide 10mg. | 100 | 89 | 5722 | 509258 |
| 63 | P-0063 | Inj. Metoclopramide 10mg/2ml | 10 | 79 | 6516 | 514764 |
| 64 | P-0064 | (a) Tab. Dimenhydrinate 50mg | 25 | 192 | 1142 | 219264 |
| | | (b) Tab.Cyclizine 50mg | 100 | 109.6 | 0 | 0 |
| 65 | P-0065 | (a) Inj.Dimenhydrinate50mg/ml | 25 | 170 | 4627 | 786590 |
| | | (b) Inj.Cyclizine 50mg/ml. | 20 | 100 | 2 | 200 |
| 66 | P-0066 | (a) Syp. Dimenhydrinate 12.5mg/4ml | 60ml | 34.54 | 17630 | 608940.2 |
| | | (b) Syp. Cyclizine 12.5mg/5ml | 1 | 15 | 0 | 0 |
| 67 | P-0067 | Tab. Prochlorperazine 5mg. | 100 | 30 | 16 | 480 |
| 68 | P-0068 | Tab. Meclizine 2 HCL 25mg + Vit B6 50mg. | 100 | 330 | 30 | 9900 |
| 69 | P-0069 | Tab. Levosulpride 25mg. | 30 | 86.7 | 820 | 71094 |
| 70 | P-0070 | Tab.Domperidone 10mg | 50 | 3650 | 40760 | 148774000 |
| 71 | P-0071 | Susp. Domperidone 5mg / 5ml | 120ml | 41 | 33560 | 1375960 |
| 72 | P-0072 | Tab. Doxylamine Succinate 10mg + Pyridoxine HCL 10mg | 30 | 190 | 1670 | 317300 |
| 73 | P-0073 | Inj.Promethazine 25mg/ml | 1 | 50 | 0 | 0 |
| 74 | P-0074 | Inj. Ondansetron 8mg/4ml | 5 | 67.5 | 3680 | 248400 |
| 75 | P-0075 | Tab. Ondansetron 8mg. | 10 | 250 | 1295 | 323750 |
| 76 | P-0076 | Syp. Promethazine HCL 25mg/5ml. | 1 | 30 | 10 | 300 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------|-----------|----------------|----------|------------------|
| | | (I) DRUGS ACTING ON CARDIOVASCULAR SYSTEM: | | | 0 | 0 |
| 77 | P-0077 | Tab. Captopril 25mg. | 30 | 68 | 10480 | 712640 |
| 78 | P-0078 | Tab. Atenolol 50mg. | 20 | 22.4 | 38490 | 862176 |
| 79 | P-0079 | Inj. Dobutamine 250mg/ml | 5 | 620 | 527 | 326740 |
| 80 | P-0080 | Tab. Isosorbide Dinitrate 10mg. | 100 | 40 | 0 | 0 |
| | | Tab. Isosorbide Mononitrate 20mg. | 20 | 44 | 1000 | 44000 |
| 81 | P-0081 | Tab. Digoxin 250mcg. | 25 | 65 | 1687 | 109655 |
| 82 | P-0082 | Inj. Digoxin 500mcg/2ml | 5 | 68 | 40 | 2720 |
| 83 | P-0083 | Tab. Diltiazem 30mg. | 30 | 68.7 | 0 | 0 |
| | | Tab. Diltiazem 60mg. | 20 | 78.8 | 10250 | 807700 |
| | | Tab./Cap. Diltiazem 90mg SR | 20 | 131 | 100 | 13100 |
| | | Tab./Cap. Diltiazem 180mg SR | 15 | 550 | 0 | 0 |
| 84 | P-0084 | Inj. Dopamine 40mg/ml,(Vial of 5ml). | 1 | 53.94 | 894 | 48222.36 |
| 85 | P-0085 | Tab. Methyldopa 250mg. | 100 | 853.79 | 1859 | 1587195.61 |
| 86 | P-0086 | Cap. / Tab.Nifedipine 10mg | 30 | 150 | 763 | 114450 |
| | | Tab.Nifedipine 20mg | 30 | 206 | 920 | 189520 |
| 87 | P-0087 | Tab. Propranolol 10mg. | 50 | 107 | 3750 | 401250 |
| | | Tab. Propranolol 40mg | 50 | 230 | 472 | 108560 |
| 88 | P-0088 | Tab. Nebivolol 2.5mg | 14 | 73.73 | 0 | 0 |
| | | Tab. Nebivolol 5mg | 14 | 49 | 7370 | 361130 |
| 89 | P-0089 | Tab. Verapamil 40mg. | 50 | 115 | 200 | 23000 |
| | | Tab. Verapamil 80mg. | 50 | 191 | 2150 | 410650 |
| | | Tab. Verapamil 240mg SR | 10 | 96 | 60 | 5760 |
| 90 | P-0090 | Tab. Amlodipine Besylate 5mg. | 20 | 23.24 | 19610 | 455736.4 |
| | | Tab. Amlodipine Besylate 10mg. | 20 | 27.6 | 99100 | 2735160 |
| 91 | P-0091 | Tab. Prazosin HCL 1mg. | 30 | 32.75 | 0 | 0 |
| 92 | P-0092 | Tab. Lisinopril 5mg. | 30 | 120 | 785 | 94200 |
| | | Tab. Lisinopril 10mg. | 30 | 90 | 20870 | 1878300 |
| 93 | P-0093 | Tab. Trimetazidin Dihydrochloride 35mg. | 20 | 85 | 15100 | 1283500 |
| 94 | P-0094 | Inj. Magnesium Sulphate 500mg/ml (10ml Amp). | 25 | 500 | 106 | 53000 |
| 95 | P-0095 | Tab. Amiodarone HCL 200mg. | 30 | 750 | 245 | 183750 |
| 96 | P-0096 | Inj. Amiodarone HCL 150mg/3ml. | 6 | 309.6 | 147 | 45511.2 |
| 97 | P-0097 | Tab.Metoprolol 25mg. | 30 | 55 | 1125 | 61875 |
| | | Tab.Metoprolol 50mg. | 30 | 57.67 | 1440 | 83044.8 |
| | | Tab.Metoprolol 100mg. | 30 | 115 | 5570 | 640550 |
| 98 | P-0098 | Tab. Aspirin 75mg (Enteric coated). | 30 | 40.05 | 98200 | 3932910 |
| | | Tab. Aspirin 300mg (Non-Enteric coated) (Water soluble) | 30 | 52 | 598 | 31096 |
| 99 | P-0099 | Tab. Losartan Potassium 50mg. | 20 | 45.6 | 139130 | 6344328 |
| | | Tab. Losartan Potassium 100mg. | 20 | 400 | 0 | 0 |
| 100 | P-0100 | Inj. Milrinone 1mg/ml (10ml) | 1 | 1693 | 50 | 84650 |
| 101 | P-0101 | Inj. Metoprolol Tartrate 5mg. | 5 | 220 | 42 | 9240 |
| 102 | P-0102 | Inj. Isosorbide Dinitrate 10mg/10ml. | 10 | 200 | 668 | 133600 |
| 103 | P-0103 | Tab. Indapamide Hemihydrate 1.5mg SR | 30 | 291.84 | 2702 | 788551.68 |
| 104 | P-0104 | Tab. Atorvastatin 20mg | 30 | 60.3 | 87550 | 5279265 |
| | | Tab. Atorvastatin 40mg | 10 | 100 | 0 | 0 |
| 105 | P-0105 | Tab. Perindopril 4mg | 10 | 233.7 | 1500 | 350550 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 106 | P-0106 | Tab. Carvedilol 3.125mg | 10 | 31 | 140 | 4340 |
| | | Tab. Carvedilol 6.25mg | 30 | 65.4 | 22620 | 1479348 |
| | | Tab. Carvedilol 25mg | 10 | 300 | 0 | 0 |
| 107 | P-0107 | Tab. Clopidogrel 75mg | 28 | 80.8 | 35790 | 2891832 |
| | | Tab. Clopidogrel 300mg | 14 | 75 | 109 | 8175 |
| 108 | P-0108 | Tab. Ramipril 2.5mg | 28 | 218.4 | 700 | 152880 |
| | | Tab. Ramipril 5mg | 28 | 249.2 | 900 | 224280 |
| 109 | P-0109 | Inj. Verapamil 2.5mg/ml | 5 | 121.75 | 19 | 2313.25 |
| 110 | P-0110 | Tab. Bisoprolol 2.5mg. | 14 | 31 | 900 | 27900 |
| | | Tab. Bisoprolol 5mg. | 20 | 45 | 42850 | 1928250 |
| | | Tab. Bisoprolol 10mg. | 20 | 99 | 0 | 0 |
| 111 | P-0111 | Tab. Glyceryl Trinitrate 0.5mg | 30 | 50 | 606 | 30300 |
| | | Tab. Glyceryl Trinitrate 2.6mg | 30 | 89 | 24070 | 2142230 |
| | | Tab. Glyceryl Trinitrate 6.4mg | 30 | 143 | 49098 | 7021014 |
| 112 | P-0112 | Tab. Clopidogrel 75mg+ Aspirin 75mg (Acetyl Salicylic acid) | 10 | 69 | 2010 | 138690 |
| | | Tab. Clopidogrel 75mg + Aspirin 150mg (Acetyl Salicylic acid) | 10 | 50 | 0 | 0 |
| 113 | P-0113 | Tab. Gemfibrozil 600mg. | 20 | 178 | 20 | 3560 |
| 114 | P-0114 | Tab. Hydrochlorothiazide 12.5mg + Irbesartan 300mg. | 10 | 440 | 0 | 0 |
| 115 | P-0115 | Tab. Nifedipine (extended release) 30mg. | 20 | 500.19 | 1726 | 863327.94 |
| | | Tab. Nifedipine (extended release) 60mg. | 20 | 600 | 240 | 144000 |
| 116 | P-0116 | Inj. Glyceryl Trinitrate 1mg/1ml | 1 | 50 | 0 | 0 |
| | | Glyceryl Trinitrate 10mg Transdermal Deponit Patch | 30 | 250 | 3 | 750 |
| | | Glyceryl Trinitrate Spray | 1 | 350 | 9 | 3150 |
| 117 | P-0117 | Inj. Calcium Chloride 10% (100mg/ml) Elemental Calcium 27.2mg/ml | 10 | 444 | 35 | 15540 |
| 118 | P-0118 | Cap. Fenofibrate 67mg | 30 | 445 | 16 | 7120 |
| 119 | P-0119 | Inj. Sod. Nitroprusside 25mg/ml | 5 | 826 | 0 | 0 |
| 120 | P-0120 | Inj. Isosorbide Mononitrate 2mg/5ml | 25 | 500 | 0 | 0 |
| 121 | P-0121 | Inj. Adenosine 3mg/ml | 10 | 500 | 3 | 1500 |
| 122 | P-0122 | Inj. Hydralazine 20mg/ml | 10 | 35 | 105 | 3675 |
| 123 | P-0123 | Tab. Hydralazine 25mg | 20 | 70 | 112 | 7840 |
| 124 | P-0124 | Tab. Amlodipine 5mg + Hydrochlorothiazide 12.5mg | 20 | 110 | 800 | 88000 |
| 125 | P-0125 | Tab. Amlodipine 5mg + Olmesartan 20mg | 20 | 131 | 704 | 92224 |
| | | Tab. Amlodipine 5mg + Olmesartan 40mg | 20 | 448 | 0 | 0 |
| 126 | P-0126 | Tab. Rosuvastatin 5mg | 10 | 46.2 | 500 | 23100 |
| | | Tab. Rosuvastatin 10mg | 10 | 32.7 | 3754 | 122755.8 |
| 127 | P-0127 | Inj. Morphine 10mg /ml | 5 | 500 | 6 | 3000 |
| 128 | P-0128 | Tab. Metolazone 2.5mg | 30 | 200 | 10 | 2000 |
| | | Tab. Metolazone 5mg | 30 | 300 | 50 | 15000 |
| 129 | P-0129 | Tab. Losartan Potassium 50mg + Hydrochlorothiazide 12.5mg | 10 | 40.08 | 13906 | 557352.48 |
| | | Tab. Losartan Potassium 100mg + Hydrochlorothiazide 25mg | 10 | 100 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|------------------------------------------------------------------|-----------|----------------|------|------------------|
| 130 | P-0130 | Tab. Lisinopril 10mg + Hydrochlorthiozide 12.5mg | 20 | 670 | 0 | 0 |
| | | Tab. Lisinopril 20mg + Hydrochlorthiozide 25mg | 14 | 700 | 0 | 0 |
| 131 | P-0131 | Tab. Nicorandil 10mg | 20 | 185 | 100 | 18500 |
| | | Tab. Nicorandil 20mg | 20 | 300 | 0 | 0 |
| 132 | P-0132 | Tab. Ranolazine XR 500mg | 14 | 143.5 | 1000 | 143500 |
| 133 | P-0133 | Tab. Cilostazol 50mg | 30 | 700 | 6 | 4200 |
| | | Tab. Cilostazol 100mg | 30 | 900 | 52 | 46800 |
| 134 | P-0134 | Tab. Bosentan Monohydrate 62.5mg | 14 | 749.7 | 990 | 742203 |
| 135 | P-0135 | Tab. Valsartan 80mg | 28 | 139.16 | 300 | 41748 |
| | | Tab. Valsartan 160mg | 14 | 150 | 40 | 6000 |
| 136 | P-0136 | Tab. Valsartan 80mg + Hydrochlorthiazide 12.5mg | 28 | 86.52 | 0 | 0 |
| | | Tab. Valsartan 160mg + Hydrochlorthiazide 25mg | 28 | 150 | 0 | 0 |
| 137 | P-0137 | Tab. Valsartan 160 + Amlodipine 5mg | 28 | 149 | 2210 | 329290 |
| | | Tab. Valsartan 160 + Amlodipine 10mg | 28 | 169 | 810 | 136890 |
| 138 | P-0138 | Tab. Ivabradine 5mg | 14 | 400 | 2500 | 1000000 |
| | | Tab. Ivabradine 7.5mg | 14 | 400 | 0 | 0 |
| 139 | P-0139 | Tab. Valsartan 160mg + Amlopidine 5mg + Hydrochlorthiazide 25mg | 28 | 265 | 940 | 249100 |
| | | Tab. Valsartan 160mg + Amlopidine 10mg + Hydrochlorthiazide 25mg | 28 | 300 | 210 | 63000 |
| | | Tab. Valsartan 320mg + Amlopidine 10mg + Hydrochlorthiazide 25mg | 14 | 500 | 0 | 0 |
| 140 | P-0140 | Tab. Lercanidipine HCL 10mg | 10 | 225 | 10 | 2250 |
| 141 | P-0141 | Sacubitril 48.6mg + Valsartan 51.4mg | 28 | 1000 | 480 | 480000 |
| | | Sacubitril 97.2mg + Valsartan 102.8mg | 14 | 998 | 0 | 0 |
| | | Sacubitril + Valsartan 50mg | 14 | 800 | 480 | 384000 |
| 142 | P-0142 | Tab. Eplerenone 25mg | 14 | 500 | 4 | 2000 |
| | | Tab. Eplerenone 50mg | 10 | 592.1 | 0 | 0 |
| 143 | P-0143 | Tab. Ticagrelor 90mg | 20 | 1200 | 140 | 168000 |
| 144 | P-0144 | Tab. Indapamide SR / Amlopidine 1.5mg/5mg | 30 | 500 | 10 | 5000 |
| | | Tab. Indapamide SR / Amlopidine 1.5mg/10mg | 30 | 600 | 0 | 0 |
| 145 | P-0145 | Tab. Perindopril / Indapamide 4mg/1.25mg | 10 | 293 | 0 | 0 |
| 146 | P-0146 | Inj. Labetalol 50mg | 1 | 35 | 382 | 13370 |
| 147 | P-0147 | Tab. Labetalol 100mg | 20 | 150 | 1458 | 218700 |
| 148 | P-0148 | Cap/Tab. Coenzyme Q10 100mg (Ubidecarenone) | 20 | 300 | 70 | 21000 |
| | | (J) DRUGS ACTING ON CNS | | | 0 | 0 |
| 149 | P-0149 | Cap. Flunarizine 5mg | 12 | 40.15 | 400 | 16060 |
| 150 | P-0150 | Tab. Betahistine Di-Hydrochloride 8mg | 30 | 105 | 370 | 38850 |
| | | Tab. Betahistine Di-Hydrochloride 16mg | 30 | 110 | 4010 | 441100 |
| 151 | P-0151 | Tab. Pizotifen 0.5mg. | 30 | 200 | 0 | 0 |
| 152 | P-0152 | Tab. Zolmitriptan 2.5mg | 3 | 700 | 50 | 35000 |
| 153 | P-0153 | Inj. Iopromide 370/100 | 1 | 2399 | 1000 | 2399000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 154 | P-0154 | Inj. Iodixanol 270mg | 1 | 1700 | 0 | 0 |
| 155 | P-0155 | Lidocaine Cetrime Spray 10% | 1 | 250 | 12 | 3000 |
| 156 | P-0156 | Inj. Iohexol 350mg 50ml | 1 | 1439 | 0 | 0 |
| | | Inj. Iohexol 350mg 100ml | 1 | 2346 | 700 | 1642200 |
| | | Inj. Iohexol 300mg 50ml | 1 | 1500 | 0 | 0 |
| | | Inj. Iohexol 300mg 100ml | 1 | 2500 | 0 | 0 |
| 157 | P-0157 | Sodium Amidotriazoate 0.1g Meglumine amidotriazoate 0.66g 370mg/ml | 1 | 1037 | 200 | 207400 |
| | | (K) ANTI-COAGULANTS: | | | 0 | 0 |
| 158 | P-0158 | Inj.Streptokinase 1.50miu. | 1 | 4665 | 50 | 233250 |
| 159 | P-0159 | Inj.Heparin 5000 IU. | 1 | 750 | 13588 | 10191000 |
| 160 | P-0160 | Tab.Warfarin Sod. 5mg | 100 | 435 | 585 | 254475 |
| | | Tab.Warfarin Sod. 2.5mg | 30 | 200 | 0 | 0 |
| 161 | P-0161 | Inj. Enoxaparin (Low mol Wt. Heparin) 40mg | 1 | 811 | 4520 | 3665720 |
| | | Inj. Enoxaparin (Low mol Wt. Heparin) 60mg | 1 | 1042 | 1910 | 1990220 |
| | | Inj. Enoxaparin (Low mol Wt. Heparin) 80mg | 1 | 2000 | 100 | 200000 |
| 162 | P-0162 | Inj.Abciximab 2mg/5ml | 1 | 24000 | 0 | 0 |
| 163 | P-0163 | Inj.Tirofiban 0.25mg/ml | 1 | 24000 | 14 | 336000 |
| 164 | P-0164 | Tab. Beraprost Sodium 20mcg | 30 | 450 | 6 | 2700 |
| 165 | P-0165 | Tab. Rivaroxaban 10mg | 10 | 109 | 3840 | 418560 |
| | | Tab. Rivaroxaban 20mg | 10 | 181 | 30 | 5430 |
| | | Tab. Rivaroxaban 2.5mg | 14 | 101.75 | 0 | 0 |
| 166 | P-0166 | Inj. Reteplase 10 I.U | 1 | 2000 | 0 | 0 |
| 167 | P-0167 | Tab. Apixaben 10mg | 30 | 500 | 13 | 6500 |
| 168 | P-0168 | Cap. Dabigatran 150mg | 30 | 5000 | 0 | 0 |
| 169 | P-0169 | Inj. Bivalirudin | 1 | 5000 | 0 | 0 |
| | | (L) CLOTTING AGENTS: | | | 0 | 0 |
| 170 | P-0170 | Tab. Eltrombopag 25mg | 28 | 75000 | 10 | 750000 |
| | | Tab. Eltrombopag 50mg | 28 | 126000 | 10 | 1260000 |
| 171 | P-0171 | Inj.Tranexamic Acid 250mg/5ml. | 5 | 114 | 12650 | 1442100 |
| 172 | P-0172 | Caps Tranexamic Acid 250mg. | 20 | 157 | 2380 | 373660 |
| | | Caps Tranexamic Acid 500mg. | 20 | 295 | 7180 | 2118100 |
| 173 | P-0173 | Inj.Factor VIII 250Units | 1 | 8900 | 1 | 8900 |
| | | Inj.Factor VIII 500Units | 1 | 9000 | 1 | 9000 |
| | | (M) ANALGESICS/ANTIPYRETICS/ ANTI- INFLAMMATORY/MUSCLE RELAXANTS/ ANTI RHEUMATICS: | | | 0 | 0 |
| 174 | P-0174 | Tab. Mefenamic Acid 250mg | 600 | 727.72 | 4645 | 3380259.4 |
| | | Tab. Mefenamic Acid 500mg | 200 | 250 | 1259 | 314750 |
| 175 | P-0175 | Tab. Paracetamol 500mg. | 200 | 280 | 60125 | 16835000 |
| 176 | P-0176 | Inj. Paracetamol 300mg/2ml | 5 | 250 | 196 | 49000 |
| | | Inf. Paracetamol 1000mg /100ml | 100ml | 69.95 | 63660 | 4453017 |
| 177 | P-0177 | Susp. Paracetamol 120mg/5ml | 60ml | 31.5 | 214800 | 6766200 |
| | | Susp. Paracetamol BP 250mg/5ml. | 90ml | 66 | 5727 | 377982 |
| 178 | P-0178 | Paracetamol 80mg/0.8ml Drops. | 30ml | 59 | 1460 | 86140 |
| 179 | P-0179 | Tab. Ibuprofen 200mg. | 100 | 255.8 | 2042 | 522343.6 |
| | | Tab. Ibuprofen 400mg | 100 | 250 | 3126 | 781500 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|----------------------------------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 180 | P-0180 | Susp. Ibuprofen 100mg/5ml. | 90ml | 32 | 119307 | 3817824 |
| 181 | P-0181 | Tab. Diclofenac Sodium 50mg. | 20 | 15.8 | 221200 | 3494960 |
| 182 | P-0182 | Inj. Diclofenac Sodium 75mg/3ml. | 100 | 522.8 | 4050 | 2117340 |
| 183 | P-0183 | Tab. Piroxicam 10mg. | 40 | 80 | 1800 | 144000 |
| | | Cap/Tab. Piroxicam 20mg. | 10 | 25.2 | 78900 | 1988280 |
| 184 | P-0184 | Diclofenac Sod. Gel. | 20gm | 39 | 82200 | 3205800 |
| 185 | P-0185 | Oint Oleorescin of Capsicum 0.30% + Eucalyptol 0.11% + Thymol 0.1% + Methyl Salicylate 12-17% + Menthol + Glycerine. | 50gm | 72.2 | 1760 | 127072 |
| 186 | P-0186 | Diethylamine Salicylate Gel | 1 | 150 | 0 | 0 |
| 187 | P-0187 | Inj. Nalbuphin HCL 10mg/ml. | 10 | 270 | 3810 | 1028700 |
| 188 | P-0188 | Tab. Paracetamol 500mg + Codeine 15mg | 100 | 270 | 4 | 1080 |
| | | Tab. Paracetamol 500mg + Codeine 30mg | 30 | 50 | 100 | 5000 |
| 189 | P-0189 | Tab. Orphenadine 50mg + Paracetamol 650mg. | 30 | 136 | 113300 | 15408800 |
| 190 | P-0190 | Tab. Tizanidine 2mg. | 10 | 23.5 | 99705 | 2343067.5 |
| 191 | P-0191 | Cap. Celecoxib 100mg | 20 | 70 | 40 | 2800 |
| | | Cap. Celecoxib 200mg. | 20 | 70 | 0 | 0 |
| 192 | P-0192 | Tab. Meloxicam 7.5mg | 10 | 40.5 | 380 | 15390 |
| | | Tab. Meloxicam 15mg | 10 | 85 | 0 | 0 |
| 193 | P-0193 | Tab. Trypsin & Chymotrypsin 6:1 ratio | 20 | 150 | 4420 | 663000 |
| 194 | P-0194 | Cap. Tramadol HCL 50mg. | 30 | 137.7 | 15589 | 2146605.3 |
| 195 | P-0195 | Inj. Tramadol HCL 100mg. | 10 | 144.9 | 4840 | 701316 |
| 196 | P-0196 | Tab. Naproxen Sodium 275mg equivalent Naproxen 250mg | 20 | 150 | 900 | 135000 |
| | | Tab. Naproxen Sodium 550mg equivalent Naproxen 500mg | 30 | 244 | 5390 | 1315160 |
| 197 | P-0197 | Tab. Nimesulide 100mg. | 20 | 46 | 29950 | 1377700 |
| 198 | P-0198 | Tab. Ibuprofen 200mg + Pseudoephedrine 30mg. | 100 | 416 | 640 | 266240 |
| | | Tab. Ibuprofen 400mg + Pseudoephedrine 60mg. | 100 | 800 | 591 | 472800 |
| 199 | P-0199 | Syp. Ibuprofen 100mg + Pseudoephedrine 15mg | 120ml | 75.91 | 9220 | 699890.2 |
| 200 | P-0200 | Tab. Sulphasalazine 500mg. | 30 | 150 | 230 | 34500 |
| 201 | P-0201 | Tab. Diclofenac Potassium 50mg. | 20 | 21 | 54324 | 1140804 |
| 202 | P-0202 | Cap.Thiocolchicoside 4mg | 20 | 150 | 640 | 96000 |
| 203 | P-0203 | Tab. Leflunomide 10mg | 30 | 413 | 20 | 8260 |
| | | Tab. Leflunomide 20mg | 30 | 420 | 1520 | 638400 |
| | | Tab. Leflunomide 100mg | 10 | 400 | 0 | 0 |
| 204 | P-0204 | Tab.Acelofenac 100mg | 30 | 70.28 | 100 | 7028 |
| 205 | P-0205 | Tab.Diclofenac Sodium 50mg,Misoprostol 200mcg | 20 | 30 | 1720 | 51600 |
| 206 | P-0206 | Inj. Papaverin HCL 15.4mg/ml | 5 | 250 | 0 | 0 |
| 207 | P-0207 | Tab.Piroxicam-beta-Cyclodextrin 191.3 equal to 20mg Piroxicam. | 20 | 77 | 20 | 1540 |
| 208 | P-0208 | Diclofenac Sodium Suppository 25mg | 10 | 50 | 0 | 0 |
| | | Diclofenac Sodium Suppository 50mg | 5 | 50 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| | | Diclofenac Sodium Suppository 100mg | 5 | 50 | 0 | 0 |
| 209 | P-0209 | Tab. Paracetamol 500mg, Caffeine 30mg, Codeine 15mg | 100 | 250 | 50 | 12500 |
| 210 | P-0210 | Tab . Etoricoxib 60mg | 10 | 100 | 0 | 0 |
| 211 | P-0211 | Tab. Lornoxicam 8mg | 10 | 99 | 0 | 0 |
| 212 | P-0212 | Cap. Diacerein 50mg | 30 | 1000 | 0 | 0 |
| 213 | P-0213 | Tab. Diclofenic free acid | 20 | 200 | 40 | 8000 |
| 214 | P-0214 | Tab. Trypsin 24mg, Chymotrypsin 1mg, Papain 60mg, Pancreatin 100mg, Bromelain 45mg, rutin | 40 | 350 | 100 | 35000 |
| 215 | P-0215 | Tab. Baclofen 10mg | 30 | 162 | 159 | 25758 |
| 216 | P-0216 | Cap. Morphine 30mg | 30 | 690 | 4 | 2760 |
| | | Cap. Morphine 10mg | 30 | 1700 | 10 | 17000 |
| 217 | P-0217 | Inf.Ibuprofen 400mg/100ml | vial | 168.3 | 0 | 0 |
| | | (N) ANTI-CONVULSANTS: | | | 0 | 0 |
| 218 | P-0218 | Tab. Carbamazepine 200mg. | 50 | 204.85 | 5935 | 1215784.75 |
| 219 | P-0219 | Tab. Divalprex Sodium 250mg | 100 | 432.23 | 1490 | 644022.7 |
| | | Tab. Divalprex Sodium 500mg | 100 | 384 | 2816 | 1081344 |
| 220 | P-0220 | Syp. Sodium Valproate equivalent to valproic Acid 250mg / 5ml | 120ml | 154.42 | 4060 | 626945.2 |
| 221 | P-0221 | Tab. Clonazepam 0.5mg. | 50 | 155 | 920 | 142600 |
| | | Tab. Clonazepam 2mg. | 30 | 200 | 42 | 8400 |
| 222 | P-0222 | Drops Clonazepam 0.25%. | 1 | 180 | 190 | 34200 |
| 223 | P-0223 | Tab. Topiramate 25mg | 30 | 115 | 1300 | 149500 |
| | | Tab. Topiramate 50mg | 10 | 83.9 | 890 | 74671 |
| 224 | P-0224 | Susp. Carbamazepine 100mg/5ml | 120ml | 83.73 | 960 | 80380.8 |
| 225 | P-0225 | Tab. / Cap. Gabapentin 300mg. | 10 | 60 | 13400 | 804000 |
| | | Tab. / Caps. Gabapentin 100mg | 10 | 38 | 22650 | 860700 |
| 226 | P-0226 | Tab. Oxcarbazepine 300mg | 50 | 600 | 30 | 18000 |
| 227 | P-0227 | Tab./Cap. Duloxetine 30mg. | 10 | 79 | 2654 | 209666 |
| | | Tab./Cap. Duloxetine 60mg. | 10 | 171.5 | 4 | 686 |
| 228 | P-0228 | Tab. Levetiracetam 250mg | 30 | 258 | 440 | 113520 |
| | | Tab. Levetiracetam 500mg | 10 | 117.6 | 12410 | 1459416 |
| 229 | P-0229 | Tab. Clomipramine 10mg | 100 | 225 | 2 | 450 |
| | | Tab. Clomipramine 25mg | 100 | 500 | 12 | 6000 |
| | | Tab. Clomipramine 75mg | 30 | 200 | 0 | 0 |
| 230 | P-0230 | Cap. Pregablin 75mg | 14 | 45.5 | 23570 | 1072435 |
| | | Cap. Pregablin 150mg | 14 | 125.74 | 600 | 75444 |
| 231 | P-0231 | Syp. Levetiracetam 100mg/ml | 60ml | 163 | 2750 | 448250 |
| 232 | P-0232 | Tab. Lamotrigine 50mg | 30 | 1200 | 810 | 972000 |
| 233 | P-0233 | Inj. Phenytoin IV 250mg | 1 | 2000 | 0 | 0 |
| 234 | P-0234 | Inf. Divalproex Sodium 500mg | 5ml | 145.97 | 600 | 87582 |
| 235 | P-0235 | Susp.phenytoin 30mg | 120ml | 40 | 6 | 240 |
| 236 | P-0236 | Inj.Levetiracetam 500mg | 5ml | 239 | 230 | 54970 |
| 237 | P-0237 | Inj.Lacosamide 10mg/ml | 20ml | 370 | 20 | 7400 |
| 238 | P-0238 | Tab. Lacosamide 50mg | 14 | 258 | 60 | 15480 |
| | | Tab. Lacosamide 100mg | 14 | 372 | 540 | 200880 |
| | | Tab. Lacosamide 200mg | 14 | 400 | 0 | 0 |
| 239 | P-0239 | Syp.Lacosamide 10mg/ml | 100ml | 250 | 40 | 10000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|--------------------------------------------|-----------|----------------|-------|------------------|
| | | (0) HYPNOTICS/SEDATIVES/ANXIOLYTICS: | | | 0 | 0 |
| 240 | P-0240 | Tab. Phenobarbitone 30mg. | 30 | 400 | 24 | 9600 |
| 241 | P-0241 | Tab. Diazepam 5mg. | 30 | 42 | 9534 | 400428 |
| 242 | P-0242 | Inj. Diazepam 10mg/2ml | 5 | 242 | 534 | 129228 |
| 243 | P-0243 | Tab. Chlorpromazine 25mg | 300 | 297 | 0 | 0 |
| 244 | P-0244 | Inj. Pentazocine 30mg/ml. | 10 | 115 | 0 | 0 |
| 245 | P-0245 | Tab. Bromazepam 3mg. | 30 | 163 | 7804 | 1272052 |
| 246 | P-0246 | Tab. Alprazolam 0.5mg. | 30 | 150 | 6390 | 958500 |
| 247 | P-0247 | Tab. Buspirone HCL 5mg. | 20 | 300 | 60 | 18000 |
| 248 | P-0248 | Tab. / Cap. Fluoxetine HCL 20mg. | 100 | 444 | 400 | 177600 |
| 249 | P-0249 | Tab. Risperidone 1mg. | 20 | 37 | 960 | 35520 |
| | | Tab. Risperidone 2mg. | 20 | 49 | 3300 | 161700 |
| | | Tab. Risperidone 3mg. | 6 | 100 | 0 | 0 |
| 250 | P-0250 | Risperidone Oral Solution 1mg/ml | 30ml | 80 | 20 | 1600 |
| 251 | P-0251 | Tab. / Cap. Atomoxetine 18mg | 28 | 330 | 0 | 0 |
| 252 | P-0252 | Cap. Temazepam 30mg | 30 | 60 | 0 | 0 |
| 253 | P-0253 | Tab. Haloperidol 5mg. | 30 | 20 | 380 | 7600 |
| 254 | P-0254 | Inj. Haloperidol 5mg/ml. | 5 | 40 | 6 | 240 |
| 255 | P-0255 | Inj. Flumazenil 100mcg/ml | 5 | 26000 | 0 | 0 |
| 256 | P-0256 | Inj. Midazolam 1mg/1ml (3ml) | 5 | 295 | 10 | 2950 |
| | | Inj. Midazolam 1mg/1ml (5ml) | 5 | 300 | 930 | 279000 |
| 257 | P-0257 | Tab. Quetiapine 25mg | 30 | 165 | 60 | 9900 |
| | | Tab. Quetiapine 100mg | 30 | 142 | 1666 | 236572 |
| 258 | P-0258 | Tab. Olanzapine 10mg | 10 | 180 | 1170 | 210600 |
| 259 | P-0259 | Syp. Haloperidol 2mg/ml | 60ml | 50 | 10 | 500 |
| 260 | P-0260 | Inj. Phenobarbitone | 1 | 50 | 60 | 3000 |
| 261 | P-0261 | Tab. Nitrazepam 5mg | 10 | 100 | 0 | 0 |
| 262 | P-0262 | Tab. Aripiprazole 10mg | 30 | 250 | 40 | 10000 |
| | | Tab. Aripiprazole 20mg | 30 | 295 | 4 | 1180 |
| | | Tab. Aripiprazole 30mg | 30 | 350 | 0 | 0 |
| 263 | P-0263 | Inj. Zuclopenthixol 100mg | 2ml | 150 | 0 | 0 |
| | | (P) ANTI-DEPRESSANTS/ PSYCHOSTIMULANTS. | | | 0 | 0 |
| 264 | P-0264 | Tab. Mirtazapine 15mg | 30 | 400 | 100 | 40000 |
| | | Tab. Mirtazapine 30mg | 30 | 500 | 390 | 195000 |
| | | Tab. Mirtazapine 45mg | 30 | 550 | 0 | 0 |
| 265 | P-0265 | Tab. Clozapine 25mg. | 50 | 1500 | 40 | 60000 |
| | | Tab. Clozapine 100mg. | 50 | 3000 | 20 | 60000 |
| 266 | P-0266 | Tab. Fluvoxamine Maleate 50mg. | 10 | 500 | 230 | 115000 |
| 267 | P-0267 | Tab. Escitalopram 10mg. | 14 | 31 | 11516 | 356996 |
| | | Tab. Escitalopram 20mg. | 14 | 69 | 1600 | 110400 |
| 268 | P-0268 | Tab. Paroxetine HCL 10mg | 20 | 150 | 6 | 900 |
| | | Tab. Paroxetine HCL 12.5mg CR | 30 | 200 | 116 | 23200 |
| | | Tab. Paroxetine HCL 20mg | 30 | 350 | 420 | 147000 |
| | | Tab. Paroxetine HCL 25mg CR | 30 | 350 | 870 | 304500 |
| 269 | P-0269 | Tab. Sertraline HCL 50mg. | 30 | 150 | 1150 | 172500 |
| | | Tab. Sertraline HCL 100mg. | 20 | 220 | 6 | 1320 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 270 | P-0270 | Tab. Olanzapine 6mg + Fluoxetine 25mg | 14 | 200 | 0 | 0 |
| 271 | P-0271 | Tab. Imipramine 75mg | 10 | 10 | 50 | 500 |
| 272 | P-0272 | Syp. Fluoxetine 20mg/5ml | 60ml | 200 | 2 | 400 |
| 273 | P-0273 | Tab. Dothiepin HCL 25mg | 100 | 80 | 2 | 160 |
| | | Tab. Dothiepin HCL 75mg | 30 | 60 | 2 | 120 |
| | | (Q) ANTI-PARKINSONISM: | | | 0 | 0 |
| 274 | P-0274 | Tab. Ropinirole 0.25mg | 21 | 238 | 170 | 40460 |
| | | Tab. Ropinirole 1mg | 21 | 418 | 100 | 41800 |
| 275 | P-0275 | Inj. Procyclidine HCl 10mg/2ml. | 10 | 270 | 0 | 0 |
| 276 | P-0276 | Tab. Procyclidine 5mg. | 100 | 136 | 957 | 130152 |
| 277 | P-0277 | Tab. Levodopa 250mg+Carbidopa 25mg. | 100 | 994 | 454 | 451276 |
| 278 | P-0278 | Tab. Amantadine Sulphate 100mg | 20 | 340 | 1470 | 499800 |
| 279 | P-0279 | Tab. Selegiline 5mg | 20 | 250 | 20 | 5000 |
| 280 | P-0280 | Tab. Memantine 10mg | 56 | 231 | 322 | 74382 |
| 281 | P-0281 | Tab. Trihexyphenidyl 2mg | 100 | 30 | 1 | 30 |
| | | (R) ANTI-HISTAMINES: | | | 0 | 0 |
| 282 | P-0282 | Tab. Clemastine 1mg. | 60 | 70 | 1000 | 70000 |
| 283 | P-0283 | Tab. Pheniramine Maleate 25mg | 250 | 100 | 5415 | 541500 |
| 284 | P-0284 | Inj. Pheniramine Maleate 22.7mg equivalent to 25mg Pheniramine Salicylate per ml in 2ml ampoule | 50 | 100 | 354 | 35400 |
| 285 | P-0285 | Syp. Pheniramine Maleate 15mg/5ml. | 60ml | 70 | 2940 | 205800 |
| 286 | P-0286 | Syp. Cetirizine 1mg/1ml | 60ml | 24 | 104080 | 2497920 |
| 287 | P-0287 | Tab. Cetirizine 10mg | 500 | 405 | 11697 | 4737285 |
| 288 | P-0288 | Tab. Cinnarizine 25mg. | 50 | 133 | 82 | 10906 |
| | | Cap. Cinnarizine 75mg. | 12 | 200 | 0 | 0 |
| 289 | P-0289 | Tab. Ebastine 10mg. | 10 | 42 | 316 | 13272 |
| 290 | P-0290 | Syp. Clemastine 0.25mg/5ml | 120ml | 50 | 0 | 0 |
| 291 | P-0291 | Tab. Levocetirizine 5mg. | 10 | 24 | 3806 | 91344 |
| 292 | P-0292 | Tab. Fexofenadine 60mg | 20 | 50 | 200 | 10000 |
| | | Tab. Fexofenadine 120mg | 10 | 45 | 1650 | 74250 |
| 293 | P-0293 | Tab. Fexofenadine 60mg + Pseudoephedrine 120mg | 10 | 150 | 30 | 4500 |
| 294 | P-0294 | Tab. Hydroxyzine 10mg | 50 | 45 | 0 | 0 |
| | | Tab. Hydroxyzine 25mg | 50 | 70 | 0 | 0 |
| 295 | P-0295 | Syp. Levocetirizine 5mg/5ml | 60ml | 100 | 0 | 0 |
| | | (S) NEUROTONICS: | | | 0 | 0 |
| 296 | P-0296 | Tab. Co-Dergocrine Mesylate 1.5mg | 30 | 233 | 1730 | 403090 |
| 297 | P-0297 | Co-Dergocrine Mesylate Oral Solution | 30ml | 176 | 414 | 72864 |
| 298 | P-0298 | Tab. Nimodipine 30mg. | 30 | 1000 | 10 | 10000 |
| 299 | P-0299 | Inj. Piracetam 1gm/5ml | 5 | 300 | 2 | 600 |
| | | syp Piracetam 1gm/5ml | 12 | 500 | 1 | 500 |
| 300 | P-0300 | Tab. Galantamine (as hydrobromide) 4mg | 14 | 2000 | 10 | 20000 |
| 301 | P-0301 | Inj. Botulinum Toxina A | 1 | 100 | 1 | 100 |
| | | Inj. Botulinum Toxina B | 1 | 100 | 1 | 100 |
| 302 | P-0302 | Inj. Citicoline 250mg/ml | 5 | 400 | 2 | 800 |
| | | Inj. Citicoline 1g/ml | 1 | 200 | 2 | 400 |
| | | (T) DRUGS ACTING ON EAR: | | | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|----------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 303 | P-0303 | Gentamycine Ear Drops 0.3%. | 1 | 50 | 140 | 7000 |
| 304 | P-0304 | Soda Glycerine Ear Drops. | 1 | 30 | 2700 | 81000 |
| 305 | P-0305 | Drops Polymyxin-B Sulphate 10,000 Units Lignocaine HCl 50mg. Propylene Glycol to make 1ml | 5ml | 28 | 22110 | 619080 |
| 306 | P-0306 | Triamcinolone Acetonide 1mg, Neomycine 2.5mg, Gramicidin 0.25mg, Nystatin 100,000 Units Ear Drops. | 1 | 100 | 40 | 4000 |
| 307 | P-0307 | Ear Drops Ofloxacin 0.3% | 5ml | 57 | 306 | 17442 |
| | | Ear Drops Ofloxacin 0.6% | 5ml | 59.00% | 106 | 62.54 |
| 308 | P-0308 | Ear Drops. Tobramycin 0.3% | 5ml | 80 | 566 | 45280 |
| 309 | P-0309 | Ear Drops. Tobramycin 0.3% + Dexamethasone 0.1% | 5ml | 100 | 980 | 98000 |
| 310 | P-0310 | Ciprofloxacin + Dexamethasone Ear Drops. | 5ml | 76 | 3650 | 277400 |
| 311 | P-0311 | Ciprofloxacin + Lignocaine Ear Drops. | 5ml | 60 | 2350 | 141000 |
| 312 | P-0312 | Betamethasone 0.1% + Neomycine 0.5% Ear Drops. | 7.5ml | 75 | 2750 | 206250 |
| | | (U) DRUGS ACTING ON NASOPHARYNX: | | | 0 | 0 |
| 313 | P-0313 | Xylometazoline 0.1% Nasal Spray | 20ml | 75 | 1700 | 127500 |
| | | Oxymetazoline 5mg / 10ml Nasal Drops | 1 | 60 | 224 | 13440 |
| 314 | P-0314 | Beclomethasone 100mcg Nasal Spray. | 1 | 550 | 26 | 14300 |
| 315 | P-0315 | Flunisolide 0.025% Nasal Spray. | 15ml | 190 | 3420 | 649800 |
| 316 | P-0316 | Azelastin HCL 0.1% Nasal Spray. | 1 | 184 | 20 | 3680 |
| 317 | P-0317 | Cromoglycate Sodium 4% Nasal Spray. | 1 | 150 | 10 | 1500 |
| 318 | P-0318 | Cromoglycate Sodium + Xylometazoline Nasal Spray. | 15ml | 200 | 110 | 22000 |
| 319 | P-0319 | Normal Saline Nasal Drops | 1 | 25 | 760 | 19000 |
| 320 | P-0320 | Triamcinolone nasal spray 15mg/ actu | 1 | 150 | 20 | 3000 |
| 321 | P-0321 | Lignocaine, cetylpyridinium, menthol, eucalyptol oral anesthetic | 1 | 100 | 30 | 3000 |
| | | (V) THYROID AND ANTITHYROID DRUGS | | | 0 | 0 |
| 322 | P-0322 | Tab. Thyroxine 50mcg. | 100 | 150 | 1145 | 171750 |
| 323 | P-0323 | Tab. Levo Thyroxine 50mcg | 100 | 142 | 1580 | 224360 |
| | | Tab. Levo Thyroxine 100mcg | 100 | 343 | 0 | 0 |
| 324 | P-0324 | Tab. Carbimazole 5mg. | 100 | 165 | 1350 | 222750 |
| 325 | P-0325 | Tab. Propylthiouracil 50mg | 30 | 123 | 0 | 0 |
| | | Tab. Propylthiouracil 100mg | 30 | 150 | 0 | 0 |
| | | (W) DRUGS ACTING ON ENDOCRINE/FEMALE SYSTEM. | | | 0 | 0 |
| 326 | P-0326 | Inj. Medroxy Progesterone Acetate 150mg | 1 | 245 | 10 | 2450 |
| 327 | P-0327 | Inj. Oxytocin 5iu. | 50 | 522 | 2527 | 1319094 |
| 328 | P-0328 | Inj. Methylergometrine 0.2mg/ml | 1 | 400 | 10 | 4000 |
| 329 | P-0329 | Tab. Estrogen Conjugated 0.3mg. | 30 | 350 | 6 | 2100 |
| 330 | P-0330 | Tab. Levonorgestril 1.5mg + Ethinyloestradiol 0.03mg + Tab. Ferrous Fumerate | 21 | 30 | 261 | 7830 |
| 331 | P-0331 | Tab. Clomiphene Citrate 50mg. | 20 | 352 | 1196 | 420992 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|--------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 332 | P-0332 | Inj. Hydroxyprogesterone Caproate 250mg/ml. | 5 | 150 | 3397 | 509550 |
| 333 | P-0333 | Tab. Methyl Estrenolone 5mg+Methyl Oestradiol 0.3mg. | 21 | 200 | 100 | 20000 |
| 334 | P-0334 | Inj. Dinoprost 5mg/ml | 1 | 650 | 10 | 6500 |
| 335 | P-0335 | Tab. Dinoprostone 3mg. | 1 | 296 | 1000 | 296000 |
| 336 | P-0336 | Tab. Norethisterone 5mg. | 30 | 250 | 4650 | 1162500 |
| 337 | P-0337 | Tab. Bromocriptine Mesylate 2.5mg | 30 | 325 | 156 | 50700 |
| 338 | P-0338 | Tab. Dydrogesterone 10mg | 20 | 633 | 6890 | 4361370 |
| 339 | P-0339 | Tab.Estradiol Valerate 2mg + Norgesterol 0.5mg | 21 | 130 | 142 | 18460 |
| 340 | P-0340 | Tab.Cyproterone Acetate 2mg + Ethinylestradiol 35mcg. | 21 | 73 | 302 | 22046 |
| 341 | P-0341 | Cap.Danazol 200mg. | 30 | 1069 | 6 | 6414 |
| | | Cap.Danazol 400mg. | 30 | 1200 | 0 | 0 |
| 342 | P-0342 | Tab.Tibolone 2.5mg | 20 | 900 | 2 | 1800 |
| 343 | P-0343 | Tab. Misoprostol 200mcg | 10 | 74 | 4655 | 344470 |
| 344 | P-0344 | Inj. Terlipressin acetate 1mg (With Diluent 5ml) | 1 | 630 | 20 | 12600 |
| 345 | P-0345 | Cap. Utrogestan 100mg | 20 | 1300 | 4 | 5200 |
| 346 | P-0346 | Inj. Human Chorionic Gonadotropin 5000 I.U | 1 | 350 | 0 | 0 |
| 347 | P-0347 | Tab. Estradiol Valerate and Cyproterone Acetate | 30 | 350 | 24 | 8400 |
| | | (X) CORTICOSTEROIDS: | | | 0 | 0 |
| 348 | P-0348 | Inj.Dexamethasone Sod. Phosphate 4mg/ml (1ml Vial). | 25 | 195 | 7189 | 1401855 |
| 349 | P-0349 | Inj. Hydrocortisone Sod. Succinate 250mg. | 1 | 73 | 43200 | 3153600 |
| 350 | P-0350 | Tab. Prednisolone 5mg. | 1000 | 1420 | 1573 | 2233660 |
| | | Tab. Prednisolone 5mg (Enteric Coated) | 100 | 255 | 148 | 37740 |
| 351 | P-0351 | Inj. Triamcinolone Acetonide 40mg. | 1 | 50 | 890 | 44500 |
| 352 | P-0352 | Inj.Methylprednisolone Acetate 40mg/ml | 1 | 200 | 100 | 20000 |
| 353 | P-0353 | Tab. Dexamethasone 0.5mg | 1000 | 500 | 68 | 34000 |
| 354 | P-0354 | Tab. Betamethasone 0.5mg | 500 | 500 | 82 | 41000 |
| 355 | P-0355 | Syp.Prednisolone 5mg/5ml | 60ml | 75 | 20 | 1500 |
| | | (Y) ANABOLICS/DRUGS AFFECTING BONE METABOLISM. | | | 0 | 0 |
| 356 | P-0356 | Tab. Alendronate Sodium 10mg | 10 | 250 | 0 | 0 |
| | | Tab. Alendronate Sodium 70mg | 4 | 460 | 90 | 41400 |
| 357 | P-0357 | Tab.Raloxifene HCL 60mg. | 14 | 250 | 0 | 0 |
| 358 | P-0358 | Inj. Epoetin alpha 2000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized). | 1 | 210 | 2000 | 420000 |
| | | Inj. Epoetin alpha 4000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized). | 6 | 2280 | 3650 | 8322000 |
| | | Inj. Epoetin alpha 10000 iu (Recombinant human Erythropoietin) (Vial / Pr-filled / Lyophilized). | 1 | 550 | 420 | 231000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 359 | P-0359 | Tab.Alendronate Sodium equivalent alendronic acid+,Cholecalciferol 70mcg | 10 | 500 | 0 | 0 |
| 360 | P-0360 | Inj.Zoledronic acid 4mg | 1 | 13000 | 30 | 390000 |
| | | Inj.Zoledronic acid 5mg | 1 | 18000 | 1 | 18000 |
| 361 | P-0361 | Tab. Azathioprine 50mg | 100 | 1200 | 51 | 61200 |
| 362 | P-0362 | Strontium Ranelate Powder 2gm | 7 | 525 | 0 | 0 |
| 363 | P-0363 | Inj. Calcitonin 100 units / ml | 5 | 100 | 0 | 0 |
| 364 | P-0364 | Tab. Ibandronic Acid 150mg | 1 | 460 | 80 | 36800 |
| 365 | P-0365 | Inj. Sodium hyaluronate 10mg/ml | 1 | 1600 | 0 | 0 |
| | | (Z) DRUGS ACTING ON GENITO URINARY | | | 0 | 0 |
| | | SYSTEM/DIURETICS & BLOOD ALKALIZERS. | | | 0 | 0 |
| 366 | P-0366 | Tab. Norfloxacin 400mg. | 14 | 140 | 700 | 98000 |
| 367 | P-0367 | Cap/Tab Pipemedic Acid 400mg. | 100 | 250 | 20 | 5000 |
| 368 | P-0368 | Tab. Allopurinol 300mg | 30 | 150 | 6363 | 954450 |
| | | Tab. Allopurinol 100mg | 50 | 150 | 725 | 108750 |
| 369 | P-0369 | Tab. Potassium Chloride 500mg. | 30 | 15 | 85 | 1275 |
| 370 | P-0370 | Syp. Di-Sodium Hydrogen Citrate 26.3gm / 100ml | 1 | 150 | 9900 | 1485000 |
| 371 | P-0371 | Tab. Frusemide 20mg. | 100 | 162 | 121 | 19602 |
| | | Tab. Frusemide 40mg. | 100 | 200 | 6044 | 1208800 |
| 372 | P-0372 | Inj. Frusemide 20mg | 50 | 284 | 1355 | 384820 |
| | | Inj. Frusemide 40mg | 5 | 30 | 60 | 1800 |
| 373 | P-0373 | Tab. Spironolactone 25mg. | 100 | 200 | 4 | 800 |
| | | Tab. Spironolactone 100mg. | 10 | 95 | 9730 | 924350 |
| 374 | P-0374 | Tab. Frusemide 40mg + Amiloride HCL 5mg. | 30 | 155 | 9140 | 1416700 |
| 375 | P-0375 | Tab.Terazocin 2mg | 30 | 700 | 120 | 84000 |
| | | Tab.Terazocin 5mg | 30 | 1400 | 115 | 161000 |
| 376 | P-0376 | Tab.Flavoxate HCL 200mg. | 30 | 431 | 30 | 12930 |
| 377 | P-0377 | Tab.Tolterodine 2mg | 28 | 430 | 600 | 258000 |
| 378 | P-0378 | Tab. Doxazine Mesylate 2mg | 20 | 600 | 1790 | 1074000 |
| 379 | P-0379 | Tab. Finasteride 5mg. | 10 | 500 | 2 | 1000 |
| 380 | P-0380 | Tab. Desmopressin 0.1mg | 30 | 5000 | 4 | 20000 |
| | | Tab. Desmopressin 0.2mg | 30 | 8000 | 0 | 0 |
| 381 | P-0381 | Tab.Oxybutynin HCL 3mg | 30 | 500 | 0 | 0 |
| | | Tab.Oxybutynin HCL 5mg | 100 | 2800 | 0 | 0 |
| 382 | P-0382 | Tab. / Cap. Tamsulosin 0.4mg. | 20 | 86 | 14200 | 1221200 |
| 383 | P-0383 | Tab. Potassium Citrate 10 miliequivalent | 30 | 100 | 50 | 5000 |
| 384 | P-0384 | Cap. Dutasteride 0.5mg. | 30 | 2100 | 0 | 0 |
| 385 | P-0385 | Sachet Sodium Bicarbonate 1.716g,Sodium citrate0.613g,citric acid 0.702g,tartaric acid 0.858g/4gm | 100 | 300 | 352 | 105600 |
| 386 | P-0386 | Tab. Dutasteride 0.5mg + Tamsulosin 0.4mg | 20 | 890 | 330 | 293700 |
| 387 | P-0387 | Powder Sodium Polystyrene Sulphonate (Sachet) | 20 | 70 | 6 | 420 |
| 388 | P-0388 | Tab. Febuxostat 40mg | 20 | 147 | 980 | 144060 |
| | | Tab. Febuxostat 80mg | 20 | 219 | 700 | 153300 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|--------------------------------------------------------|-----------|----------------|-------|------------------|
| 389 | P-0389 | Tab. Potasium Chloride 573mg + Tab. Bumetanide 0.5mg | 20 | 50 | 0 | 0 |
| 390 | P-0390 | Tab.Frusemide 40mg,Spironolactone50mg | 30 | 203 | 17125 | 3476375 |
| | | Tab.Frusemide 20mg,Spironolactone50mg | 20 | 150 | 750 | 112500 |
| 391 | P-0391 | Desmopressin Nasal Spray 10mcg | 1 | 4400 | 0 | 0 |
| 392 | P-0392 | Cap. Cyclosporin-A 25mg | 50 | 2100 | 145 | 304500 |
| | | Cap. Cyclosporin-A 50mg | 50 | 4250 | 30 | 127500 |
| | | Cap. Cyclosporin-A 100mg. | 50 | 8500 | 102 | 867000 |
| 393 | P-0393 | Tab. Mycophenolate Mofetil 500mg. | 50 | 2775 | 339 | 940725 |
| 394 | P-0394 | Tab. Mycophenolic Acid 180mg (as Mycophenolate Sodium) | 120 | 6000 | 0 | 0 |
| | | Tab. Mycophenolic Acid 360mg (as Mycophenolate Sodium) | 120 | 3000 | 0 | 0 |
| 395 | P-0395 | Tab. Everolimus 0.25mg | 60 | 9500 | 30 | 285000 |
| | | Tab. Everolimus 0.5mg | 30 | 10000 | 0 | 0 |
| | | Tab. Everolimus 5mg | 30 | 315000 | 0 | 0 |
| 396 | P-0396 | Tab. Flavoxate and Propyphenazone. | 30 | 657 | 0 | 0 |
| 397 | P-0397 | Tab. Eplerenone 50mg | 10 | 500 | 0 | 0 |
| 398 | P-0398 | Tab. Sevelamer 400mg | 30 | 1000 | 4 | 4000 |
| | | Tab. Sevelamer 800mg | 30 | 2000 | 0 | 0 |
| 399 | P-0399 | Tab. Solifenacin 5mg | 10 | 340 | 1520 | 516800 |
| | | Tab. Solifenacin 10mg | 10 | 500 | 0 | 0 |
| 400 | P-0400 | Tab. Sirolimus 0.5mg | 20 | 12000 | 0 | 0 |
| | | Tab. Sirolimus 1mg | 20 | 23000 | 0 | 0 |
| 401 | P-0401 | Cap. Tacrolimus 0.5mg | 30 | 650 | 150 | 97500 |
| | | Cap. Tacrolimus 1mg | 30 | 950 | 270 | 256500 |
| 402 | P-0402 | Tab. / Cap. Nitrofurantoin 100mg | 100 | 400 | 1 | 400 |
| 403 | P-0403 | Tab. Potassium citrate 1000mg | 30 | 150 | 0 | 0 |
| | | (AA) VAGINAL PREPARATIONS/ANTI-FUNGALS. | | | 0 | 0 |
| 404 | P-0404 | Vaginal Cream (a) Clotrimazole 2% | 60gm | 70 | 11660 | 816200 |
| | | (b)Clotrimazole 10% | 1 | 250 | 0 | 0 |
| | | (c)Isoconazole 1% | 1 | 250 | 2 | 500 |
| | | (d) Fenticonazole Nitrate 2% | 40gm | 250 | 40 | 10000 |
| 405 | P-0405 | Clotrimazole Vaginal pessery 500mg. | 1 | 39 | 5370 | 209430 |
| 406 | P-0406 | Nystatin Drops 100,000 Units/ml. | 1 | 52 | 16515 | 858780 |
| 407 | P-0407 | Cap. Fluconazole 50mg | 7 | 150 | 200 | 30000 |
| | | Cap. Fluconazole 150mg. | 1 | 17 | 30880 | 524960 |
| 408 | P-0408 | (a) Clotrimazole lotion 1%. | 1 | 150 | 2660 | 399000 |
| | | (b) Clotrimazole solution 1%. | 1 | 150 | 600 | 90000 |
| 409 | P-0409 | Clotrimazole 1% Cream. | 20gm | 72 | 18200 | 1310400 |
| 410 | P-0410 | Cap.Itraconazol 100mg. | 4 | 69 | 3740 | 258060 |
| 411 | P-0411 | Cream Clindamycin Phosphate 2% | 40gm | 180 | 648 | 116640 |
| 412 | P-0412 | Cream Clotrimazole 1%+Hydrocortisone 1% | 10gm | 52 | 18200 | 946400 |
| 413 | P-0413 | Cream Ketoconazole 2% | 1 | 250 | 0 | 0 |
| | | | | | 0 | 0 |
| 414 | P-0414 | Lotion Ketoconazole 2% | 60ml | 250 | 0 | 0 |
| 415 | P-0415 | Sulphanilamide Vaginal Cream | 1 | 125 | 500 | 62500 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-----------------------------------------------------|-----------|----------------|--------|------------------|
| 416 | P-0416 | Miconazole Oral Gel 2% | 20gm | 107 | 122 | 13054 |
| | | (AB) ANTIBIOTICS. | | | 0 | 0 |
| 417 | P-0417 | Cap. Ampicillin 250mg. | 100 | 350 | 300 | 105000 |
| | | Cap. Ampicillin 500mg. | 100 | 687 | 500 | 343500 |
| 418 | P-0418 | Inj.Ampicillin 500mg. | 1 | 31 | 3550 | 110050 |
| | | Inj.Ampicillin 250mg | 1 | 50 | 0 | 0 |
| 419 | P-0419 | Syp. Amoxicillin 125mg/5ml. | 90ml | 59 | 96340 | 5684060 |
| 420 | P-0420 | Cap. Amoxicillin 250mg. | 100 | 410 | 7030 | 2882300 |
| | | Cap. Amoxicillin 500mg. | 100 | 550 | 18750 | 10312500 |
| 421 | P-0421 | Cap. Ampicillin 250mg + Cloxacillin 250mg. | 100 | 800 | 2590 | 2072000 |
| | | Cap. Ampicillin 125mg + Cloxacillin 125mg. | 100 | 445.04 | 1000 | 445040 |
| 422 | P-0422 | Inj. Ampicillin 250mg + Cloxacillin 250mg. | 1 | 30 | 0 | 0 |
| 423 | P-0423 | Inj. Benzyl Penicilline 0.5 MIU | 1 | 25 | 0 | 0 |
| | | Inj. Benzyl Penicilline 1 MIU | 1 | 35 | 40 | 1400 |
| 424 | P-0424 | Inj. Lincomycin 600mg(Activity)2ml. | 5 | 154 | 1350 | 207900 |
| 425 | P-0425 | Cap. Lincomycin 500mg. | 12 | 105 | 750 | 78750 |
| 426 | P-0426 | Tab. Ofloxacin 200mg. | 30 | 145 | 4504 | 653080 |
| | | Tab. Ofloxacin 400mg. | 10 | 134 | 70 | 9380 |
| 427 | P-0427 | (a) inf. Ciprofloxacin 200mg/100ml | 1 | 38 | 18650 | 708700 |
| | | (b) Inf. Ofloxacin 200mg | 1 | 250 | 0 | 0 |
| 428 | P-0428 | Inj. Cefotaxime 500mg. | Vial | 59 | 3700 | 218300 |
| | | Inj. Cefotaxime 1000mg | 1 | 83 | 11800 | 979400 |
| 429 | P-0429 | Inj. Cefuroxime 750mg. | 1 | 129 | 2500 | 322500 |
| 430 | P-0430 | Tab. Amoxicillin 250mg+Clavulanic Acid 125mg | 6 | 76 | 11900 | 904400 |
| | | Tab. Amoxicillin 500mg + Clavulanic Acid 125mg. | 6 | 100 | 114440 | 11444000 |
| | | Tab. Amoxicillin 875 + Clavulanic Acid 125mg | 6 | 119 | 6840 | 813960 |
| 431 | P-0431 | Inj. Amoxicillin 500mg + Clavulanic Acid 100mg. | 1 | 84 | 4400 | 369600 |
| | | Inj. Amoxicillin 1000mg, Clavulanic Acid 200mg. | 1 | 137 | 5680 | 778160 |
| 432 | P-0432 | Susp. Amoxicillin 125mg, + Clavulanic Acid 31mg/5ml | 90ml | 106 | 26200 | 2777200 |
| | | Susp. Amoxicillin 125mg, + Clavulanic Acid 31mg/5ml | 60ml | 75 | 79700 | 5977500 |
| | | Susp. Amoxicillin 400mg, + Clavulanic Acid 57mg/5ml | 35ml | 85 | 7200 | 612000 |
| | | Susp. Amoxicillin 400mg, + Clavulanic Acid 57mg/5ml | 70ml | 135 | 500 | 67500 |
| 433 | P-0433 | (a) Tab/Cap Cephalexin 250mg | 12 | 120 | 0 | 0 |
| | | (b) Tab/Cap Cephalexin 500mg | 12 | 150 | 700 | 105000 |
| 434 | P-0434 | (a) Tab/Cap Cephadrine 250mg. | 12 | 140 | 0 | 0 |
| | | (b) Tab/Cap Cephadrine 500mg. | 12 | 194 | 5010 | 971940 |
| 435 | P-0435 | (a) Susp. Cephalexin 125mg/5ml. | 90ml | 200 | 200 | 40000 |
| | | (b) Susp.Cephadrine 125mg/5ml. | 60ml | 73 | 20650 | 1507450 |
| | | (c) Susp.Cephadrine 250mg/5ml. | 60ml | 125 | 10 | 1250 |
| 436 | P-0436 | Inj. Cephalzoline 500mg. | 1 | 164 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------|-----------|----------------|--------|------------------|
| | | Inj. Cephalexin 500mg. | 1 | 138 | 0 | 0 |
| | | Inj. Cephadrine 500mg. | Vial | 150 | 600 | 90000 |
| | | Inj. Cephadrine 1gm. | Vial | 60 | 10 | 600 |
| 437 | P-0437 | Tab. Trimethoprim 160mg,Sulphamethoxazole 800mg. | 100 | 535 | 6242 | 3339470 |
| 438 | P-0438 | Susp. Trimethoprim 40mg, Sulphamethoxazole 200mg/5ml. | 50ml | 41 | 92320 | 3785120 |
| 439 | P-0439 | Tab. Ciprofloxacin 250mg. | 10 | 43 | 9300 | 399900 |
| | | Tab. Ciprofloxacin 500mg. | 10 | 55 | 152900 | 8409500 |
| 440 | P-0440 | Cap. Doxycycline 100mg. | 120 | 644 | 4785 | 3081540 |
| 441 | P-0441 | Inj. Ceftriaxone 500mg | 1 | 50 | 25900 | 1295000 |
| | | Inj. Ceftriaxone 1000mg | 1 | 65 | 234200 | 15223000 |
| 442 | P-0442 | Inj. Ceftizoxime 500mg | 1 | 180 | 0 | 0 |
| | | Inj. Ceftizoxime 1000mg | 1 | 300 | 1000 | 300000 |
| 443 | P-0443 | Inj. Benzathine Penicilline 0.6 miu. | 1 | 20 | 0 | 0 |
| | | Inj. Benzathine Penicilline 1.2 miu. | 1 | 35 | 110 | 3850 |
| 444 | P-0444 | Inj. Gentamycin 40mg. | 5 | 65 | 200 | 13000 |
| | | Inj. Gentamycin 80mg. | 5 | 80 | 614 | 49120 |
| 445 | P-0445 | Tab. Clarithromycin 250mg. | 10 | 97 | 6510 | 631470 |
| | | Tab. Clarithromycin 500mg. | 10 | 142 | 14350 | 2037700 |
| 446 | P-0446 | Inj. Clarithromycin 500mg (Lyophilized) | 1 | 250 | 260 | 65000 |
| 447 | P-0447 | Inj. Ceftazidime 500mg. | 1 | 91 | 3350 | 304850 |
| | | Inj. Ceftazidime 1gm. | 1 | 126 | 5508 | 694008 |
| 448 | P-0448 | Susp. Nalidixic Acid 250mg/5ml. | 1 | 250 | 504 | 126000 |
| 449 | P-0449 | Cap. Cefixime 400mg. | 5 | 199 | 39992 | 7958408 |
| 450 | P-0450 | Susp.Cefixime 200mg/5ml | 30ml | 120 | 10405 | 1248600 |
| | | Susp.Cefixime 100mg/5ml | 60ml | 110 | 87500 | 9625000 |
| 451 | P-0451 | Inj.Cefoperazone + Salbactum 1gm | 1 | 85 | 4500 | 382500 |
| | | Inj.Cefoperazone + Salbactum 2gm | 1 | 119 | 13230 | 1574370 |
| 452 | P-0452 | Inj. Piperacillin 4gm + Tazabactam 500mg. | 1 | 274 | 12300 | 3370200 |
| 453 | P-0453 | Tab.Levofloxacin 250mg | 10 | 55 | 1000 | 55000 |
| | | Tab.Levofloxacin 500mg | 10 | 62 | 54550 | 3382100 |
| 454 | P-0454 | Inj.Levofloxacin 250mg | 1 | 35 | 0 | 0 |
| | | Inj.Levofloxacin 500mg | 1 | 41.95 | 1310 | 54954.5 |
| 455 | P-0455 | Cap.Clindamycin HCL 150mg | 10 | 150 | 100 | 15000 |
| | | Cap.Clindamycin HCL 300mg | 16 | 130.2 | 120 | 15624 |
| 456 | P-0456 | Susp.Clarithromycin 125mg/5ml | 60ml | 145 | 14050 | 2037250 |
| 457 | P-0457 | Cap. / Tab.Azithromycin 250mg | 6 | 59.4 | 7000 | 415800 |
| | | Cap. / Tab.Azithromycin 500mg | 5 | 94.5 | 19864 | 1877148 |
| 458 | P-0458 | Inj.Amikacin 100mg. | 5 | 30 | 1140 | 34200 |
| | | Inj.Amikacin 250mg | 1 | 40 | 1050 | 42000 |
| | | Inj.Amikacin 500mg | 1 | 47 | 4570 | 214790 |
| 459 | P-0459 | Tab.Cefuroxime Axetil 250mg. | 14 | 829.37 | 0 | 0 |
| 460 | P-0460 | Susp. Cefuroxime Axetil 125mg/5ml. | 1 | 190 | 0 | 0 |
| 461 | P-0461 | Inj.Vancomycin HCL 500mg (Lyophilized) | 1 | 165 | 450 | 74250 |
| | | Inj.Vancomycin HCL 1000mg (Lyophilized) | 1 | 275 | 2250 | 618750 |
| 462 | P-0462 | Inj.Cefepime HCL 500mg | 1 | 300 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|------------------------------------------------------|-----------|----------------|-------|------------------|
| | | Inj.Cefepime HCL 1000mg | 1 | 500 | 0 | 0 |
| 463 | P-0463 | Inj. Azithromycin 500mg | 1 | 171 | 10 | 1710 |
| 464 | P-0464 | Inj. Imipenam + Cilastatin (500mg) | 1 | 525 | 5800 | 3045000 |
| 465 | P-0465 | Clarithromycin 125mg/5ml Oral drops. | 30ml | 150 | 0 | 0 |
| 466 | P-0466 | Tab. Moxifloxacin 400mg. | 5 | 95.1 | 16810 | 1598631 |
| 467 | P-0467 | Inf. Moxifloxacin 400mg. | 1 | 115 | 7650 | 879750 |
| 468 | P-0468 | Inj. Tecopenam Sodium. | 1 | 2500 | 10 | 25000 |
| 469 | P-0469 | Tab.Linezolid 600mg | 12 | 249.2 | 2382 | 593594.4 |
| 470 | P-0470 | Inf. Linezolid 200mg | 1 | 400 | 0 | 0 |
| | | Inf. Linezolid 400mg | 1 | 450 | 0 | 0 |
| | | Inf. Linezolid 600mg | 300ml | 209 | 2650 | 553850 |
| 471 | P-0471 | Syp. Linezolid 100mg/5ml | 60ml | 300 | 224 | 67200 |
| 472 | P-0472 | Inj. Meropanam 500mg | 1 | 288 | 2700 | 777600 |
| | | Inj. Meropanam 1g | 1 | 438 | 7935 | 3475530 |
| 473 | P-0473 | Tab. Sodium Fusidate 250mg | 10 | 300 | 6 | 1800 |
| 474 | P-0474 | Inj. Fusidic Acid (as Diethanalamine Fusidate) 580mg | 1 | 150 | 4 | 600 |
| 475 | P-0475 | Susp. Sodium Fusidate 250mg / 5ml | 1 | 250 | 0 | 0 |
| 476 | P-0476 | Tab. Rifaximin 200mg | 20 | 200 | 0 | 0 |
| | | Tab. Rifaximin 550mg | 10 | 260 | 9190 | 2389400 |
| 477 | P-0477 | Cap. Fosfomycin 500mg | 10 | 100 | 310 | 31000 |
| 478 | P-0478 | Cap. Cefaclor 250mg | 12 | 250 | 0 | 0 |
| | | Cap. Cefaclor 500mg | 12 | 300 | 0 | 0 |
| 479 | P-0479 | Drops Cefaclor 50mg | 15ml | 149.17 | 90 | 13425.3 |
| | | Drops Cefaclor 100mg | 1 | 160 | 1000 | 160000 |
| | | Susp. Cefaclor 125mg | 60ml | 244.89 | 300 | 73467 |
| | | Susp. Cefaclor 250mg | 1 | 300 | 0 | 0 |
| 480 | P-0480 | Inj. Teicoplanin 200mg | 1 | 950 | 20 | 19000 |
| | | Inj. Teicoplanin 400mg | 1 | 1362 | 0 | 0 |
| 481 | P-0481 | Inj. Tigecycline 50mg | 1 | 1680 | 10 | 16800 |
| 482 | P-0482 | Inj. Colistimethate Sodium 80mg | 1 | 600 | 30 | 18000 |
| 483 | P-0483 | Susp.Ampicillin 125mg/5ml | 60ml | 200 | 0 | 0 |
| | | Susp.Ampicillin 250mg/5ml | 60ml | 230 | 0 | 0 |
| 484 | P-0484 | Susp. Ciproflxacin 125mg/5ml | 60ml | 57.98 | 5120 | 296857.6 |
| | | Susp. Ciproflxacin 250mg/5ml | 60ml | 98 | 520 | 50960 |
| 485 | P-0485 | Susp. Azithromycin 100mg/5ml | 15ml | 150 | 850 | 127500 |
| | | Susp. Azithromycin 200mg/5ml | 15ml | 88.4 | 460 | 40664 |
| | | Susp. Azithromycin 250mg/5ml | 15ml | 120 | 0 | 0 |
| 486 | P-0486 | Inj Amoxicillin and Salbactam 500mg | 1 | 100 | 0 | 0 |
| | | Inj Amoxicillin and Salbactam 750mg | 1 | 122 | 0 | 0 |
| | | Inj Amoxicillin and Salbactam 1000mg | 1 | 195 | 2500 | 487500 |
| | | Inj Amoxicillin and Salbactam 1.5g | 1 | 195 | 0 | 0 |
| 487 | P-0487 | Tab. Dapsone 100mg | 10 | 295 | 0 | 0 |
| | | (AC) ANTI TUBERCULOSIS | | | 0 | 0 |
| 488 | P-0488 | Tab. Ethambutol 400mg. | 5 | 10 | 0 | 0 |
| 489 | P-0489 | Tab. Pyrazinamide 500mg. | 10 | 5 | 0 | 0 |
| 490 | P-0490 | Tab/Cap. Rifampicin 600mg. | 30 | 50 | 0 | 0 |
| | | Tab/Cap. Rifampicin 150mg | 30 | 50 | 0 | 0 |
| | | Tab/Cap. Rifampicin 300mg. | 30 | 90 | 0 | 0 |
| | | Tab/Cap. Rifampicin 450mg. | 30 | 150 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-----------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 491 | P-0491 | Syp. Rifampicin 100mg/5ml | 60ml | 120 | 0 | 0 |
| 492 | P-0492 | Syp. Rifampicin 100mg+Isoniazid 50mg/5ml | 60ml | 200 | 0 | 0 |
| 493 | P-0493 | Syp. Isoniazid 50mg/5ml | 120ml | 200 | 0 | 0 |
| 494 | P-0494 | Inj. Streptomycin 1gm. | 5 | 150 | 40 | 6000 |
| 495 | P-0495 | Tab. Ethambutol HCl 300mg,+INH 75mg +Rifampicin 150mg. | 80 | 300 | 0 | 0 |
| 496 | P-0496 | Tab. Rifampicin 150mg+Isoniazid 75mg+Pyrazinamide 400mg + Ethambutol 275mg. | 80 | 300 | 0 | 0 |
| 497 | P-0497 | Tab.Ethionamide 250mg | 30 | 150 | 0 | 0 |
| 498 | P-0498 | Tab. Cycloserin 250mg. | 30 | 100 | 0 | 0 |
| | | (AD) ANTIMALARIALS. | | | 0 | 0 |
| 499 | P-0499 | Susp. Sulphadoxin 500mg+Pyrimethamine 25mg/5ml. | 1 | 250 | 100 | 25000 |
| 500 | P-0500 | Tab. Chloroquine Sulphate/Phosphate 250mg. | 100 | 186 | 1400 | 260400 |
| 501 | P-0501 | Tab. Sulfadoxine 500mg+Pyrimethamine 25mg. | 30 | 100 | 270 | 27000 |
| 502 | P-0502 | Tab.Halofantrine HCL 250mg. | 30 | 120 | 0 | 0 |
| 503 | P-0503 | Cap. Artemether 40mg. | 10 | 225 | 0 | 0 |
| 504 | P-0504 | Syp. Artemether 15mg/5ml | 1 | 150 | 900 | 135000 |
| 505 | P-0505 | Inj. Artemether 80mg/ml. | 5 | 450 | 202 | 90900 |
| 506 | P-0506 | Tab. Artimether 80mg + Lumefantrine 480mg. | 6 | 279.65 | 1360 | 380324 |
| | | Tab. Artimether 20mg + Lumefantrine 120mg. | 16 | 278.16 | 240 | 66758.4 |
| 507 | P-0507 | Susp. Arthmethether 15mg/5ml + Lumefantrine 90mg/5ml. | 60ml | 173.08 | 640 | 110771.2 |
| | | Susp. Arthmethether 30mg/5ml + Lumefantrine 180mg/5ml. | 60ml | 200 | 300 | 60000 |
| | | (AE) ANTI-DIABETICS. | | | 0 | 0 |
| 508 | P-0508 | Tab. Glibenclamide 5mg. | 500 | 740 | 2897 | 2143780 |
| 509 | P-0509 | Inj. Insulin NPH (Isophane Insuline) 100 Units/ml. | 1 | 370 | 6860 | 2538200 |
| | | Insulin Aspart - Human Insulin Analogue 100 I.U /ml | 5 | 3569.2 | 0 | 0 |
| 510 | P-0510 | Inj. Humen Insulin 70/30 (Recombinent DNA origin). | 1 | 365 | 146630 | 53519950 |
| | | Insulin Aspart / Protamine Crystalized (premix) Human Insulin Analogue 30 | 5 | 4947 | 0 | 0 |
| | | Insulin Aspart / Protamine Crystalized (premix) Human Insulin Analogue 50 | 5 | 4712 | 0 | 0 |
| 511 | P-0511 | Tab. Metformin 500mg. | 50 | 65.59 | 132130 | 8666406.7 |
| | | Tab. Metformin 850mg | 30 | 90 | 0 | 0 |
| 512 | P-0512 | Tab. Gliclazide 30mg. MR | 30 | 76.43 | 9500 | 726085 |
| | | Tab. Gliclazide 60mg. MR | 30 | 115.24 | 18290 | 2107739.6 |
| 513 | P-0513 | Inj. Insulin Plain 100 Units/ml (Regular) | 1 | 370 | 9175 | 3394750 |
| | | Insulin detemir (Basal Insulin Analogue) | 5 | 4329.5 | 0 | 0 |
| 514 | P-0514 | Tab. Acarbose 50mg. | 30 | 286 | 0 | 0 |
| | | Tab. Acarbose 100mg. | 30 | 500 | 0 | 0 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 515 | P-0515 | Tab.Glimepiride 2mg | 30 | 36.3 | 83210 | 3020523 |
| 516 | P-0516 | Tab. Pioglitazone 15mg | 14 | 113 | 0 | 0 |
| | | Tab. Pioglitazone 30mg | 14 | 164 | 0 | 0 |
| | | Tab. Pioglitazone 45mg | 14 | 194 | 0 | 0 |
| 517 | P-0517 | Tab. Pioglitazone 15mg + Metformin 500mg. | 14 | 97.36 | 560 | 54521.6 |
| | | Tab. Pioglitazone 15mg + Metformin 850mg. | 14 | 115.63 | 0 | 0 |
| 518 | P-0518 | Salt Free Albumin 20% | 1 | 14000 | 70 | 980000 |
| 519 | P-0519 | Tab. Sitagliptin 50mg | 14 | 65 | 1440 | 93600 |
| 520 | P-0520 | Tab. Gliclazide 80mg + Metformin 500mg | 20 | 172 | 0 | 0 |
| | | Tab. Gliclazide 160mg + Metformin 1000mg | 20 | 200 | 0 | 0 |
| 521 | P-0521 | Tab. Repaglinide 1mg | 30 | 600 | 0 | 0 |
| | | Tab. Repaglinide 2mg | 30 | 800 | 0 | 0 |
| 522 | P-0522 | Tab. Glibenclamide 5mg + Metformin 500mg | 30 | 250 | 0 | 0 |
| 523 | P-0523 | Tab. Sitagliptin 50mg + Metformin 500mg | 14 | 69 | 126500 | 8728500 |
| 524 | P-0524 | Tab. Vildagliptin 50mg | 10 | 275 | 10 | 2750 |
| 525 | P-0525 | Vildagliptin 50mg + Metformin 850mg | 14 | 348.99 | 0 | 0 |
| | | Vildagliptin 50mg + Metformin 1000mg | 14 | 155 | 2000 | 310000 |
| 526 | P-0526 | Glimepride 1mg + Metformin 500mg | 30 | 106 | 0 | 0 |
| | | Glimepride 2mg + Metformin 500mg | 30 | 117.3 | 1100 | 129030 |
| 527 | P-0527 | Tab. Dapagliflozin 5mg | 14 | 190.61 | 100 | 19061 |
| | | Tab. Dapagliflozin 10mg | 14 | 112.2 | 5180 | 581196 |
| 528 | P-0528 | Tab. Empagliflozin 10mg | 14 | 175.14 | 150 | 26271 |
| | | Tab. Empagliflozin 25mg | 14 | 296.44 | 0 | 0 |
| 529 | P-0529 | Tab. Empagliflozin 5mg + Metformin 1000mg | 14 | 189.04 | 110 | 20794.4 |
| 530 | P-0530 | Tab. Dapagliflozin 5mg / Metformin 1000mg | 14 | 228.48 | 0 | 0 |
| 531 | P-0531 | Tab. Linagliptin 5mg | 10 | 250 | 0 | 0 |
| 532 | P-0532 | Tab. Empagliflozin + Linagliptin 10/5mg | 14 | 350 | 0 | 0 |
| | | Tab. Empagliflozin + Linagliptin 25/5mg | 14 | 500 | 0 | 0 |
| | | (AF) VITAMINS/MINERALS/HAEMATIN ICS: | | | 0 | 0 |
| 533 | P-0533 | Syp. Calcium. | 110ml | 90 | 18900 | 1701000 |
| 534 | P-0534 | (a) Tab. Calcium Gluconate. | 30 | 65 | 1700 | 110500 |
| | | (b) Tab. Calcium Lactate 300mg | 30 | 100 | 0 | 0 |
| | | (c) Tab. Calcium Phosphate | 30 | 80 | 0 | 0 |
| | | (d) Tab. Calcium Carbonate 50mg | 30 | 120 | 10800 | 1296000 |
| | | (e) Tab. Calcium Carbonate 1250mg | 30 | 120 | 0 | 0 |
| | | (f) Tab. Calcium Acetate 667mg | 30 | 80 | 500 | 40000 |
| 535 | P-0535 | Inj. Thiamine 100mg, Pyridoxine 100mg, Cyanocobalamine 1000mcg/3ml. | 25 | 493.97 | 437 | 215864.89 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 536 | P-0536 | Syp. Ferrous Sulphate | 120ml | 80 | 1100 | 88000 |
| | | Syp. Ferrous Gluconate, Vitamin B1 1mg, B2 1mg, B6 1.5mg, Nicotinamide 15mg, Biotin 300mcg | 120ml | 68.31 | 14300 | 976833 |
| 537 | P-0537 | Syp. Ferrous Sulphate 131mg, Ascorbic acid 125mg, cyanocobamine 6.25mcg, D-Pantothenol 2.5mg, Nicotinamide 7.5mg, B6 1.5mg, B2 1.5mg, B1 1.5mg with Folic Acid | 120ml | 69.69 | 12700 | 885063 |
| 538 | P-0538 | (a)Tab. Ferrous Sulphate with Folic Acid. | 30 | 151.87 | 15876 | 2411088.12 |
| | | (b)Tab. Ferrous Fumerate with Folic Acid. | 30 | 22 | 84400 | 1856800 |
| 539 | P-0539 | Tab. Folic Acid 5mg. | 30 | 40 | 6720 | 268800 |
| | | Tab. Methylfolate 400mcg | 30 | 40 | 100 | 4000 |
| 540 | P-0540 | Tab. Vit-B-Complex with Vitamin C | 30 | 108.41 | 4800 | 520368 |
| 541 | P-0541 | Syp. Vit. B.Complex | 120ml | 66.55 | 30700 | 2043085 |
| 542 | P-0542 | Tab. Pyridoxine 50mg. | 20 | 42 | 935 | 39270 |
| 543 | P-0543 | Drops Multivitamin each 0.6ml contains:- Vitamin A 1.5mg, Vitamin D 10mcg Vitamin B1 1.5mg, Vitamin B2 1.2mg + Vitamin B6 0.5mg, Vitamin C 50mg, Nicotinamide 10mg | 10ml | 150 | 260 | 39000 |
| 544 | P-0544 | Drop Iron polymaltose | 30ml | 60 | 20 | 1200 |
| 545 | P-0545 | Tab. Vitamin C 500mg. | 40 | 128.66 | 955 | 122870.3 |
| 546 | P-0546 | Inj. Calcitriol (Vitamin D analogue) 1mcg/ml. | 10 | 1700 | 20 | 34000 |
| 547 | P-0547 | Inj. Calcium Gluconate 10ml. | 1 | 50 | 3670 | 183500 |
| 548 | P-0548 | Tab. Multivitamin with Minerals. | 30 | 94.11 | 6050 | 569365.5 |
| 549 | P-0549 | Tab. Alfacalcidol 0.50mcg. | 20 | 175.95 | 6500 | 1143675 |
| 550 | P-0550 | Drops Alfacalcidol 2mcg/ml | 20ml | 200 | 20 | 4000 |
| 551 | P-0551 | Inj. Iron Sorbitol Citric Acid Complex BP equivalent to 75mg Iron+Hydroxocobalamine Acetate 75mcg as vit-B12 + Folic Acid 750mcg. | 10 | 324 | 0 | 0 |
| 552 | P-0552 | Inj. Cholecalciferol (Vit-D3) 200,000 IU equal to 5mg/ml (Amp). | 1 | 174.9 | 84550 | 14787795 |
| 553 | P-0553 | Inj. Phytomenadione 10mg | 1 | 210 | 350 | 73500 |
| | | Inj. Phytomenadione 2mg/2ml | 1 | 120 | 1210 | 145200 |
| 554 | P-0554 | Cap. Ferrous Sulphate 150mg (eq to 47mg Fe) + Folic Acid 0.5mg + Thiamine mononitrate 2mg + Riboflavine 2mg + Pyridoxine HCL 1mg+ Nicotinamide 10mg + Ascorbic Acid 50mg. | 56 | 230 | 11200 | 2576000 |
| 555 | P-0555 | Tab. Calcium + Vit-D | 30 | 74.4 | 115610 | 8601384 |
| 556 | P-0556 | Inj. Iron Sucrose 20mg/ml | 5 | 241.25 | 6550 | 1580187.5 |
| 557 | P-0557 | Tab. Iron Polymaltose Complex equal to Iron 100mg, Folic Acid 0.35mg. | 30 | 79 | 30 | 2370 |
| 558 | P-0558 | Tab .Mecobalamine 500mcg | 100 | 162 | 40000 | 6480000 |
| 559 | P-0559 | Inj. Mecobalamine 500mcg/ml | 10 | 85 | 14120 | 1200200 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 560 | P-0560 | Tab./ Cap. Ossein mineral Complex 830mg (Equiv to Calcium 177.6mg, Phosphorus 82.2mg, residual mineral salt 24.8mg Collagen 224mg, other proteins 88.4mg trece elements FL, Mg, Zn, Fe, Ni, Cu) corresponding to approximate 440mg Hydroxyapatite, Vitamin D | 30 | 79 | 6010 | 474790 |
| 561 | P-0561 | Syp. / Susp. Per 5ml; Ossein mineral complex i.e Hydroxyapatite compd. 250 mg (equiv to calcium 53.5, Phosphorous 24.8 mg, residual mineral salts 7.5mg, collagen 87.5 mg, other proteins 20 mg, trace elements Fl, Mg, Zn, Fe, Ni, Cu), Vit D | 120ml | 88 | 1300 | 114400 |
| 562 | P-0562 | Cap. Ferrous gluconate 250 mg, vits B12, vit C 50mg, folic acid 1mg, sorbitol 25 mg cooper sulphate 200mcg manganese sulphate 200 mcg. | 30 | 150 | 0 | 0 |
| 563 | P-0563 | Tab. Vitamin B1, B6, B12 combination | 60 | 157.25 | 1200 | 188700 |
| 564 | P-0564 | Cap./ Tab. Vitamin A | | | 40 | 0 |
| 565 | P-0565 | Drops Vitamin A | 1 | 150 | 20 | 3000 |
| 566 | P-0566 | Cap. Vitamin E 200mg | 100 | 400 | 20 | 8000 |
| | | Cap. Vitamin E 400mg | 100 | 700 | 104 | 72800 |
| 567 | P-0567 | Inj. Ferric carboxymaltose 50mg/ml | 1 | 150 | 210 | 31500 |
| 568 | P-0568 | Tab. Histidine 38mg, Isolucine 67mg, leucine 101mg, lysine 105mg, methionine 59mg, threonine 53mg, trptophan 23mg, tyrosine 30mg | 100 | 800 | 4 | 3200 |
| 569 | P-0569 | Cap Omega-3-Acid Ethyl Esters | 60 | 1000 | 30 | 30000 |
| | | (AG) EXPECTORANTS/COUGH SUPPRESSANTS/ | | | 0 | 0 |
| | | ANTI- TUSSIVE/BRONCHOSPASM RELAXANTS. | | | 0 | 0 |
| 570 | P-0570 | Syp.Dextromethorphen 10mg, Pseudoephedrine 30mg + Chlorpheniramine Meleate 2mg | 1 | 30 | 7012 | 210360 |
| 571 | P-0571 | (a)Syp.Aminophylline 32mg, Diphenhydramine 8mg,Ammonium Chloride 30mg, Menthol 0.98mg per 5ml.(NORMAL) | 120ml | 28.35 | 441380 | 12513123 |
| | | (b)Syp.Aminophylline 32mg, Diphenhydramine 8mg,Ammonium Chloride 30mg, Menthol 0.98mg, per 5ml.(SUGAR FREE) | 120ml | 52.79 | 800 | 42232 |
| 572 | P-0572 | Syp Ammonium Chloride 100mg,Sodium Citrate 60mg, Chlorpheniramine Maleate 2mg, Ephedrine HCL 7mg, Menthol 1mg/5ml. | 1 | 35 | 29020 | 1015700 |
| 573 | P-0573 | Syp Theophylline Sodium Glycinate 150mg / 5ml | 1 | 30 | 500 | 15000 |
| 574 | P-0574 | Tab.Theophylline 300mg. | 100 | 642 | 260 | 166920 |
| 575 | P-0575 | Inj. Aminophylline 250mg/10ml. | 5 | 150 | 33 | 4950 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 576 | P-0576 | Inj. Salbutamol 0.5mg/ml. | 5 | 150 | 0 | 0 |
| 577 | P-0577 | Tab. Salbutamol 2mg. | 100 | 350 | 2530 | 885500 |
| 578 | P-0578 | Syp. Pholcodine 5mg / 5ml | 1 | 30 | 150 | 4500 |
| 579 | P-0579 | Salbutamol 100mcg per Inhalation, 200 Puff | 1 | 158 | 4960 | 783680 |
| 580 | P-0580 | Salbutamol 100mcg, Beclomethasone Dipropionate 50mcg, 200 Inhalation. | 1 | 195 | 12430 | 2423850 |
| 581 | P-0581 | Syp. Terbutaline 1.5mg/5ml. | 60ml | 26 | 59300 | 1541800 |
| 582 | P-0582 | Tab. Terbutaline Sulphate 2.5mg. | 100 | 125 | 4845 | 605625 |
| 583 | P-0583 | Budesonide 200mcg + Formeterol 6 mcg Inhaler | 1 | 350 | 10 | 3500 |
| 584 | P-0584 | Solution Ipratropium Bromide 250mcg/ml for nebuliser. | 20ml | 116.82 | 3474 | 405832.68 |
| 585 | P-0585 | Salmetrol 50mcg + Fluticasone 100mg. Powder | 1 | 700 | 40 | 28000 |
| | | Salmetrol 50mcg + Fluticasone 250mg. Powder | 1 | 750 | 40 | 30000 |
| | | Salmetrol 50mcg + Fluticasone 500mg. Powder | 1 | 800 | 940 | 752000 |
| 586 | P-0586 | Tab.Bambuterol HCL 10mg. | 30 | 98 | 200 | 19600 |
| | | Tab.Bambuterol HCL 20mg. | 10 | 272 | 500 | 136000 |
| 587 | P-0587 | Tab. Montelukast 4mg | 14 | 61 | 100 | 6100 |
| | | Tab. Montelukast 10mg | 14 | 53.5 | 46620 | 2494170 |
| 588 | P-0588 | Inhaler Beclomethasone Dipropionate 50 mcg | 1 | 450 | 0 | 0 |
| | | Inhaler Beclomethasone Dipropionate 100 mcg | 1 | 629.75 | 70 | 44082.5 |
| | | Inhaler Beclomethasone Dipropionate 250 mcg | 1 | 473.12 | 50 | 23656 |
| | | Inhaler Beclomethasone Dipropionate 800 mcg | 1 | 500 | 0 | 0 |
| 589 | P-0589 | Syp. Acefylline 125mg/5ml. | 1 | 82 | 13600 | 1115200 |
| 590 | P-0590 | Sachets Acetylcysteine 200mg / 3gm | 30 | 500 | 114 | 57000 |
| 591 | P-0591 | Syp. Salbutamol 2mg/5ml. | 120ml | 28 | 3080 | 86240 |
| | | Salbutamol Solution 5mg/ml. (Nebulizing) | 20ml | 43 | 1720 | 73960 |
| 592 | P-0592 | Formeterol Fumerate 6mcg + Beclomethasone Diapropionate 100mcg / Dose | 1 | 1031 | 2050 | 2113550 |
| 593 | P-0593 | Monteleukast 4mg Powder | 14 | 79 | 1556 | 122924 |
| 594 | P-0594 | Beclomethasone Dipropionate Solution for Nebulisation | 10 | 76.41 | 5270 | 402680.7 |
| 595 | P-0595 | Tab. Formoterol fumarate 80mcg | 10 | 230 | 0 | 0 |
| 596 | P-0596 | Tab. Bamifylline 600mg | 30 | 640 | 662 | 423680 |
| 597 | P-0597 | Tab. Doxofyline 400mg | 10 | 66.64 | 14210 | 946954.4 |
| 598 | P-0598 | Syp. Doxofyline 100mg/5ml | 60ml | 59.9 | 600 | 35940 |
| 599 | P-0599 | Inj. Terbutaline 0.5mg | 5 | 85 | 0 | 0 |
| 600 | P-0600 | Syp. Pholcodine: 1.5mg, 5ml, Alcohol: 3.8% V/V, Promethazine (HCL): 1.5mg/5ml | 1 | 28 | 500 | 14000 |
| 601 | P-0601 | Syp. ACefyline 125mg/5ml, Diphenhydramine 45mg/5ml | 60ml | 45 | 100 | 4500 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|----------------------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 602 | P-0602 | Inhaler Fluticasone Propionate 125mcg/actu | 1 | 400 | 0 | 0 |
| | | Inhaler Fluticasone Propionate 250mcg/actu | 1 | 500 | 0 | 0 |
| 603 | P-0603 | Syp Diphenhydramine 12.5mg/5ml | 60ml | 15 | 0 | 0 |
| | | Syp Diphenhydramine 13.5mg/5ml | 60ml | 20 | 0 | 0 |
| 604 | P-0604 | Cap. Tiotropium 18mcg DPI | 30 | 550.5 | 200 | 110100 |
| | | (AH) OPHTHALMIC PREPARATIONS: | | | 0 | 0 |
| 605 | P-0605 | Nepafenac 0.1% Eye Drops | 5ml | 115 | 5100 | 586500 |
| 606 | P-0606 | Chloramphenicol Drops 0.5%. | 10ml | 38 | 22400 | 851200 |
| 607 | P-0607 | Oint. Chloramphenicol 1%. | 1 | 30 | 1335 | 40050 |
| 608 | P-0608 | Oint. Chloramphenicol 1%, Hydrocortisone Acetate 0.5%. | 1 | 35 | 1130 | 39550 |
| 609 | P-0609 | Polymyxin-B Sulphate 5000 units, Neomycin Sulphate 3400 units, bacitracin 400 units, hydrocortisone 10mg Oint. | 3gm | 28.6 | 10345 | 295867 |
| 610 | P-0610 | Prednisolone Acetate 1% Drops. | 5ml | 47 | 5970 | 280590 |
| 611 | P-0611 | Betamethasone 0.1% drops. | 7.5ml | 43 | 1310 | 56330 |
| 612 | P-0612 | Tab.Acetazolamide 250mg. | 30 | 197 | 134 | 26398 |
| 613 | P-0613 | (a) Drops Betoxalol 0.5% | 1 | 100 | 0 | 0 |
| | | (b)Timolol Drops 0.5% | 5ml | 84 | 1456 | 122304 |
| | | (c) Levobunolol Drops 0.5%. | 1 | 185 | 20 | 3700 |
| 614 | P-0614 | Sodium Cromoglycate drops 4%. | 1 | 58 | 390 | 22620 |
| 615 | P-0615 | Phenylephrine 10% Drops. | 1 | 80 | 71 | 5680 |
| 616 | P-0616 | Tropicamide1% Drops. | 15ml | 120 | 134 | 16080 |
| 617 | P-0617 | Drops Dexemethasone 0.1% Neomycine Sulphate 0.35%, Hyperomellose 0.5%, Polymyxin B-Sulphate 6000 units/ml. | 1 | 120 | 446 | 53520 |
| 618 | P-0618 | Drops Pyrilamine maleate 0.1%, Phenylepherine HCL 0.12%. | 10ml | 70 | 504 | 35280 |
| 619 | P-0619 | Diclofenac Sod. Eye Drops. | 5ml | 42 | 2126 | 89292 |
| 620 | P-0620 | Ciprofloxacin 0.3% Eye Drops. | 5ml | 42 | 3280 | 137760 |
| 621 | P-0621 | Tobramycine Eye Drops. | 5ml | 68 | 6980 | 474640 |
| 622 | P-0622 | Acyclovir Eye Ointment 3% | 4.5gm | 200 | 118 | 23600 |
| 623 | P-0623 | Drops .Proparacaine HCL 0.5% + Benzalkonium Chloride 0.01% | 1 | 121 | 65 | 7865 |
| 624 | P-0624 | Drops. Cyclopentolate HCL 1%. | 1 | 150 | 25 | 3750 |
| 625 | P-0625 | Drops Naphazoline HCL 0.025% + Phenarmine Maleate 0.3%. | 1 | 135 | 290 | 39150 |
| 626 | P-0626 | Drops Fluoromethalone 0.1% + Tetrahyrozoline HCL 0.25% | 5ml | 49 | 5540 | 271460 |
| 627 | P-0627 | Drops Atropine Sulphate 1%. | 1 | 45 | 114 | 5130 |
| 628 | P-0628 | Drops Travoprost 40mcg/ml. | 2.5ml | 395 | 1706 | 673870 |
| 629 | P-0629 | Oint. Polymixin B Sulphate 10000 u + Zinc Bacitracin 500 Units/gm. | 6gm | 28.7 | 11220 | 322014 |
| 630 | P-0630 | Drops Dorzolamide HCL 2%. | 1 | 250 | 74 | 18500 |
| 631 | P-0631 | Drops Dorzolamide HCL 2% + Timolol Maleate 0.5%. | 5ml | 136 | 2570 | 349520 |
| 632 | P-0632 | Drops Latanoprost 50mcg/ml | 2.5ml | 290 | 1695 | 491550 |
| 633 | P-0633 | Drops Brinzolamide 1% | 1 | 175 | 4 | 700 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 634 | P-0634 | Drops Brimonidine Tartrate 0.2% | 5ml | 155 | 1710 | 265050 |
| 635 | P-0635 | Drops Ofloxacin 0.3%. | 5ml | 39 | 1034 | 40326 |
| 636 | P-0636 | Drops Fusidic Acid 1% | 1 | 80 | 140 | 11200 |
| 637 | P-0637 | Drops Tobramycin 0.3% + Dexamethasone 0.1% | 5ml | 36 | 6980 | 251280 |
| 638 | P-0638 | Drops Natamycin 5% | 5ml | 120 | 84 | 10080 |
| 639 | P-0639 | Drops Dexamethasone 0.1%. | 1 | 100 | 172 | 17200 |
| 640 | P-0640 | Drops Sod. Cromoglycate 40mg + Tetrahydrozoline HCL 0.5mg/ml. | 1 | 200 | 860 | 172000 |
| 641 | P-0641 | Drops Lodoxamide Tromethamine 0.1%. | 1 | 280 | 0 | 0 |
| 642 | P-0642 | Drops Chloramphenicol 0.5% + Dexamethasone 0.1%. | 1 | 120 | 800 | 96000 |
| 643 | P-0643 | Drops Polyvinyl Alcohol 1.4%. | 1 | 100 | 4960 | 496000 |
| 644 | P-0644 | Oint. Miconazol Nitrate 2% | 1 | 106 | 0 | 0 |
| 645 | P-0645 | Polyacrylic Acid gel | 1 | 130 | 3670 | 477100 |
| 646 | P-0646 | Drops Moxifloxacin 0.5% | 5ml | 32.95 | 10020 | 330159 |
| 647 | P-0647 | Eye Drops Olopatadine 1mg (1%) | 5ml | 200 | 740 | 148000 |
| | | Eye Drops Olopatadine 2mg (2%) | 1 | 313 | 200 | 62600 |
| 648 | P-0648 | Eye Drops Loteprednol etabonate 0.5% | 5ml | 185 | 74 | 13690 |
| 649 | P-0649 | 5% Hypertonic Saline Eye Drops | 1 | 50 | 110 | 5500 |
| 450 | P-0650 | Moxifloxacin Eye Ointment | 1 | 100 | 100 | 10000 |
| 651 | P-0651 | Cyclosporin Eye Drops | 1 | 300 | 4 | 1200 |
| 652 | P-0652 | Phenylephrine (Hcl) 0.12% w/w, prednisolone :- 0.2% w/w, sulphacetamide : 10% w/w | 1 | 250 | 20 | 5000 |
| | | (AI) DERMATOLOGICAL PREPARATIONS. | | | 0 | 0 |
| 653 | P-0653 | Oint (Skin) Polymyxin B.Sulphate 10,000 Units, Zinc Bacitracin 500 units. | 20gm | 66 | 50275 | 3318150 |
| 654 | P-0654 | Betamethasone Skin Oint. 0.1%. | 20gm | 60 | 36350 | 2181000 |
| 655 | P-0655 | Permethrine 5% Cream. | 30 gm | 39 | 62700 | 2445300 |
| 656 | P-0656 | Cream Betamethasone 0.1%. | 20gm | 56 | 30900 | 1730400 |
| 657 | P-0657 | Cream Clobetasol Propionate 0.05%. | 20gm | 74 | 10900 | 806600 |
| | | Ointment Clobetasol | 1 | 33 | 7200 | 237600 |
| 658 | P-0658 | Ext. Cepae 10gm + Hepasim Sod.5000 IU + Allantoin 1gm + water Soluble fat free hydrogel base gel. | 1 | 150 | 0 | 0 |
| 659 | P-0659 | Susp. Acyclovir 200mg/5ml. | 1 | 400 | 0 | 0 |
| 660 | P-0660 | Tab. Acyclovir 400mg | 20 | 1000 | 74 | 74000 |
| | | Tab. Acyclovir 800mg | 10 | 2223.5 | 910 | 2023385 |
| 661 | P-0661 | Cream Hydroquinone 2%. | 1 | 35 | 1120 | 39200 |
| | | Cream Hydroquinone 4%. | 10gm | 51 | 1620 | 82620 |
| 662 | P-0662 | Cream Tretinoin 0.05%. | 1 | 150 | 250 | 37500 |
| 663 | P-0663 | Oint.Betamethasone Dipropionate 0.05% + Salicylic Acid 3% | 15gm | 48 | 11400 | 547200 |
| 664 | P-0664 | Cream Hydrocortisone 1%. | 10gm | 80 | 4350 | 348000 |
| | | Ointment Hydrocortisone 1%. | 5gm | 100 | 300 | 30000 |
| 665 | P-0665 | Cream Benzoyl Peroxide 4%. | 1 | 250 | 20 | 5000 |
| 666 | P-0666 | Oint. Bacitracin Zinc B.P 500u + Polymixin B Sulphate 10,000u, Lignocain B.P 40mg/gm. | 20gm | 30 | 4740 | 142200 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------|-----------|----------------|-------|------------------|
| 667 | P-0667 | Cap. Isotretinoin 20mg. | 10 | 2000 | 200 | 400000 |
| 668 | P-0668 | Tab. Terbinafine 250mg. | 10 | 78.5 | 12500 | 981250 |
| 669 | P-0669 | Clindamycine 10ml Gel. | 10gm | 107 | 1400 | 149800 |
| 670 | P-0670 | Mupirocine Ointment 2% | 15gm | 250 | 0 | 0 |
| 671 | P-0671 | Betamethasone Lotion. | 60ml | 86 | 3350 | 288100 |
| 672 | P-0672 | Tab.Ivermectin 3mg | 10 | 250 | 40 | 10000 |
| | | Tab.Ivermectin 6mg | 10 | 375 | 146 | 54750 |
| 673 | P-0673 | Cream Acyclovir 5% | 1 | 450 | 16 | 7200 |
| 674 | P-0674 | Isotretinoin Gel 0.05% | 10gm | 250 | 2620 | 655000 |
| 675 | P-0675 | Isotretinoin + Clindamycine Gel | 1 | 250 | 200 | 50000 |
| 676 | P-0676 | Benzyl Peroxide 5% + Clindamycin 1% Gel / Cream | 1 | 180 | 0 | 0 |
| 677 | P-0677 | Cream Fucidic acid 2% | 15gm | 75 | 15520 | 1164000 |
| | | Fucidic Acid 2% Ointment | 15gm | 100 | 3060 | 306000 |
| 678 | P-0678 | Cream Fenticonazole 2% | 10gm | 150 | 400 | 60000 |
| 679 | P-0679 | Fluticasone Cream 0.05% | 5gm | 52.66 | 5800 | 305428 |
| | | Fluticasone Ointment 0.05% | 10gm | 130 | 1000 | 130000 |
| 680 | P-0680 | Inj. Omalizumab | 1 | 38000 | 0 | 0 |
| 681 | P-0681 | Inj. Secukinumab 150mg | 1 | 59468 | 0 | 0 |
| 682 | P-0682 | Cream Terbinafine 1% w/w 10gm | 1 | 39 | 5000 | 195000 |
| 683 | P-0683 | Oint. Triamcinolone in ora base 0.1% w/w 5g | 5g | 135 | 60 | 8100 |
| 684 | P-0684 | Oint. Tacrolimus 0.1% 10gm | 1 | 174 | 1050 | 182700 |
| | | Oint. Tacrolimus 0.03% 10gm | 1 | 78 | 0 | 0 |
| 685 | P-0685 | Oint. Psoriatic B.P | 1 | 200 | 0 | 0 |
| 686 | P-0686 | Cap. Acitretin 25mg | 30 | 714 | 0 | 0 |
| 687 | P-0687 | Gel Fluocinolone 0.025% | 15gm | 215 | 6 | 1290 |
| 688 | P-0688 | Ointment Fluocinolone 0.025% | 15gm | 350 | 6 | 2100 |
| 689 | P-0689 | Ointment Mometasone Furoate 0.1% | 5gm | 238 | 6 | 1428 |
| 690 | P-0690 | Petroleum Jelly | 1 | 35 | 5250 | 183750 |
| 691 | P-0691 | Sun Block SPF 50 or above | 1 | 350 | 60 | 21000 |
| 692 | P-0692 | Lactic Acid 15% + Salicylic Acid 16.7% in Flexible Colloidal Base | 1 | 200 | 4 | 800 |
| 693 | P-0693 | Tab. Tofacitinib Citrate 5mg | 10 | 4000 | 2 | 8000 |
| | | (AJ) LOCAL/ GENERAL ANAESTHETICS: | | | 0 | 0 |
| 694 | P-0694 | Inj.Glycopyrrolate 0.5mg + Neostigmine methylsulphate 2.5mg/1ml Amp | 10 | 539 | 196 | 105644 |
| 695 | P-0695 | Inj.Ketamine HCL 50mg/ml. (2ml) | 5 | 200 | 624 | 124800 |
| | | Inj.Ketamine HCL 50mg/ml. (10ml) | vial | 35 | 1060 | 37100 |
| 696 | P-0696 | Inj. Bupivacaine 0.5%.(Plain) (10ml) | 10 | 235 | 28 | 6580 |
| | | Inj.Bupivacaine Spinal 0.5% (4ml) | 5 | 200 | 0 | 0 |
| | | Inj.Bupivacaine Spinal 0.75% (2ml) | 5 | 166 | 1510 | 250660 |
| 697 | P-0697 | Lignocaine Gel. 2%. | 1 | 17 | 16600 | 282200 |
| | | Lignocaine Ointment 5%. | 15gm | 20 | 1314 | 26280 |
| 698 | P-0698 | Inj. Lignocaine 2% (2ml) | 1 | 30 | 100 | 3000 |
| | | Inj. Lignocaine 2% (10ml) | 50 | 770 | 174 | 133980 |
| 699 | P-0699 | Inj. Lignocaine 2% with Adrenaline 0.001%. | 5 | 200 | 212 | 42400 |
| 700 | P-0700 | Lignocaine Solution 4%. | 1 | 200 | 10 | 2000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-------------------------------------------------------------------------------|-----------|----------------|------|------------------|
| 701 | P-0701 | Isoflorane Liquid Inhalation | 1 | 2855 | 369 | 1053495 |
| 702 | P-0702 | Sevoflurane Liquid for Inhalation | 1 | 8124 | 120 | 974880 |
| 703 | P-0703 | Inj .Propofol 10mg/ml | 5 | 1700 | 858 | 1458600 |
| 704 | P-0704 | Inj.Ephedrine HCL 30mg/ml | 1 | 75 | 32 | 2400 |
| 705 | P-0705 | Inj. Adrenaline 1mg/ml | 5 | 15 | 1022 | 15330 |
| 706 | P-0706 | Inj.Ketorolac 30mg/ml | 5 | 120 | 400 | 48000 |
| 707 | P-0707 | Inj.Fentanyl 0.05mg/ml | 10 | 2660 | 0 | 0 |
| 708 | P-0708 | Inj. Etomidate 20mg/10ml | 1 | 450 | 0 | 0 |
| 709 | P-0709 | Inj. Nor-Adrenaline 1mg/ml | 10 | 775 | 162 | 125550 |
| 710 | P-0710 | Inj. Phenyl Ephedrine 10mg/ml | 1 | 282 | 370 | 104340 |
| 711 | P-0711 | Inj. Glycopyrrolate 0.2mg / ml | 10 | 153 | 6 | 918 |
| 712 | P-0712 | Inj. Ropivacaine 50mg/10ml | 1 | 142 | 0 | 0 |
| 713 | P-0713 | Inj. Lignocain 2% with Adrenaline .001% Dental Cartridge Ampoule 1.2ml, 1.8ml | 1 | 50 | 3250 | 162500 |
| | | (AK) ANAESTHETICS ADJUVANTS (NEUROMUSCULAR BLOCKER). | | | 0 | 0 |
| 714 | P-0714 | Inj. Atracurium Besylate 10mg/ml (2.5ml) | 5 | 470 | 80 | 37600 |
| | | Inj. Atracurium Besylate 10mg/ml (3ml) | 5 | 595 | 1382 | 822290 |
| | | Inj. Atracurium Besylate 10mg/ml (5ml) | 5 | 600 | 26 | 15600 |
| 715 | P-0715 | Inj. Suxamethonium Chloride 100mg. | 10 | 388 | 121 | 46948 |
| 716 | P-0716 | Inj. Cisatracurium 50mg/5ml | 5 | 2550 | 0 | 0 |
| 717 | P-0717 | Dexmedetomidine 200mcg / 2mcg | 2 | 1800 | 2 | 3600 |
| | | (AL) ANTISEPTIC/DISINFECTANTS | | | 0 | 0 |
| 718 | P-0718 | Chloroxylonol Solution B.P. | 45ml | 30 | 170 | 5100 |
| 719 | P-0719 | Chlorhexidine Gluconate 1.5% Solution. | 1 | 50 | 0 | 0 |
| | | Chlorhexidine Gluconate 4% GEL | 1 | 50 | 0 | 0 |
| 720 | P-0720 | Chlorhexidine Gluconate Solution 1.5% + Cetrime 15%. | 1 | 50 | 0 | 0 |
| 721 | P-0721 | Skin Lotion Povidone Iodine 10gm/100ml. | 450ml | 416 | 8698 | 3618368 |
| | | Skin Lotion Povidone Iodine 10gm/100ml. | 60ml | 77 | 4260 | 328020 |
| 722 | P-0722 | Surgical Scrub Povidone Iodine 7.5mg/100ml | 450ml | 468 | 1522 | 712296 |
| | | Surgical Scrub Povidone Iodine 7.5mg/100ml | 60ml | 748 | 96 | 71808 |
| 723 | P-0723 | Tetrachlorodecaoxide Solution. | 50ml | 200 | 240 | 48000 |
| 724 | P-0724 | Chlorhexidine Gluconate w/v 0.2% Mouth Wash. | 1 | 200 | 40 | 8000 |
| 725 | P-0725 | Alcohol base Antiseptic Lotion/gel. | 1 | 410 | 500 | 205000 |
| 726 | P-0726 | Dedecyl Dimethyl Ammonium Chloride Solution | 1 | 1000 | 0 | 0 |
| 727 | P-0727 | Hydrogen Peroxide | 450ml | 1000 | 116 | 116000 |
| 728 | P-0728 | Carbolic Acid | 400ml | 1000 | 308 | 308000 |
| 729 | P-0729 | Formaline | 400ml | 1000 | 248 | 248000 |
| 730 | P-0730 | Methylated Spirit | 1 Ltr | 1000 | 2570 | 2570000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------------------------------------------------------------|-----------|----------------|--------|------------------|
| 731 | P-0731 | Povidone Iodine Mouthwash / Gargles 1% | 60ml | 65 | 4 | 260 |
| | | (AM) DRESSINGS. | | | 0 | 0 |
| 732 | P-0732 | Cotton Bandages Guaze BPC specification Loose Woven | 30mtr | 904 | 6834 | 6177936 |
| 733 | P-0733 | Cotton Bandages BPC 5cm x 6m. | 12 | 297 | 3089 | 917433 |
| | | Cotton Bandages BPC 6.5cm x 6m. | 12 | 387 | 2480 | 959760 |
| 734 | P-0734 | Cotton Crape Bandages 7.5cm x 4.5m. | 12 | 768 | 1175 | 902400 |
| | | Cotton Crape Bandages 10cmx 4.5m. | 12 | 846 | 1080 | 913680 |
| 735 | P-0735 | Cotton Wool BPC 500gm. | 500gm | 290 | 10760 | 3120400 |
| 736 | P-0736 | Plaster of paris Bandages BPC Cal. Sulphate Hydrated 90% Kubab Gauze Cloth 10% 10cmx 2.7m. | 48 | 5328 | 116 | 618048 |
| | | Bandages Plaster of paris 15cmx2.7meter. | 48 | 6576 | 86 | 565536 |
| 737 | P-0737 | Plaster of paris, spool of 7.5cmx10m Bandage | 1 | 1000 | 4495 | 4495000 |
| 738 | P-0738 | (a) Lano Paraffin Gauze Sterilized dressing impregnated with Framycetin 10cmx 10cm: | 1 | 1000 | 0 | 0 |
| | | (b)Antibiotic Tulle Dressing | 10 | 167 | 136 | 22712 |
| | | (e) Anticeptic Tulle Dressing | 1 | 200 | 1050 | 210000 |
| 739 | P-0739 | Cream silver Sulphadiazine 1% W/W | 1 | 94 | 3960 | 372240 |
| 740 | P-0740 | Calcium Sodium Alignate Dressing | 1 | 300 | 10 | 3000 |
| | | (AN) I.V. SOLUTIONS: | | | 0 | 0 |
| 741 | P-0741 | Inf. Sodium Chloride 4g/litre, Sod, Lactate 5.9gm/litre, potassium chloride 2.6gm per litre | 1 | 450 | 0 | 0 |
| 742 | P-0742 | Inj. Dextran 6% | 1 | 200 | 0 | 0 |
| | | Inj. Dextran 4% | 1 | 200 | 2 | 400 |
| 743 | P-0743 | Inj. Dextrose 25% (Amp) | 1 | 200 | 11910 | 2382000 |
| 744 | P-0744 | Inj. Dextrose in water 10% | 1000ml | 65 | 2973 | 193245 |
| 745 | P-0745 | Inj. Distilled water 5ml. | 5ml | 6.9 | 2000 | 13800 |
| 746 | P-0746 | Inj. Dextrose 25% | 1000ml | 50 | 720 | 36000 |
| 747 | P-0747 | Inj. Dextrose 5% | 1000ml | 58.5 | 17470 | 1021995 |
| 748 | P-0748 | Inj. Dextrose 5% with Normal Saline | 1000ml | 59.2 | 4220 | 249824 |
| 749 | P-0749 | Inj. Hartman's Solution | 1000ml | 54 | 108070 | 5835780 |
| 750 | P-0750 | Inj. Mannitol 10%. | 1 | 140 | 7 | 980 |
| | | Inj. Mannitol 20%. | 500ml | 156 | 548 | 85488 |
| 751 | P-0751 | Inj. Potassium Chloride 15%W/V | 1 | 9.1 | 20 | 182 |
| | | Inj. Potassium Chloride 7.45%W/V | 1 | 12.7 | 9480 | 120396 |
| 752 | P-0752 | (a) Inj. Normal Saline 0.9% | 20ml | 20 | 100 | 2000 |
| | | (b) Inj. Normal Saline 0.9% | 100ml | 37 | 35900 | 1328300 |
| | | (c) Inj. Normal Saline 0.9% | 500ml | 38 | 2460 | 93480 |
| | | (d) Inj. Normal Saline 0.9% | 1000ml | 51.7 | 67320 | 3480444 |
| | | (e) Inj. Normal Saline 0.45% | 1000ml | 20 | 0 | 0 |
| 753 | P-0753 | Inj. Sodium Bicarbonate 8.4%. | 50ml | 27 | 2100 | 56700 |
| 754 | P-0754 | Inj. Polygelline 35gm with Electrolyte per 1000ml | 500ml | 421 | 2875 | 1210375 |
| 755 | P-0755 | Infusion contains Dextrose 5%+Sodium Chloride 0.45% (1/2 Normal Saline) | 500ml | 41 | 650 | 26650 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------|------|------------------|
| | | Infusion contains Dextrose 5%+Sodium Chloride 0.45% (1/2 Normal Saline) | 1000ml | 70 | 0 | 0 |
| 756 | P-0756 | Infusion contains Dextrose 4.3% + Sodium Chloride 0.18%. | 500ml | 36 | 6700 | 241200 |
| 757 | P-0757 | Amino acid Solution 7% I/V | 1 | 3000 | 60 | 180000 |
| | | Amino acid with electrolytes + Carbohydrate + Vitamins | 1 | 3000 | 0 | 0 |
| 758 | P-0758 | Lipid emulsion I/V | 1 | 2500 | 5 | 12500 |
| | | Lipid Solution I/V | 1 | 2500 | 5 | 12500 |
| 759 | P-0759 | Infusion Containing Ca. Chloride 2H ₂ O, Potassium Chloride 1.5gm, Sodium Acetate 3H ₂ O 2.16gm, Dextrose Anhydrous 50gm, water for Inj.) | 1 | 500 | 0 | 0 |
| | | (AO) ONCOLOGY: | | | 0 | 0 |
| 760 | P-0760 | Inj. Cyclophosphamide 200mg | 1 | 150 | 0 | 0 |
| | | Inj. Cyclophosphamide 500mg | 1 | 300 | 0 | 0 |
| | | Inj. Cyclophosphamide 1000mg | 1 | 382 | 160 | 61120 |
| 761 | P-0761 | Inj. Vincristine 1mg. | 1 | 450 | 10 | 4500 |
| 762 | P-0762 | Inj.Doxorubicin (Adriamycin) 10mg | 1 | 1398 | 0 | 0 |
| | | Inj.Doxorubicin (Adriamycin) 20mg | 1 | 1398 | 0 | 0 |
| | | Inj.Doxorubicin (Adriamycin) 50mg | 1 | 1398 | 140 | 195720 |
| 763 | P-0763 | Inj. Daunomycin 20mg. | 1 | 450 | 0 | 0 |
| 764 | P-0764 | Tab. Tamoxifen 10mg. | 30 | 191 | 630 | 120330 |
| 765 | P-0765 | Inj. Fluorouracil 250mg | 1 | 137 | 10 | 1370 |
| | | Inj. Fluorouracil 500mg | 1 | 137 | 300 | 41100 |
| 766 | P-0766 | Inj. Vinblastine Sulphate 10mg. | 1 | 580 | 0 | 0 |
| 767 | P-0767 | Inj. Methotrexate 500mg | 5 | 1800 | 0 | 0 |
| | | Inj. Methotrexate 50mg | 1 | 286 | 10 | 2860 |
| 768 | P-0768 | Tab. Methotrexate 2.5mg | 10 | 200 | 750 | 150000 |
| | | Tab. Methotrexate 10mg. | 10 | 350 | 70 | 24500 |
| 769 | P-0769 | Inj. Cisplatinum / Cisplatin 10mg | 1 | 1100 | 0 | 0 |
| | | Inj. Cisplatinum / Cisplatin 25mg | 1 | 1200 | 0 | 0 |
| | | Inj. Cisplatinum / Cisplatin 50mg | 1 | 939 | 40 | 37560 |
| 770 | P-0770 | Inj. Bleomycine HCL 15mg | 1 | 1245 | 40 | 49800 |
| 771 | P-0771 | Inj. Dactinomycin 0.5mg. | 1 | 240 | 0 | 0 |
| 772 | P-0772 | Inj. Cytarabine 100mg, | 1 | 1200 | 0 | 0 |
| | | Inj. Cytarabine 500mg. | 1 | 2000 | 2 | 4000 |
| 773 | P-0773 | Inj. Dacarbazine 200mg. | 1 | 730 | 10 | 7300 |
| 774 | P-0774 | Inj. Etoposide 100mg. | 1 | 720 | 20 | 14400 |
| 775 | P-0775 | Cap. Hydroxyurea 500mg. | 100 | 1450 | 20 | 29000 |
| 776 | P-0776 | Tab. Megestrol Acetate 160mg. | 30 | 1600 | 0 | 0 |
| 777 | P-0777 | Tab. Mercaptopurine 50mg. | 30 | 300 | 0 | 0 |
| 778 | P-0778 | Cap. Procarbazine 50mg. | 20 | 2500 | 0 | 0 |
| 779 | P-0779 | Inj. Vinorelbine 50mg. | 1 | 9000 | 0 | 0 |
| 780 | P-0780 | Inj. Paclitaxil 30mg. | 1 | 3000 | 4 | 12000 |
| | | Inj. Paclitaxil 150mg. | 1 | 6363 | 150 | 954450 |
| 781 | P-0781 | Inj. Bevacizumab 400mg | 1 | 97325 | 10 | 973250 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|-----------------------------------------------------------------------|-----------|----------------|------|------------------|
| 782 | P-0782 | Tab Cyproterone Acetate 50mg | 50 | 2900 | 0 | 0 |
| 783 | P-0783 | Inj. Epirubicin HCL 10mg. | 1 | 671 | 0 | 0 |
| | | Inj. Epirubicin HCL 50mg. | 1 | 2500 | 100 | 250000 |
| 784 | P-0784 | Inj. Carboplatin 50mg | 1 | 1000 | 0 | 0 |
| | | Inj. Carboplatin 200mg. | 1 | 1500 | 0 | 0 |
| | | Inj. Carboplatin 450mg. | 1 | 4000 | 100 | 400000 |
| 785 | P-0785 | Inj. Mesna 400mg, 100mg/ml (4ml Amp). | 1 | 800 | 50 | 40000 |
| 786 | P-0786 | Inj. Ifosfamide 500mg. | 1 | 800 | 0 | 0 |
| | | Inj. Ifosfamide 1000mg | 1 | 1300 | 50 | 65000 |
| 787 | P-0787 | Inj. Gemcitabine 200mg. | 1 | 1675 | 0 | 0 |
| | | Inj. Gemcitabine 1gm. | 1 | 8000 | 30 | 240000 |
| 788 | P-0788 | Tab. Flutamide 250mg. | 100 | 5000 | 0 | 0 |
| 789 | P-0789 | Inj. Goserelin Acetate 3.6mg. | 1 | 16000 | 0 | 0 |
| 790 | P-0790 | Inj. Topotecan 4mg | 1 | 25000 | 10 | 250000 |
| 791 | P-0791 | Inj. Docetaxel 20mg (With Solvent). | 1 | 950 | 10 | 9500 |
| 792 | P-0792 | Inj. Ca.Leuovorin /Ca. Folate/ Folinic Acid (As Calcium Salt)50mg. | 1 | 500 | 150 | 75000 |
| 793 | P-0793 | Tab.Cyclophosphamide 50mg | 20 | 2500 | 0 | 0 |
| 794 | P-0794 | Tab. Anastrozol 1mg | 28 | 6800 | 10 | 68000 |
| 795 | P-0795 | (a) Inj. Pamidronate Disodium 15mg | 1 | 2300 | 0 | 0 |
| | | (b) Inj. Pamidronate Disodium 30mg | 1 | 3000 | 0 | 0 |
| 796 | P-0796 | Cap. Pamidronate Disodium 100mg | 3 | 6000 | 0 | 0 |
| 797 | P-0797 | Inj. Filgrastim 300mcg/ml | 1 | 3900 | 40 | 156000 |
| 798 | P-0798 | Inj.Octreotide Acetate 0.05mg | | 425 | 50 | 21250 |
| | | Inj.Octreotide Acetate 0.1mg | 1 | 1850 | 1800 | 3330000 |
| | | Inj.Octreotide Acetate 20mg | 1 | 78000 | 2 | 156000 |
| 799 | P-0799 | Tab. Capecitabine 500mg | 120 | 25000 | 24 | 600000 |
| 800 | P-0800 | Inj.Leuprorelin Acetate 3.75mg | 1 | 8000 | 4 | 32000 |
| 801 | P-0801 | Tab.Letrozole 2.5mg | 10 | 475 | 455 | 216125 |
| 802 | P-0802 | Inj. Trastuzumab 440mg | 1 | 110500 | 4 | 442000 |
| | | Inj. Trastuzumab 600mg | 1 | 110500 | 120 | 13260000 |
| | | Inf. Trastuzumab Emtansine 100mg | 1 | 86500 | 6 | 519000 |
| | | Inf. Trastuzumab Emtansine 160mg | 1 | 138000 | 6 | 828000 |
| 803 | P-0803 | Tab. Chlorambucil 2mg | 30 | 2000 | 0 | 0 |
| 804 | P-0804 | Cap. Thalidomide 50mg | 10 | 525 | 0 | 0 |
| | | Cap. Thalidomide 100mg | 10 | 1300 | 0 | 0 |
| 805 | P-0805 | Tab. Imatinab 100mg | 60 | 50000 | 40 | 2000000 |
| | | Tab. Imatinab 200mg | 60 | 40000 | 0 | 0 |
| | | Tab. Imatinab 400mg | 30 | 70000 | 0 | 0 |
| 806 | P-0806 | Tab. Nilotinib 200mg | 28 | 106400 | 40 | 4256000 |
| 807 | P-0807 | Tab. Sorafenib 200mg | 60 | 20940 | 80 | 1675200 |
| 808 | P-0808 | Inj. Oxaliplatin 50mg | 1 | 10000 | 4 | 40000 |
| | | Inj. Oxaliplatin 100mg | 1 | 20000 | 60 | 1200000 |
| 809 | P-0809 | Cap. Lenalidomide 10mg | 28 | 9000 | 10 | 90000 |
| | | Cap. Lenalidomide 25mg | 21 | 20000 | 0 | 0 |
| 810 | P-0810 | Inj. Rituximab 100mg | 2 | 29325 | 0 | 0 |
| | | Inj. Rituximab 500mg | 1 | 72675 | 20 | 1453500 |
| 811 | P-0811 | Tab. Pazopanib 200mg | 30 | 53000 | 0 | 0 |
| | | Tab. Pazopanib 400mg | 30 | 75000 | 2 | 150000 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|----------------------------------------------|-----------|----------------|-----|------------------|
| 812 | P-0812 | Inj. Fludarabine 50mg | 1 | 88000 | 2 | 176000 |
| 813 | P-0813 | Tab. Roxulitinim 5mg | 20 | 10000 | 2 | 20000 |
| | | Tab. Roxulitinim 10mg | 20 | 15000 | 2 | 30000 |
| | | Tab. Roxulitinim 15mg | 20 | 17000 | 0 | 0 |
| 814 | P-0814 | Tab. Abiraterone 250mg | 120 | 134000 | 10 | 1340000 |
| 815 | P-0815 | Inj. Cabazitaxel 60mg | 1 | 252000 | 0 | 0 |
| 816 | P-0816 | Tab. Gefitinib 250mg | 30 | 19000 | 0 | 0 |
| 817 | P-0817 | Inj. Mitoxantrone 20mg | 1 | 4000 | 0 | 0 |
| 818 | P-0818 | Cap/tab. Lenvatinib 10mg | 30 | 20000 | 0 | 0 |
| 819 | P-0819 | Cap. Temozolamide 20mg | 5 | 7000 | 0 | 0 |
| | | Cap. Temozolamide 100mg | 5 | 35000 | 2 | 70000 |
| | | Cap. Temozolamide 250mg | 5 | 77000 | 0 | 0 |
| 820 | P-0820 | Inj. Carmustine 100mg | 1 | 10000 | 0 | 0 |
| 821 | P-0821 | Cap. Lomustine 40mg | 30 | 12000 | 0 | 0 |
| 822 | P-0822 | Cap. Sunitinib 12.5mg | 30 | 134560 | 1 | 134560 |
| | | Cap. Sunitinib 25mg | 30 | 266371 | 1 | 266371 |
| | | Cap. Sunitinib 50mg | 30 | 521507 | 0 | 0 |
| 823 | P-0823 | Inj. Pemetrexed 100mg | 1 | 16874 | 0 | 0 |
| | | Inj. Pemetrexed 500mg | 1 | 6918826 | 0 | 0 |
| 824 | P-0824 | Tab. Everolimus 0.25mg | 30 | 6964 | 20 | 139280 |
| | | Tab. Everolimus 0.75mg | 30 | 17410 | 0 | 0 |
| | | Tab. Everolimus 5mg | 30 | 315000 | 0 | 0 |
| | | Tab. Everolimus 10mg | 30 | 450000 | 0 | 0 |
| 825 | P-0825 | Tab. Exemestane 25mg | 30 | 7700 | 0 | 0 |
| 826 | P-0826 | Inj. Irinotecan 40mg | 1 | 8000 | 0 | 0 |
| | | Inj. Irinotecan 100mg | 1 | 20000 | 6 | 120000 |
| 827 | P-0827 | Cap. Aprepitant 40mg | 2s | 400 | 0 | 0 |
| | | Cap. Aprepitant 80mg | 2s | 800 | 0 | 0 |
| | | Cap. Aprepitant 125mg | 2s | 1000 | 0 | 0 |
| 828 | P-0828 | Inf. Atezolizumab 840mg | 1 | 325000 | 0 | 0 |
| | | Inf. Atezolizumab 1200mg | 1 | 355000 | 0 | 0 |
| 829 | P-0829 | Inj. Bortezomib 3.5mg | 1 | 30000 | 4 | 120000 |
| 830 | P-0830 | Cap. Palbociclib 75mg | 21 | 473000 | 0 | 0 |
| | | Cap. Palbociclib 100mg | 21 | 473000 | 0 | 0 |
| | | Cap. Palbociclib 125mg | 21 | 478000 | 2 | 956000 |
| 831 | P-0831 | Tab. Ribociclib 200mg | 63 | 475000 | 2 | 950000 |
| 832 | P-0832 | Inf. Pertuzumab 420mg/14ml | 1s | 150000 | 0 | 0 |
| 833 | P-0833 | Tab. Erlotinib 100mg | 30 | 25000 | 0 | 0 |
| | | Tab. Erlotinib 150mg | 30 | 30000 | 0 | 0 |
| | | (AP) IMMUNOGLOBULIN: | 1 | | 0 | 0 |
| 834 | P-0834 | Inj. Rho. (D) Immune Globulin (Human) 300mcg | 1 | 2000 | 620 | 1240000 |
| 835 | P-0835 | Inj. Hepatitis-B Immune Globulin 200iu/ml | 1 | 949 | 110 | 104390 |
| 836 | P-0836 | Inj. IVIG | 1 | 2500 | 2 | 5000 |
| | | Inj. VZIG | 1 | 2500 | 0 | 0 |
| | | (AQ) ANTIVIRALS. | | | 0 | 0 |
| 837 | P-0837 | Inj. Acyclovir 500mg (Lyophilized) | 30 | 253 | 20 | 5060 |
| 838 | P-0838 | Tab. Adefovir Dipivoxil 10mg. | 30 | 6000 | 0 | 0 |
| 839 | P-0839 | Tab. Entecavir 0.5mg | 30 | 847.9 | 610 | 517219 |

| S# | NEW PESSI # | ITEMS | pack size | Estimated Rate | Qty | Estimated amount |
|-----|-------------|---------------------------------------|-----------|----------------|--------------|------------------|
| 840 | P-0840 | Tab. Tenofovir Disoproxil 300mg | 30 | 1650 | 202 | 333300 |
| 841 | P-0841 | Inj. Remdesivir 100mg | 1 | 5000 | 4 | 20000 |
| | | (AR) ANTIDOTES. | | | 0 | 0 |
| 842 | P-0842 | Inj. Desferrioxamine Mesylate 500mg. | 10 | 3600 | 1290 | 4644000 |
| 843 | P-0843 | Tab.Penicillamine 250mg | 30 | 150 | 0 | 0 |
| 844 | P-0844 | Tab.Deferasirox 400mg | 30 | 10000 | 280 | 2800000 |
| | | Tab.Deferasirox 100mg | 1 | 2600 | 9400 | 24440000 |
| 845 | P-0845 | Inj. Protamine Sulphate 10mg/ml | 10 | 1400 | 202 | 282800 |
| 846 | P-0846 | Anti Snake Venome | 1 | 2500 | 15 | 37500 |
| 847 | P-0847 | Anti Rabbits Vaccine | 1 | 1000 | 271 | 271000 |
| 848 | P-0848 | Inj. Naloxone 0.4mg/ml | 10 | 634 | 2 | 1268 |
| 849 | P-0849 | Inj. Flumazenil 100mcg/ml | 5 | 26000 | 0 | 0 |
| | | (AS) ANDROGENS / ANTI ANDROGENS | | | 0 | 0 |
| 850 | P-0850 | Tab. Bicalutamide 50mg | 20 | 1800 | 60 | 108000 |
| | | (AT) VASOTHERAPEUTICS | | | 0 | 0 |
| 851 | P-0851 | Tab. Diosmin 450mg + Hesperidine 50mg | 20 | 388 | 4700 | 1823600 |
| 852 | P-0852 | Inj. 5% Phenol with almond oil | 1 | 250 | 4 | 1000 |
| | | (AU)AMINOQUINOLONES | | | 0 | 0 |
| 853 | P-0853 | Tab.Hydroxychloroquine sulphate 200mg | 30 | 250 | 2390 | 597500 |
| | | (AV)DISPOSABLE SYRINGES | | | 0 | 0 |
| 854 | P-0854 | Disposable Syringes 1CC | 100 | 724 | 310 | 224440 |
| | | Disposable Syringes 1CC Insuline | 100 | 1199 | 5943 | 7125657 |
| 855 | P-0855 | Auto-disable Syringes 2.5CC | 100 | 1200 | 0 | 0 |
| 856 | P-0856 | Auto-disable Syringes 3CC | 100 | 1019 | 1320 | 1345080 |
| 857 | P-0857 | Auto-disable Syringes 5CC | 100 | 789 | 14967 | 11808963 |
| 858 | P-0858 | Disposable Syringes 10CC | 100 | 1150 | 5327 | 6126050 |
| 859 | P-0859 | Disposable Syringes 20CC | 50 | 894 | 496 | 443424 |
| 860 | P-0860 | Disposable Syringes 50CC | 25 | 1437 | 264 | 379368 |
| 861 | P-0861 | Disposable Syringes 60CC | 50 | 3250 | 45 | 146250 |
| 862 | P-0862 | I/V Set | 25 | 503 | 16602 | 8350806 |
| 863 | P-0863 | I.V. Cannula 14G | 50 | 4200 | 0 | 0 |
| | | I.V. Cannula 16G | 50 | 4787 | 6 | 28722 |
| | | I.V. Cannula 18G | 100 | 4124 | 170 | 701080 |
| | | I.V. Cannula 20G | 100 | 4124 | 758 | 3125992 |
| | | I.V. Cannula 22G | 100 | 4124 | 1424 | 5872576 |
| | | I.V. Cannula 24G | 50 | 2099 | 1302 | 2732898 |
| | | (AW)VACCINES | | | 0 | 0 |
| 864 | P-0864 | Hepatitis-B Vaccine 10mcg | 1 | 600 | 50 | 30000 |
| | | Hepatitis-B Vaccine 20mcg | 10 | 900 | 21 | 18900 |
| 865 | P-0865 | Inj. Tetanus Toxoide | 1 | 471 | 2360 | 1111560 |
| 866 | P-0866 | Inj. Pneumovac-23 Vaccine | 1 | 1200 | 0 | 0 |
| | | | | | Total | 968613384 |

INFORMATION REGARDING ISSUANCE AND RECEIVING OF TENDER FORMS

| Sr. No. | Description | Name of Officer / Official |
|----------------|---------------------------------------|-----------------------------------|
| 1. | Tender Issuing officer | Director (Purchase) |
| 2. | Tender Distribution official | Junior Clerk |
| 3. | Tender Receiving Officers / officials | Junior Clerk |

INSTRUCTIONS TO BIDDERS

1. **Scope of Bid:** THE PUNJAB EMPLOYEE'S SOCIAL SECURITY INSTITUTION (PESSI), invites sealed bids from PESSI Pre-qualified Pharmaceutical Manufacturers/Sole Agents of Foreign Principals to conclude the framework contract for supply of Medicines/Drugs including Medical devices for PESSI Hospitals and Directorates as per quantities and specifications described in Specifications of Medicines Year 2023-24 of the Bidding Documents. The nature of contract shall be Local Contract.
2. **Source of Funds:** THE PUNJAB EMPLOYEE'S SOCIAL SECURITY INSTITUTION (PESSI), has allocated the budget from its own funds for the purchase of medicines for PESSI Hospitals/Directorates under the relevant head of Account.
3. **Eligible bidders:** This Invitation for Bids is open to all PESSI Pre-qualified Manufacturers and in case of imported goods, their Sole Agents / Importer in Pakistan, for concluding the framework contract for supply of Drugs / Medicines including Medical devices on Free Delivery basis to CMSD, Defence Road, Lahore. In case of any subsequent/supplementary order from PESSI Hospitals/Directorates, the supplier shall be responsible for the delivery at consignee end. The importer /sole agent must possess a valid authorization from the Foreign Principal / Manufacturer and drugs sale license issued by the competent authority in Pakistan and in case of manufacturer they should have a documentary proof of valid drugs manufacturing license. The bidder shall also have to submit a copy of valid registration certificate from Ministry of Health, Islamabad / Drug Regulatory Authority Pakistan. The bidders shall not be under a declaration of ineligibility for corrupt and fraudulent practices, declared by any Government (Federal/Provincial/District), Local Body or Public Sector Organization.
4. **Corrupt Practices and Mechanism to Debar/Blacklist the Defaulted Bidder.**
 - 4.1 The Government of Punjab defines Corrupt and Fraudulent Practices as "the offering, giving, receiving, or soliciting of anything of value to influence the action of a public official or the contractor in the procurement process or in contract execution to the detriment of the procuring agency; or misrepresentation of facts in order to influence a procurement process or the execution of a contract, collusive practices among bidders (prior to or after bid submission) designed to establish bid prices at artificial, non-competitive levels and to deprive the procuring agency of the benefits of free and open competition and any request for, or solicitation of anything of value by any public official in the course of the exercise of his duty; it may include any of the following practices:
 - (i) coercive practice by impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence the actions of a party to achieve a wrongful gain or to cause a wrongful loss to another party;
 - (ii) collusive practice by arrangement between two or more parties to the procurement process or contract execution, designed to achieve with or without the knowledge of the procuring agency to establish prices at artificial, non-competitive levels for any wrongful gain;
 - (iii) corrupt practice by offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence the acts of another party for wrongful gain;
 - (iv) fraudulent practice by any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;
 - (v) obstructive practice by harming or threatening to harm, directly or indirectly, persons or their property to influence their participation in a procurement process, or affect the execution of a contract or deliberately destroying,

falsifying, altering or concealing of evidence material to the investigation or making false statements before investigators in order to materially impede an investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation, or acts intended to materially impede the exercise of inspection and audit rights;

- 4.2 Indulgence in corruption and fraudulent practices is liable to result in rejection of Bids, cancellation of contracts, debarring and blacklisting of the Bidder, for a stated or indefinite period of time.
- 4.3 The following are the events which would lead to initiate under the PPRA Rules 2014 (amended) Blacklisting / Debarment process;
- i. Submission of false fabricated / forged documents for procurement in tender.
 - ii. Not attaining required quality of work.
 - iii. Inordinate tardiness in accomplishment of assigned/agreed responsibilities / contractual obligations resulting loss to procuring agency.
 - iv. Non execution of work as per terms & condition of contract.
 - v. Any unethical or unlawful professional or business behavior detrimental to good conduct and integrity of the public procurement process.
 - vi. Involvement in any sort of tender fixing.
 - vii. Persistent and intentional violation of important conditions of contract
 - viii. Non-adherence to quality specification despite being importunately pointed out.
 - ix. Security consideration of the State i.e., any action that jeopardizes the security of the State or good repute of the procuring agency.

5. **PROCEDURE:** The procedure mentioned in Punjab Procurement Rules 2014 (amended) will be followed.

6. **Eligible Goods and Services:** For these purposes, the term “**Goods**” includes any Goods that are the subject of this Invitation for Bids as defined in General Condition of Contract 1(c) and the term “**Services**” shall includes related services as defined in General Condition of Contract Clause 1(e).

7. **Cost of Bidding:** The bidder shall bear all costs associated with the preparation and submission of its bid, and the Procuring Agency shall in no case be responsible or liable for those costs, regardless of the manner or outcome of the bidding process.

8. **Bidding for Selective Items.**

8.1 A Bidder, if he so chooses, can bid for selective items from the list of goods provided in the Specifications of Medicines for the year 2023-24. A Bidder is also at a liberty to bid for all the items Specifications of Medicines for the year 2023-24. However, Bidders cannot bid for partial quantities of any item mentioned in Specifications of Medicines for the year 2023-24. The bid must be for the total quantity of an item required in the Specifications of Medicines for the year 2023-24.

THE BIDDING PROCEDURE

9. **Single stage – two envelopes bidding procedure shall be applied**

9.1 Single stage – two envelopes bidding procedure shall be applied:-

- i. the bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals;

- ii. the envelopes shall be marked as “Financial Proposal” and “Technical Proposal”;
- iii. in the first instance, the “Technical Proposal” shall be opened and the envelope marked as “Financial Proposal” shall be retained unopened in the custody of the procuring agency;
- iv. the procuring agency shall evaluate the technical proposal in the manner prescribed in advance, without reference to the price and shall reject any proposal which does not conform to the specified requirements;
- v. during the technical evaluation no amendments in the technical proposal shall be permitted;
- vi. after the evaluation and approval of the technical proposals, the procuring agency shall open the financial proposals of the technically accepted bids, publically at a time, date and venue announced and communicated to the bidders in advance, within the bid validity period;
- vii. The financial proposal of the bids found technically non-responsive shall be retained unopened and shall be returned on the expiry of the grievance period or the decision of the complaint, if any, filed by the non-responsive bidder, whichever is later: provided that the procuring agency may return the sealed financial proposal earlier if the disqualified or non-responsive bidder, contractor or consultant submits an affidavit, through an authorized representative, to the effect that he is satisfied with the proceedings of the procuring agency]; and
- viii. the successful lowest bidder shall be awarded the contract;

THE BIDDING DOCUMENTS

10. Content of Bidding Documents

- i. The goods required, applicable bidding procedures, and Contract Terms are prescribed in the Bidding Documents. In addition to the invitation for Bids, the Bidding Documents include:-
 - a. Instructions to bidders;
 - b. General Conditions of Contract;
 - c. Special Conditions of Contract;
 - d. Schedule of Requirements.
 - e. Delivery time, completion schedule and price schedule.
 - f. Contract Form;
 - g. Manufacturer’s Authorization Form;
 - h. Bid Form;
 - i. Bid Evaluation Criteria
 - j. Technical specification comprising list of medicines and Drug Specification Proforma.
 - ii. The bidder is expected to examine all instructions, forms, terms, and specifications in the bidding documents.
 - iii. Failure to furnish all information required by the bidding documents or to submit a bid not substantially responsive to the bidding documents in every respect shall be at the bidder’s risk and may result in the rejection of its bid.
- 11. Clarification of Bidding Documents: (1)** No bidder shall be allowed to alter or modify his bid after the closing time for the submission of the bids.
- (2) The procuring agency may, if necessary after the opening of the bids, seek and accept such clarifications of the bid as do not change the substance of the bid.
 - (3) Any request for clarification in the bid, made by the procuring agency and its response, shall invariably be in writing.

PREPARATION OF BIDS

12. **Language of Bid:** The bid prepared by the bidder, as well as all correspondence and documents relating to the bid exchanged by the bidder and the Procuring Agency shall be written in English. Supporting documents and printed literature furnished by the bidder may be in another language provided they are accompanied by an accurate translation in English, in which case, for purposes of interpretation of the Bid, the translation shall govern.

13. **Documents Comprising the Bid:** The bid shall comprise the following components:

- (a) Bid Form and Price Schedule completed in accordance with instruction to bidders (to be submitted along with financial proposal);
- (b) Documentary evidence established in accordance with instruction to bidders that the bidder is eligible to bid and is qualified to perform the Contract if its bid is accepted;
- (c) Documentary evidence established in accordance with instruction to bidders that the goods to be supplied by the bidder are eligible goods and conform to the bidding documents; and
- (d) Bid Security, furnished in accordance with instruction to bidders.

14. **Bid Form & Price Schedule:** The bidder shall complete the Bid Form and an appropriate Price Schedule furnished in the bidding documents, indicating the goods to be supplied, a brief description of the goods, their strength, packing, quantity, and prices.

15. **Bid Prices:**

- i. The bidder shall indicate on the appropriate Price Schedule the unit prices and total bid price of the goods, it proposes to supply under the Contract.
- ii. Form of price Schedule is to be filled in very carefully, preferably typed. Any alteration / correction must be initiated. Every page is to be signed and stamped at the bottom. Serial number of the quoted item may be marked with red / yellow marker.
- iii. The bidder should quote the prices of goods according to the strength / technical specifications as provided in the Form of Price Schedule and Technical Specifications. The specifications of goods, different from the demand of bid enquiry, shall straightway be rejected.
- iv. The bidder is required to offer competitive price. All prices must include the General Sales Tax (GST) and other taxes and duties, where applicable. If there is no mention of taxes, the offered / quoted price shall be considered as inclusive of all prevailing taxes/duties. The benefit of exemption from or reduction in the GST or other taxes shall be passed on to the Procuring Agency.
- v. Prices offered should be for the entire quantity demanded; partial quantity offers shall straightaway be rejected. Conditional offer shall also be considered as non-responsive bidder.
- vi. While tendering your quotation, the present trend / inflation in the rate of goods and services in the market should be kept in mind. No request for increase / decrease in price due to market fluctuation in the cost of goods and services shall be entertained.

16. **Bid currencies:** Prices shall be quoted in Pak Rupees.

17. **Documents Establishing bidder's Eligibility and Qualification**

- i. The bidder shall furnish, as part of its technical bid, documents establishing the bidder's eligibility to bid and its qualifications to perform the Contract if its bid is accepted.

- ii. The documentary evidence of the bidder's eligibility to bid shall establish to the Procuring Agency's satisfaction that the bidder, at the time of submission of its bid, is an eligible as defined under instruction to the bidders
 - iii. The documentary evidence (to be submitted along with technical proposal) of the bidder's qualifications to perform the Contract if its bid is accepted shall establish to the Procuring Agency's satisfaction:
 - (a) The Sole Agent / Importer shall have to produce valid letter of authorization from Foreign Principal and in case of local Manufacturer, documentary proof including valid drug manufacturing license / registration certificate, to the effect that they are the original manufacturer of the required specifications of goods, shall be provided.
 - (b) National Tax Number (NTN) and General Sales Tax Number (GST) (if applicable) with documentary proof shall have to be provided by each bidder in the tender.
 - (c) The bidder shall submit an affidavit on e-stamp paper of Rs. 100/- that their firm is not blacklisted on any ground by any Government (Federal/Provincial/District), a local body or a Public Sector Organization. The bidder shall be debarred from bid on account of submission of false statement.
 - (d) The bidder should have minimum **two-years experience in the market**. Similarly, it is mandatory that the item to be quoted by the bidder / Manufacturer should have availability in the market minimum for the **last two years**. Documentary proof shall have to be provided in this regard.
 - (e) The bidder is required to provide with the Technical Proposal, the name of item(s) for which they have quoted their rates in the Financial Proposals.
 - (f) The bidder must indicate the registration number, make of country of origin / Manufacturer of the drugs, capacity of production of the firm, its financial status, batch capacity, necessary assurance of quality production, GMP / cGMP.
 - (g) Proof of active taxpayer
18. **Documents Establishing Goods' Eligibility and Conformity to Bidding Documents:**
- i. The bidder shall furnish along with Technical Proposal, as part of its bid, documents establishing the eligibility and conformity to the bidding documents of all goods, which the bidder proposes to supply under the Contract.
 - ii. The documentary evidence of the eligibility of the goods shall consist of a statement in the Price Schedule of the country of origin of the goods offered which a certificate of origin issued by the Manufacturer shall confirm.
 - iii. Submission of sample:
 - a) The bidder must produce along with technical proposal, Two **(02)** samples of quoted product(s) **(Commercial pack)** according to the strength demand of enquiry. No technical proposal / bid shall be considered in absence of samples.
 - b) The representative sample(s) must be from the most recent stocks, supported by valid warranty as per Drugs Act 1976.
19. **Bid security.**— The bidders shall furnish a bid security equal to 3% of estimated price of respective item in the form of Bank guarantee/CDR and the original bid security shall be attached with the Technical Bid, whereas its photocopy shall be attached with the Financial Bid.
20. **Bid validity.**— (i) A procuring agency, keeping in view the nature of the procurement, shall subject the bid to a bid validity period.
- (ii) The bids shall be valid for the period of 120-days.
 - (iii) Subject to sub-rule (5), a procuring agency shall ordinarily be under an obligation to process and evaluate the bids within the stipulated bid validity period but, under exceptional circumstances and for reasons to be recorded in writing, if an extension is considered necessary,

all the bidders shall be requested to extend their respective bid validity period but such extension shall not be for more than the original period of bid validity.

- (iv) A bidder who:
- (a) agrees to the extension of the bid validity period shall also extend the validity of the bid bond or security for the extended period of the bid validity;
 - (b) agrees to the procuring agency's request for extension of bid validity period shall not be permitted to change the substance of the bid; and
 - (c) does not agree to an extension of the bid validity period shall be allowed to withdraw the bid without forfeiture of the bid bond or security.

21. Extension of time for submission of bids.– If a procuring agency considers that it is necessary in public interest to extend the last date for the submission of the bids, it may, after recording reasons, do so in the manner similar to the original advertisement.

22. Format and Signing of Bid:

- i. The bidder shall prepare and submit its bid along with original purchase receipt. The bid shall be typed or written in indelible ink and shall be signed by the bidder or a person or persons duly authorized by the firm. The person or persons signing the bid shall initial all pages of the bid, except for un-amended printed literature.
- ii. Any interlineations, erasures, or overwriting shall be valid only if they are initialed by the person or persons signing the bid.

SUBMISSION OF BIDS

23. Sealing and Marking of Bids

- i. All bids should be submitted in proper binding / ring binding / proper file cover.
- ii. The envelopes shall be marked as “FINANCIAL PROPOSAL” and “TECHNICAL PROPOSAL” in bold and legible letters to avoid confusion. The inner and outer envelopes shall:
 - a. be addressed to the Procuring Agency at the address given in the Invitation for Bids and;
 - b. bear the name and number indicated in the Invitation for Bids.
- iii. The inner envelopes shall also indicate the name and address of the bidder to enable the bid to be returned unopened in case it is declared as “non-responsive”.
- iv. If the outer as well as inner envelope is not sealed and marked as required by instruction to bidders, the Procuring Agency shall assume no responsibility for the bid's misplacement or premature opening.

24. Deadline for Submission of Bids: Bids must be submitted by the bidder and received by the Procuring Agency at the address specified under instruction to bidders, not later than the time and date specified in the Invitation for Bids.

25. Late Bid: Any bid received by the Procuring Agency after the deadline for submission of bids prescribed by the Procuring Agency shall be rejected and returned unopened to the bidder.

26. Withdrawal of Bids: The bidder may withdraw its bid after the bid's submission and prior to the deadline prescribed for submission of bids. No bid may be withdrawn in the interval between the deadline for submission of bids and the expiration of the period of bid validity specified in instruction to bidders. Withdrawal of a bid during this interval may result in the Bidder's forfeiture of its Bid Security pursuant to the instruction to bidders.

OPENING AND EVALUATION OF BIDS

27. Opening of Bids

- i. The Procuring Agency shall initially open only the envelopes marked “**TECHNICAL PROPOSAL**” in the presence of bidders’ representatives who choose to attend, at the time, on the date, and at the place specified in the Invitation for Bids. The bidders’ representatives who are present shall sign the Attendance Sheet evidencing their attendance. However, the envelope marked as “**FINANCIAL PROPOSAL**” shall be retained in the custody of Procuring Agency without being opened and till completion of the evaluation process. On the day of opening of technical bid the technical officers of the firms shall be signed by the members of the Institutional Tender Committee, whereas, only the envelope of the financial bids shall be signed by the members of the Institutional Tender Committee for the transparency of the procuring process.
 - ii. The bidders’ names, item(s) for which they quoted their rate and such other details as the Procuring Agency, at its discretion, may consider appropriate, shall be announced at the opening of technical proposal. No bid shall be rejected at technical proposal / bid opening, except for late bids and such technical bids which shall not accompanying original 3% Bid Security of the estimated price, which shall be returned unopened to the bidder. However, at the opening of Financial Proposals (the date, time and venue would be announced later on), the bid prices, and the presence or absence of requisite Bid Security and such other details as the Procuring Agency, at its discretion, may consider appropriate, shall be announced.
 - iii. The technical bids found without Bid Security shall also be returned to the bidders. However, prior to return to the bidder, the Chairman of the Committee shall record statement / reason on such bids.
 - iv. The Procuring Agency shall prepare minutes of the bids opening (technical and financial).
28. **Clarification of Bids:** During evaluation of the bids, the Procuring Agency may, at its discretion, ask the bidder for a clarification of its bid. The request for clarification and the response shall be in writing, and no change in the prices or substance of the bid shall be sought, offered, or permitted
29. **Preliminary Examination**
- i. The Procuring Agency shall examine the bids to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished, whether the documents have been properly signed, and whether the bids are generally in order.
 - ii. In the financial bids the arithmetical errors shall be rectified on the following basis. If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected. If the bidder does not accept the correction of the errors, its bid shall be rejected, and its bid Security may be forfeited. If there is a discrepancy between words and figures, the amount in words shall prevail.
 - iii. The Procuring Agency may waive any minor informality, nonconformity, or irregularity in a bid which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any bidder.
 - iv. Prior to the detailed evaluation, the Procuring Agency shall determine the substantial responsiveness of each bid to the bidding documents. For purposes of these Clauses, a substantially responsive bid is one, which conforms to all the terms and conditions of the bidding documents without material deviations. Deviations from, or objections or reservations to critical provisions, such as those concerning Applicable Law, Drugs Act, Taxes & Duties and GMP practices shall be deemed to be a material deviation for technical proposals and Bid Security for financial proposals.

The Procuring Agency's determination of a bid's responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence.

- v. If a bid is not substantially responsive, it shall be rejected by the Procuring Agency and may not subsequently be made responsive by the bidder by correction of the nonconformity.

30. Applicable Bidding Procedure

"Single stage – Two Envelops bidding procedure" shall be applied. Single Stage: Two Envelope **Bidding Procedure**

Single stage two envelopes bidding procedure shall be used for procurement of such goods where the bids are to be evaluated on technical and financial grounds and the procedure for single stage two envelopes shall be:

- i. the bid shall be a single package consisting of two separate envelopes, containing separately the financial and the technical proposals;
- ii. the envelopes shall be marked as "Financial Proposal" and "Technical Proposal";
- iii. in the first instance, the "Technical Proposal" shall be opened and the envelope marked as "Financial Proposal" shall be retained unopened in the custody of the procuring agency;
- iv. The procuring agency shall evaluate the technical proposal in the manner prescribed in advance, without reference to the price and shall reject any proposal which does not conform to the specified requirements;
- v. during the technical evaluation no amendments in the technical proposal shall be permitted;
- vi. after the evaluation and approval of the technical proposals, the procuring agency shall open the financial proposals of the technically accepted bids, publically at a time, date and venue announced and communicated to the bidders in advance, within the bid validity period;
- vii. the financial bids found technically nonresponsive shall be returned un-opened to the respective bidders; and the lowest evaluated bidder shall be awarded the contract;

31. Contacting the Procuring Agency: No bidder shall contact the Procuring Agency on any matter relating to its bid, from the time of the bid opening to the time the Contract is awarded. If the bidder wishes to bring additional information to the notice of the Procuring Agency, it should do so in writing. Any effort by a bidder to influence the Procuring Agency in its decisions on bid evaluation, bid comparison, or Contract award may result in the rejection of the bidder's bid. Canvassing by any bidder at any stage of the Tender evaluation is strictly prohibited. Any infringement shall lead to disqualification.

32. Qualification & disqualification of bidders: i) The Procuring Agency shall determine to its satisfaction whether a Bidder, technically and financially qualified and even having the lowest evaluated responsive bid is qualified to perform the Contract satisfactorily.

ii. The Procuring Agency shall disqualify a bidder if it finds, at any time, that the information submitted by him concerning his qualification was false and materially inaccurate or incomplete.

iii. An affirmative determination shall be a prerequisite for award of the Contract to the Bidder. A negative determination shall result in rejection of the Bidder's bid, in which event the Procuring Agency shall proceed to the next lowest evaluated bid to make a similar determination of that Bidder's capabilities to perform satisfactorily.

33. Rejection of bids.– (1) Under Rule 35, PPRA Rules, the procuring agency may reject all bids or proposals at any time prior to the acceptance of a bid or proposal.

(2) The procuring agency shall upon request communicate to any bidder, the grounds for its rejection of all bids or proposals, but shall not be required to justify those grounds.

(3) The procuring agency shall incur no liability, solely by virtue of its invoking sub-rule (1) towards the bidders.

(4) The bidders shall be promptly informed about the rejection of the bids, if any.

34. **Re-bidding.**– If the procuring agency rejects all the bids under rule 35, it may proceed with the process of fresh bidding but before doing that it shall assess the reasons for rejection and may, if necessary, revise specifications, evaluation criteria or any other condition for bidders.

35. **Announcement of evaluation reports.**– A procuring agency shall announce the results of bid evaluation in the form of a report giving justification for acceptance or rejection of bids at least ten days prior to the award of procurement contract.

AWARD OF CONTRACT

36. Acceptance of Bid and Award criteria

The Bidder whose bid is found to be most closely conforming to the Evaluation Criteria prescribed and having the lowest evaluated bid, if not in conflict with any other law, rules, regulations or policy of the Punjab Government, shall be awarded the Contract, within the original or extended period of bid validity.

37 Procuring Agency's right to vary quantities at time of award

The Procuring Agency reserves the right to increase or decrease, the quantity of goods originally specified in the Price schedule and Schedule of Requirements without any change in unit price or other terms and conditions.

38 Negotiations

PPRA Rules 2014 (amended rules) shall be followed.

39. Notification of Award

- i. Prior to the expiration of the period of bid validity, the Procuring Agency shall notify the successful bidder in writing by registered letter, that its bid has been accepted.
- ii. The notification of award shall constitute the formation of the Contract.

40 Signing of Framework Contract

- i. At the same time as the Procuring Agency notifies the successful bidder that its bid has been accepted, the Procuring Agency shall send the bidder the Contract Form provided in the bidding documents, incorporating all agreements between the Parties.
- ii. Both the successful bidder and the Procuring Agency shall sign the Framework Contract (with date) on the e-stamp paper as per applicable laws, however, in case of requirement of additional paper / papers, only the yellow continuation sheet to be issued by the stamp paper vendor shall be accepted. Thereafter, the Procuring Agency shall issue Purchase Order. If the successful bidder, after completion of all Codal Formalities shows inability to sign the Framework Contract then their Bid Security shall be forfeited and the firm may be blacklisted under the PPRA Rules. In such situation, the Procuring Agency may make the award to the next lowest evaluated bidder at the risk and cost of such firms.

41. Performance Security.

- i. On the date of signing of Contract, the successful bidder shall furnish the Performance Security in the shape of bank guarantee (having validity of 02 years)

/ CDR (7% of total order value) in accordance with the Conditions of Contract, provided in the bidding documents, where-after the formal contract shall be executed between institution and supplying firm. The 3% bid Security would be returned to the bidder on request upon submission of Performance Security and signing of contract.

- ii. Failure of the successful bidder to comply with the requirement of instructions to the bidders shall constitute sufficient grounds for the annulment/termination of the award and forfeiture of the bid Security, in which event the Procuring Agency may make the award to the next lowest evaluated bidder at the risk and cost of the firm.
- iii. Performance Security shall be retained for relevant financial year. The process of release of 7% performance security shall be initiated on receipt of written request from the firm after expiry of the said financial year, release of full payment and subject to the satisfaction performance of the firm.

42. Price Reasonability Certificate

- i. The supplier shall certify on E-Stamp Paper that the prices quoted to PESSI against the items mentioned at Tender Enquiry No. _____ are not more than the Trade Prices as per MRP (Maximum Retail Price) fixed by the Federal Government under Drugs Act, 1976/DRAP Act 2012 as well as prices are not more than the prices quoted to any other Government / Semi Government and Private Institutions and Autonomous Body.
- ii. All suppliers will comply with the provision of Drugs Act 1976/DRAP Act 2012

43. Drug Act/ DRAP Compliance.

All supplies will comply with the provision of Drugs Act, 1976/DRAP Act, 2012/Punjab Drugs Act and rules framed there under.

44. Blacklisting

PPRA Rules 2014 as well as amendment Notification No. S.O(Cabinet-I)2-9/2015 dated 06.01.2016 under Rule 21 issued by the Government of Punjab Services & General Administration Department (Implementation & Coordination Wing) shall be followed.

**BIDS EVALUATION CRITERION FOR DRUGS / MEDICINES INCLUDING
MEDICAL DEVICES FOR MANUFACTURER**

Failure to comply with any compulsory parameter / knockout clauses will result in “non-responsiveness of the bidder for quoted item”. Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

- i. Original F-6 regarding payment of tender fees.
- ii. The bidder must possess valid Drug Manufacturing License issued by DRAP (Manufacturers).
- iii. Pre-qualification of the firm with PESSI regarding quoted section / dosage form.
- iv. The bidder will provide valid Drug Registration Certificate of the quoted product. The product having minimum two years’ experience will be eligible.
- v. Valid GMP Certificate issued by the DRAP.
- vi. Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfill the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.
- vii. Undertaking on E-stamp paper worth Rs. 100/- regarding “Non Declaration of Spurious/ Adulterated Batch” by any notified Drug Testing Laboratory of quoted item within last one year.
- viii. Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non-conviction from any court of law and black listing.
- ix. Two commercial packs as samples of quoted medicines for evaluation by the technical committee

MARKING CRITERIA

Technical Evaluation Criteria for Manufacturers

| Sr. # | Description | Category Points |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 1 | Source of API of Quoted Item | 15 |
| i) | Original Source /Research Molecule (Affidavit on firm's letter head) | 15 |
| ii) | Source Licensed by Original or accredited by FDA/WHO/EMA (Certificate) <i>(The bidder must provide Import record of one year (from Jul. 2021 to onwards) i.e. copy of GD/LC of quoted raw material source)</i> | 10 |
| iii) | Others Source of Raw Material with Certificate of Analysis (Jul. 2021 to onwards) | 08 |
| 2 | Bio Equivalence /Bio-similarity Study (if applicable) of Quoted Product in finished form (affidavit on Rs:100 e-stamp paper in case of research molecule) | 15 |
| i) | Original Manufacturer will be awarded full marks. | 15 |
| ii) | Bio equivalence/Bio-similarity Study from any of the below mentioned labs: <ul style="list-style-type: none"> • WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. <i>(The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).</i> | 10 |

| | | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 3 | EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS | 20 |
| | Past performance of quoted product with major Government Sector/ Semi Government / Autonomous Body / PESSI during last two financial years | |
| i) | Supply of the quoted product Higher than the advertised quantity | 20 |
| ii) | Supply of the quoted product Equivalent to the advertised quantity | 15 |
| iii) | Supply of the quoted product at least 60% of advertised quantity | 10 |
| | The bidder shall provide verifiable documentary evidences like commercial sales summary / supply order of the quoted product. | |
| 4. | Availability of quoted product at major chain pharmacies (02 marks for each pharmacy) | 10 |
| i) | Supply of quoted product at 5 or more chain pharmacies | 10 |
| ii) | Supply of quoted product at upto 4 chain pharmacies | 08 |
| iii) | Supply of quoted product at upto 3 chain pharmacies | 06 |
| iv) | Supply of quoted product upto 02 chain pharmacies | 04 |
| | The bidder shall provide verifiable documentary evidence (invoices) regarding availability of quoted items. Pharmacy chain will be any company operating at least 5 pharmacies in any one major city of Punjab. | |
| | Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 10 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. | |
| 5. | Production Capacity of the quoted product during last one year | 10 |
| i) | 06 to 08 Batches of the quoted item | 10 |
| ii) | 02 to 05 Batches of the quoted item | 07 |
| | The bidder shall provide documentary proof regarding batch history of the quoted product | |
| 6. | Quality Product | 05 |
| i) | If samples of quoted product declared sub-standard by DTL are less than 1% during last Financial year | 05 |
| ii) | If samples of quoted product declared sub-standard by DTL are 1-2% during last Financial year | 03 |
| iii) | If samples of quoted declared sub-standard by DTL are 2-3% during last Financial year | 01 |
| | The bidder will provide undertaking on Rs. 100/- notarized e-stamp paper. Data of substandard batches may be verified from Drug Testing Laboratories. | |
| | Total | 75 |

NOTE: For product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 65%.

QUALIFYING MARKS: 49 OUT OF 75 (65%)

2. Financial bids of only “Technically Qualifying Bidders” will be opened.

**BIDS EVALUATION CRITERION FOR SOLE AGENTS (DRUG /
MEDICINES)**

Failure to comply with any compulsory parameter / knockout clauses will result in “non-responsiveness of the bidder for quoted item”. Bidders comply with Compulsory Parameters / knockout clauses will be evaluated further for Marking Criteria.

COMPULSORY PARAMETERS / KNOCKOUT CRITERIA

- i. Original F-6 regarding payment of tender fees.
- ii. The bidder must possess valid Drug sale License (in case of importers).
- iii. Pre-qualification of the firm as Sole Agents and respective Foreign Principal with PESSI.
- iv. The bidder will provide valid Drug Registration Certificate of the quoted product with DRAP. The product having minimum two years’ experience will be eligible.
- v. Valid GMP Certificate from country of manufacturer.
- vi. Valid letter of authorization from manufacturer / sole agency agreement.
- vii. Specifications of medicines quoted in the technical offer will be verified from samples provided with the bid. Product that comply with the advertised specifications of medicines and fulfil the requirements as per rules shall be considered irrespective of pack size which would be acceptable according to pack size of respective qualified firms.
- viii. Undertaking on E-stamp paper worth Rs. 100/- regarding “Non Declaration of Spurious/Adulterated Batch” by any notified Drug Testing Laboratory of quoted item within last one year.
- ix. Undertaking on E-Stamp Paper worth Rs. 100/- to the effect that Non-cancellation / suspension of drug registration of quoted product of the bidder by DRAP and Non-conviction from any court of law and black listing.
- x. Two commercial packs as samples of quoted medicines for evaluation by the technical committee.

MARKING CRITERIA

TECHNICAL EVALUATION CRITERIA FOR SOLE AGENT

| Sr. # | Description | Category Points |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 1 | Source of API of Quoted Item | 10 |
| i) | Original Source /Research Molecule (Affidavit on firm's letter head) | 10 |
| ii) | Source Licensed by Original or accredited by FDA/WHO/EMA (Certificate) <i>(The bidder must provide Import record of one year (from July 2021 to onward) i.e. copy of GD/LC of quoted raw material source)</i> | 08 |
| iii) | Others Source of Raw Material with Certificate of Analysis(July 2021 to onwards) | 05 |
| 2 | Bio Equivalence / Bio-similarity Study (if applicable) of Quoted Product (affidavit on Rs:100 E-stamp paper in case of research molecule)* | 15 |
| i) | Original Manufacturer will be awarded full marks. | 15 |
| ii) | Bio equivalence/Bio-similarity Study from any of the below mentioned labs: <ul style="list-style-type: none"> • WHO prequalified Laboratories • Lab certified / Audited by SRAs of ICH (International Conference on Harmonization) Member Countries. <i>(The firm will attach Bio-equivalence/ Bio-Similarity certificate of the finished product).</i> | 10 |
| 3 | EXPERIENCE OF THE QUOTED PRODUCT FOR LAST TWO FINANCIAL YEARS | 20 |

| | | |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| | Past performance of quoted product with major Government Sector/ Semi Government / Autonomous Body / PESSI during last two financial years | |
| i) | Supply of the quoted product Higher than the advertised quantity | 20 |
| ii) | Supply of the quoted product Equivalent to the advertised quantity | 15 |
| iii) | Supply of the quoted product at least 60% of advertised quantity | 10 |
| | The bidder shall provide verifiable documentary evidences like commercial sales summary / supply order of the quoted product. | |
| 4. | Availability of quoted product at major chain pharmacies (02 marks for each pharmacy) | 10 |
| i) | Supply of quoted product at 5 or more chain pharmacies | 10 |
| ii) | Supply of quoted product at upto 4 chain pharmacies | 08 |
| iii) | Supply of quoted product at upto 3 chain pharmacies | 06 |
| iv) | Supply of quoted product upto 02 chain pharmacies | 04 |
| | The bidder shall provide verifiable documentary evidence (invoices) regarding availability of quoted items. Pharmacy chain will be any company operating at least 5 pharmacies in any one major city of Punjab. | |
| | Hospital Items / Specialized Hospital Items and Anti-Cancer Items may be exempted from said requirement. In such cases Hospitals P.O/Prescriptions or Invoice will be considered maximum up to 10 Marks. Summary of Invoices shall be provided which could be verified. Any false claim shall be considered as fraudulent practice. | |
| 6. | Local Market Business | 10 |
| | How many years the quoted product is being marketed in Pakistan. | |
| i) | 2-3 years | 03 |
| ii) | 4-5 years | 05 |
| iii) | 6 years and above | 10 |
| 8. | Drug Testing | 05 |
| | Reports of WHO/FDA Accredited International Labs performed on the product | |
| i) | 1-2 Labs | 05 |
| ii) | Testing by national Labs | 03 |
| 9. | Quality Product | 05 |
| i) | If samples of quoted product declared sub-standard by DTL are less than 1% during last Financial year | 05 |
| ii) | If samples of quoted product declared sub-standard by DTL are 1-2% during last Financial year | 03 |
| iii) | If samples of quoted declared sub-standard by DTL are 2-3% during last Financial year | 01 |
| | The bidder will provide undertaking on Rs. 100/- notarized E-stamp paper. Data of substandard batches may be verified from Drug Testing Laboratories. | |
| | TOTAL MARKS | 75 |

NOTE: For product where the criteria of Bio-Equivalence/Bio Similarity and API Source is not applicable, the bidder will be evaluated on rest of parameters and qualifying marks will be 65%.

QUALIFYING MARKS: 49 OUT OF 75 (65%)

1. Financial bids of only "Technically Qualifying Bidders" will be opened.

GENERAL CONDITIONS OF CONTRACT

1. **Definitions:** In this Contract, the following terms shall be interpreted as indicated against each.

- a. "The Contract" means the agreement proposed to be entered into between the procuring agency and the successful bidder.

- b. **“The Contract Price”** means the price payable to the Supplier under the Contract for the full and proper performance of its contractual obligations. Price reasonability certificate that the prices quoted are not more than the prices quoted in Health Department Govt. of the Punjab/ any other organization.

The rates quoted should not be more than the trade price of the respective item.

- c. **“The Goods”** means drug/ medicines, disposable syringes and I.V Cannulas etc. which the Supplier is required to supply to the Procuring Agency under the Contract.
- d. **“The Specifications”** means the specifications of medicines, the offered items should be consistent with the specifications.
- e. **“The Services”** means those services ancillary to the supply of goods, such as printing of special instructions on the label and packing, design, transportation upto CMSD, Defence Road, Lahore and other such obligations of the Supplier covered under the Contract.
- f. The **Procuring Agency:** is the Punjab Employees Social Security Institution and other PESSI Hospitals / PESSI Directorates under the administrative control of PESSI.
- g. **“The Consignee”** means Director Medical, In charge, Central Medical Store Depot, Defence Road, Lahore, for the supply order issued for medicines by the Head Office and in case of local supply orders by PESSI Hospitals and PESSI Medical Directorates then concerned Medical Superintendent & Director Medical respectively shall be consignee end.
- h. **“The Supplier”** means the individual or firm supplying the goods under this Contract.

2. **“Eligible Bidder”** PESSI pre-qualified Pharmaceutical Firm as Manufacturer and Sole Agent of Foreign Principal possessing valid manufacturing licence and valid drug sale license respectively as well as fulfilling other requirements contained in the Bidding Document and Evaluation Criteria are eligible to participate in the tender.

3. **Application:** These General Conditions shall apply to the extent that they are not inconsistent / superseded by provisions of other parts of the Contract.

4. **Standards:** The goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications.

5. **Pack adjustment** Pack adjustment of the medicines if required keeping in view packs size of the first lowest bidder will be made by PESSI.

6. **Submission of Samples:** Labeling and Packing of the product would be examined in accordance with Labeling and Packing Rules 1986 of the Drugs Act 1976. The Supplier shall provide **TWO (02) samples (commercial packs);** free of cost along with the tender failing which the offers will not be accepted.

7. **Ensuring intimation of storage arrangements:** To ensure storage arrangements for the intended supplies, the Supplier shall inform the Consignee one week in advance.

8. **Inspections and Test / Analysis**

- i) The Procuring Agency or its representative shall have the right to inspect and /or to test the goods to confirm their conformity to the specifications of the contract at no extra cost to the Procuring Agency.
- ii) The inspection committee constituted by PESSI, Head Office shall inspect the quantity and specifications of medicines who will submit a report on Inspection Certificate.
- iii) The supplier will be responsible for free replacement of stocks if the same is not found to be of the same specifications as required in the Invitation of Bids / Substandard /Spurious / Misbranded / Expired / near to Expiry. Moreover, it will replace the unconsumed expired stores without any further charges.

- iv) The Procuring Agency's right to inspect, test and, where necessary, reject the goods after the arrival at Procuring Agency's destinations shall in no way be limited or waived by reason of the goods having previously been inspected, tested, and passed by the Procuring Agency or its representative.
- v) Nothing in General Conditions of Contract shall in any way release the Supplier from any warranty or other obligations under this Contract.

9. **Chemical and physical examination of medicines**

I All the Drugs / Medicines shall be acceptable subject to chemical and physical examination. The chemical examination shall be carried out through the Drugs Testing Laboratory Government of Punjab. If the facility for test / analysis is not available with DTL, Government of Punjab then the sample will be sent to NIH, Islamabad through PQCB. If the test facilities are not available with the DTL, Government of Punjab as well as NIH Islamabad then the case shall be dealt under Section 22 of Drug Act 1976.

II The Inspection Committee constituted by PESSI, Head Office shall carry out the physical examination after receipt of supplies. If the medicines supplied are found during physical examination / inspection to be against the required specifications, approved samples, etc, even if it is of standard quality, the Procuring Agency may reject the goods, and the Supplier shall either replace the rejected goods or arrange alterations necessary for rectification of observation, to meet the required specifications free of cost. Replacement in lieu of the rejected supplies must be completed within **15** days from the date of communication of decision to the Manufacturer / Supplier by the Concerned Authority. In case after replacement or alteration, the Inspection Committee again declare the item as of against the required specifications, the supply would completely be rejected and the proportionate amount of performance security of the concerned instalment would be forfeited to the PESSI account and the firm shall be blacklisted minimum under the provisions of PPRA Rules 2014. However, if the entire supplies/ instalments are declared as of against the required specifications, the entire performance security shall be forfeited and department may proceed against the firm for its Blacklisting under Rule 21 of PPRA Rules 2014.

III Since Drug testing of medicines against local orders are not carried out being small orders, therefore, the firm shall be liable to provide the following with each delivery:-

1. Valid invoice / warranty of drugs
2. Lot release certificate / Batch release record
3. Undertaking with clear affirmation that the firm will be responsible for any defect /quality or adverse event / reaction reported with supplied drugs.

10. **Delivery and Documents:** Any erasing/cutting/crossing etc. appearing in the offer must be properly signed by the person signing the tender. Moreover all pages of the tender must be signed. Offer with any over writing in no circumstances shall be accepted. The Supplier in accordance with the terms specified in the Bidding Documents shall make delivery of the goods. The details of documents to be furnished by the Supplier are specified in Special Conditions of the Contract.

11. **Insurance** The supplier shall be solely for the insurance of goods subject to the contract.

12. **Income Tax:** All applicable taxes whether International, Federal, Provisional or local shall be borne by the supplier.;

13. **Transportation:** The Supplier shall arrange such transportation / cold chain maintenance of the goods as is required to prevent their damage or deterioration during transit to the final destination. The medicines shall be delivered at CMSD Defence Road, Lahore. In case of any subsequent/supplementary order from PESSI Hospitals/Directorates, the supplier shall be responsible for the delivery at consignee end. All taxes shall be borne by the Supplier. Transportation including loading / unloading of goods shall be arranged and paid by the Supplier. Maintenance of cold chain be ensured by the supplier during the transportation of heat sensitive / biological products.

For thermolabile drugs or which storage temperature is 2-8°C, the firm shall be bound to produce batch wise cold chain data from source of origin and thermolog data from factory to consignee's end.

14. **Incidental Services:** The Supplier shall be required to provide the incidental services as specified in Special Conditions of the Contract and the cost of which should include in the total bid price.

15. **Warranty Certificate:** The Drugs / Medicines shall be accompanied by the necessary warranty (undertaking) in accordance with the provision of the Drugs Act, 1976 and rules framed there under. The Procuring Agency shall promptly notify the Supplier in writing of any claims arising under this warranty.

16. **Payment:** The method and conditions of payment to be made to the Supplier under this Contract shall be specified in Special Conditions of the Contract. The currency of payment is Pak. Rupees.

Payment will be made by the Commissioner against bill to be submitted by the contracting firms duly supported with the inspection certificate and drug test reports. For imported items Bill Of Entry is also to be provided.

17. **Prices:** Prices charged by the Supplier for goods delivered under the Contract shall not vary from the prices quoted by the Supplier in its bid and shall remain the same till expiry of the original bid validity period provided the Procuring Agency's request for bid validity extension.

18. **Contract Amendments:** No variation in or modification of the terms of the Contract shall be made except by written amendment signed by the Parties.

19. **Subcontracts:** The Supplier shall not be allowed to sublet the job and award subcontracts under this Contract.

20. **Delays in the Supplier's Performance:** Delivery of the goods shall be made by the Supplier in accordance with the time schedule prescribed by the Procuring Agency. If at any time during performance of the Contract, the Supplier should encounter conditions impeding timely delivery of the goods, the Supplier shall promptly notify the Procuring Agency in writing of the fact of the delay, its likely duration and its cause(s). The Procuring Agency may at its discretion extend the Supplier's time for performance, with liquidated damages, in which case the extension shall be ratified by the Procuring Agency. A delay by the Supplier in the performance of its delivery obligations shall render the Supplier liable to the imposition of liquidated damages, unless an extension of time is agreed upon without the application of liquidated damages.

21. **Penalties/liquidated Damages:** In case of late delivery beyond the stipulated period, penalty as specified in Special Conditions of Contract shall be imposed upon the Supplier. The above Late Delivery (LD) is subject to General Conditions of Contract including late delivery for reasons beyond control. Once the maximum is reached, the Procuring Agency may consider termination of the Contract. In case of supply of substandard product the destruction cost will be borne by the firm i.e. burning, Dumping, Incineration. If the firm provides substandard item and fail to provide the item the payment of risk purchase (which will be purchased by the Consignee i.e Head Office or PESSI Hospitals / Directorates) the price difference shall be paid by the Firm. Broken and damaged material will be replaced by the supplier free of cost.

22. **Termination for Default:** The Procuring Agency, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Supplier, may terminate the Contract in whole or in part, if the Supplier fails to deliver any or all installments of the goods within the period(s) specified in the Contract, or within any extension thereof granted by the Procuring Agency; or if the Supplier fails to perform any other obligation(s) under the Contract and if the Supplier, in the judgment of the Procuring Agency has engaged in corrupt or fraudulent practices in competing for or in executing the Contract

23. **Force Majeure**

Notwithstanding the provisions of general conditions of contract the Supplier shall not be liable for forfeiture of its Performance Guarantee/ bid Security, or termination/ blacklisting for default if and to the extent that its delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure. For the purposes of this clause Force Majeure means an act of God or an event beyond the control of the Supplier and not involving the Supplier's fault or negligence directly or indirectly purporting to mis planning, mismanagement and/or lack of foresight to handle the situation. Such events may include but are not restricted to acts of the Procuring Agency in its sovereign capacity, wars or revolutions, fires, floods, earthquakes, strikes, epidemics, quarantine restrictions and freight embargos. If a Force Majeure situation arises, the Supplier shall promptly notify the Procuring Agency in writing with sufficient and valid evidence of such condition and the cause thereof. The Committee constituted by PESSI, Head Office for Redressal of grievances, shall examine the pros and cons of the case and all reasonable alternative means for completion of purchase order under the Contract and shall submit its recommendations to the competent authority. However, unless otherwise directed by the Procuring Agency in writing, the Supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek reasonable alternative means for performance not prevented by the Force Majeure event.

24. **Termination for Insolvency**

The Procuring Agency may at any time terminate the Contract by giving written notice of one month time to the Supplier if the Supplier becomes bankrupt or otherwise insolvent. In this event, termination shall be without compensation to the Supplier, provided that such termination shall not prejudice or affect any right of action or remedy which has accrued or shall accrue thereafter to the Parties.

25. **Arbitration and Resolution of Disputes:** The Procuring Agency and the Supplier shall make every effort to resolve amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the Contract. If, after thirty (30) days from the commencement of such informal negotiations, the Procuring Agency and the Supplier have been unable to resolve amicably a Contract dispute, either party may require that the dispute be referred to the Arbitrator for resolution through arbitration. In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration. The Commissioner, PESSI or his nominee shall act as sole arbitrator. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties

26. **Governing Language:** The Contract shall be written in English language. All correspondence and other documents pertaining to the Contract, which are exchanged by the Parties, shall be written in English.

27. **Applicable Law**

This contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.

28. **Notices**

- 1 Any Notice given by one party to the other pursuant to this contract shall be sent to the other party in writing and confirmed to other party's address specified in Special Conditions of Contract.
- 2 A notice shall be effective when delivered or on the notice's effective date, whichever is later

SPECIAL CONDITION OF CONTRACT

1. **Definitions;**

- i. The **Procuring Agency:** is the Punjab Employees Social Security Institution and other Institutions under administrative control of PESSI, Head Office i.e. PESSI,

Hospitals/PESSI, Directorates. PESSI reserves the right to purchase full or part of the stores or ignore/scrape/cancel the tender without assigning reasons.

ii. The **Supplier**; is the individual or firm supplying the goods under this contract.

2. **Availability:** All medicines supplied to PESSI should be available at major chain pharmacies having minimum 5 branches in any one major city of Punjab.

3. **Bid Security;**

The bidder shall furnish, as part of its financial proposal / bid, the Bid Securities (refundable) in Pak Rupees **@ 3% of estimated price** in the shape of Bank guarantee/CDR in the name COMMISSIONER PESSI shall be attached with the Technical Bid whereas its copy shall be attached with the financial bid. The financial bid found deficient of the bid Security shall not be considered. No personal cheque shall be acceptable. The previous bid Security (if any), if available, shall not be considered or carried forward. However, the bid security of any successful bidder shall be returned upon submission of **Performance Security** and after signing of contract. In case of unsuccessful bidder, the bid security of the bidder shall be returned.

4. **Performance Security**

After signing of contract, the successful bidders shall have to deposit bank draft of the amount equal to 7% of order value as performance security in the shape of Bank guarantee (having validity of 02 years) / CDR in the name COMMISSIONER PESSI. The bid Security will be returned to the bidder upon submission of Performance Security / CDR and signing of formal contract. Performance Security shall be retained for relevant financial year. The process of release of 7% performance security shall be initiated on receipt of written request from the firm after expiry of the said financial year and release of payments against supply of medicines during both phases.

5. **Inspection.**

Inspection and tests of drugs / medicine at final acceptance shall be in accordance with the conditions of contract. After delivery at CMSD Defence Road, Lahore, the goods shall be inspected/examined by the Inspection Committee, to physically check the goods in accordance with the approved sample and terms / conditions of the Contract. The Committee shall submit its inspection report to PESSI, Head Office, Lahore. In case of any deficiency, pointed out by the Inspection Committee in the delivered medicines the Supplier shall be bound to rectify it free of cost. For imported items Bill Of Entry is also to be provided to the inspection team otherwise inspection will not be conducted to proceed further accordingly.

6. **Testing.**

The samples shall be collected for analysis and send to DTL, Punjab. The samples drawn for Drug Testing are to be replaced by the firm at the time of supply as per rules failing which PESSI will not be responsible for delay in payment. Testing charges of samples against the supplies will be borne by the supplying firms irrespective of the result of sample. **The firm shall be bound to provide primary reference standard (s)/traceable secondary standard (s) to the concerned Drugs Testing Laboratories of Punjab as and when demanded. In case of secondary reference standard, the certificate of analysis and proof of traceability shall also be provided by the contractor.**

A certificate should be furnished by the tenderers that they will be responsible for the free provision of new stores if the same are found to be substandard or at variance with the specifications give in the tender inquiry. Stores of a specifications superior to the one specified in the tender inquiry shall, however, be considered.

If the stores are declared sub-standard by DTL Punjab / NIH Islamabad, distribution shall not be carried out and the entire stock will be confiscated and destroyed and the firm shall replace the whole stock with the fresh stock free of cost and simultaneously the case shall be dealt under section 22 of Drug Act 1976. The procuring agency may take any other punitive action including forfeiture of performance security and blacklisting under Rule 21 of PPR 2014.

7. **Delivery and Documents.**

The contract will be placed for the period from the date of its issuance till 30th June, 2024 and the same would be extendable for further period of two months subject to approval from competent authority (if required). The supply period will be 40 days from the date of issue of supply order with a grace period of 10-days which will start immediately after expiry of 30-days. Any subsequent/supplementary order placed by the Head Office/Directorates/S.S. Hospitals, shall also be complied with by the firm promptly, on the same rates as quoted/& approved by the Head Office PESSI. The Supplier shall provide the following documents at the time of delivery of goods to Consignee' end for verification and onward submission to quarter concerned, duly completed in all respect for payment.

Following documents shall be supplied to CMSD at the time of delivery of medicines:

- (i) Original copies of Delivery Note / Challan (in duplicate) in the name of In charge Director Medical CMSD, Defence Road, Lahore and Medical Superintendent PESSI Hospitals where delivery is to be made, item's description, batch No(s), Registration No, manufacturing and expiry date and quantity along with pack size.
- (ii) Original copies of the Supplier's invoices (in duplicate) showing warranty, in the name of Commissioner PESSI, Head Office, item's description, Batch No, Registration No, manufacturing and expiry date, quantity, pack size, per unit cost, and total amount.
- (iii) Undertaking on E-Stamp Paper.

Following documents shall be supplied to Purchase Cell for payment (The firms providing false documents or giving misleading statements will be debarred from the current & next tenders).

- i. Attested copies of valid drug manufacturing license / licenses & sale license, & drugs registration certificates shall be attached. The firm will have to provide the valid professional tax exemption certificate.
- ii. NTN Certificate.
- iii. Receipt of (F-6), 7% of order value.
- iv. Valid printed original Price List of relevant tender period should be attached.
- v. The firms providing false documents or giving misleading statements will be debarred from the current & next tenders.
- vi. Valid letter of authorization from the Foreign Principal in case of Sole Agent / Importer.
- vii. Proof of updated / latest Active Taxpayer.
- viii. Proof of permission for toll manufacturing from DRAP and pre-qualification of the respective firm with PESSI.
- ix. Sales Tax Registration Certificate.
- x. Professional Tax Clearance Certificate of relevant financial year.

Following documents shall be supplied at local level (Directorates and Hospitals)

- i. The firm should provide batch release certificate along with warranty under section 23(1)-(i) of Drug act, 1976 on invoice.
- ii. Undertaking with clear affirmation that the firm will be responsible for any defect /quality or adverse event / reaction reported with supplied drugs.
- iii. lot release certificates in case of biological drugs.

8. **Incidental Services**

The following incidental services shall be provided and the cost of which should include in the total bid price.

- a. The bidder shall supply drugs/medicines as far as possible as per tender requirement in commercial packing.
 - b. The following wording/insignia shall be printed in bold letters (English) **on each carton, pack, bottle, strip / blister, tubes, vial / ampoule etc.**
“PESSI PROPERTY NOT FOR SALE”
 - c. The rules for labelling and packing shall be followed as per “The Drugs (Labeling and Packing) Rules, 1986”, framed under the Drugs Act, 1976. However, the name of Drug / Medicine (Generic & Brand), equally prominent, should be printed/ written in indelible ink in English on the outer cartons and on each Pack, Bottle, Strip/ Blister, Tubes etc. Besides the name and principal place of business of the Manufacturer, the drug manufacturing license No., manufacturing date, expiry date, registration No., batch No. and retail price, name of drug, dosage and instructions, should also be written on the outer carton and on the most inner container in bold letters. Tablets / Capsules shall be supplied in **aluminium** strip / blister pack, however, in case commercial packs of tablets / capsules are packed in bottles then the quantity of the pack shall be accepted as per quantity of commercial pack and packing in excess quantities other than commercial pack size shall not be accepted. Expiry date must be printed on each **aluminium** strip / blister. The syrup should be supplied in glass / pet bottle with sealed caps as per sample provided at the time of opening of tender. 2ml and less than 2ml ampoules, heat sensitive ampoules and water for injection / distilled water supplied along with antibiotic & powder vials shall be exempted from over printing however outer cartons shall be printed as “PESSI Property not for Sale”. In case of non-fulfilment of these requirements the supply shall not be accepted.
 - d. Barcoding / QR Coding as per latest instructions of DRAP.
 - e. Glass ampoules having no paper label shall be exempted from printing from “PESSI PROPERTY NOT FOR SALE”, however, outer carton shall be printed as “PESSI PROPERTY NOT FOR SALE”.
 - f. In case of ampoules which are packed in tray, “PESSI PROPERTY NOT FOR SALE” shall be printed on the label of the tray and ampoules may be exempted from printing “PESSI PROPERTY NOT FOR SALE”, however, outer carton shall be printed as “PESSI PROPERTY NOT FOR SALE”.
 - g. Kleen Enema bottle shall be exempted from printing “PESSI PROPERTY NOT FOR SALE”, however, the plastic cover and outer carton should be printed as “PESSI PROPERTY NOT FOR SALE”.
 - h. Medicines with minimum of **80% shelf life for the locally manufactured** shall be accepted at the time of delivery.
 - i. Medicines with minimum of **75% shelf life for imported medicines** shall be accepted, however shelf life upto 70% shall be accepted with penalty equal to 1% of total value of the medicine per percentage point of the short fall in the prescribed shelf life.
 - j. Request of firm for extension in delivery period and acceptance of medicines with less shelf life shall be examined by the Purchase Committee on case to case basis.
 - k. If the Supplier / bidder charged the prices of incidental services separately in the financial bid and not included in the Contract price of goods, the same shall be included prior to comparison of rates with the other bidders.
9. **Warranty:** The drugs/medicines shall be accompanied by the necessary warranty on judicial under taking in accordance with the provision of the Drugs Act, 1976 / rules framed there under.

10. **Payment**

- a) The Payment shall be in Pak Rupees.
- b) The payment will be made in two parts for Phase I & Phase-II respectively on submission of documents along with Standard Quality DTL reports and Physical Inspection report carried out by the committee.
- c) The laboratory test / analysis charges of sample either from DTL, Punjab or from NIH, Islamabad shall be borne by the Supplier.

11. **Penalties/ Liquidated Damages.**

a. In case where the deliveries as per contract are not completed within stipulated period, the contract to the extent of non-delivered portion of supply may be cancelled followed by a Show Cause Notice. The amount of 7% performance Guarantee to the extent of non-delivered portion of supplies of relevant item/items shall be forfeited. Institution may take any other punitive action according to the performance of the firm.

If the firm fails to supply the whole instalments, the entire amount of Performance Guarantee/Security shall be forfeited and department may proceed against the firm for blacklisting under Rule 21 of PPRA Rules 2014 as well as amendment Notification No. S.O(Cabinet-I)2-9/2015 dated 06.01.2016 issued by the Government of Punjab Services & General Administration Department (Implementation & Coordination Wing) shall be followed minimum for a period of two year. Institution reserves the right to purchase the item from the 2nd-lowest firm (if any) at the risk and cost of the defaulting firm against the head office supply orders, whereas in case medicines are not supplied against local supply orders at Head Office approved rates then respective PESSI Hospital / Directorates can procure the ordered medicines from any other firm at the risk and cost of non-supplying firm without gross difference of the Head Office approve rates.

b. In case where the deliveries as per contract are not completed within the time frame specified in the schedule of requirement, the Contract to the extent of non-delivered portion of supply may be cancelled followed by a Show Cause Notice and amount of Performance Guarantee to the extent of non-delivered portion of supplies of relevant item shall be forfeited and may proceed against the firm to debar for one year from future tender and also to proceed for blacklisting under Rule 21 of PPRA Rule 2014 (amended). If the firm fails to supply the whole stock, the entire amount of Performance Guarantee/ Security shall be forfeited to the PESSI account and the firm may be blacklisted under Rule 21 of PPR Rules 2014. Institution reserves the right to purchase the item from the 2nd-lowest firm at the risk and cost of the defaulting firm.

c. Any order placed erroneously shall have to be lifted back by the firm at its own cost.

d. The delivery period given by PESSI shall be acceptable to the firms. In case of late delivery of goods beyond the periods specified in the schedule of requirements, **penalty @ 1% per week** of the cost of late delivered supply shall be imposed.

e. The delivery period of locally ordered quoted medicines by directorates and hospitals shall be 15-21 days and in case of late delivery penalty @ 1% per week of the cost of supply shall be imposed. If the firm fails to supply the stock then the purchases shall be made at the risk and cost of the firm.

e. In case of acceptance of medicines with less shelf life by the Purchase Committee than deduction shall be made @ 1% per shortfall against 80% required shelf life

12. **Arbitration and Resolution of Disputes: -**

In case of any dispute, concerning the interpretation and / or application of this Contract shall be settled through arbitration. The Commissioner, PESSI or his nominee shall act as sole

ARBITRATOR. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties.

- 13. **Governing Language:** The language of this Contract shall be in English.
- 14. **Applicable Law:** This Contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.
- 15. **Notices**

Supplier's address for notice purpose

**Procuring Agency's address
for notice purposes shall be the;**

**The Director (Purchase),
PESSI, Head Office,
3/A, Gulberg-V, Lahore.**

Note: All assessments and procuring procedures i.e. receiving, opening and awarding etc. shall be governed by the Punjab Procurement Rules 2014.

MANUFACTURER’S AUTHORIZATION FORM

To:

**The Commissioner,
PESSI.**

WHEREAS M/s. _____ who are established and reputable Manufacturers of medicines having factory located at _____ do hereby authorize _____ to submit a bid, and subsequently negotiate and sign the Contract with you against No. _____ for the goods manufactured by the firm. We hereby extend our full guarantee and warranty as per Clause _____ of the General Conditions of Contract for the goods offered for supply by the above firm against this Invitation for Bids.

{Signature on behalf of manufacturer _____}

Note: This letter of authority should be on the letterhead of the Manufacturer and should be signed by a person competent and having the power of attorney to bind the Manufacturer. It should be included by the bidder in its bid.

CONTRACT FORM

THIS FRAMEWORK CONTRACT is made at -----on-----day of----- 2023, between **PESSI** (hereinafter referred to as the “Procuring Agency”) of the First Part; and M/s----- a firm registered under the laws of Pakistan and having its registered office at ----- (hereinafter called the “Supplier”) of the Second Part (hereinafter referred to individually as “Party” and collectively as the “Parties”).

WHEREAS the Procuring Agency invited bids for procurement of medicines in pursuance where of M/s ----- being the Manufacturer/ Sole Agent of items (list enclosed) in Pakistan and ancillary services offered to supply the required item (s); and Whereas the Procuring Agency has accepted the bid by the Supplier for the supply of *item, along with cost per unit list enclosed.*

NOW THIS CONTRACT WITNESSETH AS FOLLOWS:

1. In this Contract words and expressions shall have the same meanings as are respectively assigned to them in the General/ Special Conditions of this Contract hereinafter referred to as “Contract”:
2. The following documents shall be deemed to form and be read and construed as integral part of this Contract, viz:-
 - a. Price Schedule submitted by the bidder,*
 - b. Technical Specifications;*
 - c. General Conditions of Contract;*
 - d. Special Conditions of Contract; and*
 - e. Procuring Agency’s Award of contract; and*
 - f. Purchase Order*
3. In consideration of the payments to be made by the Procuring Agency to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Procuring Agency to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of this Contract.
4. The Procuring Agency hereby covenants to pay the Supplier in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of this Contract at the time and in the manner prescribed by this Contract.
5. M/s. _____ hereby declares that it has not obtained or induced the procurement of any Contract, right, interest, privilege or other obligation or benefit from PESSI or any administrative subdivision or agency thereof or any other entity owned or controlled by it PESSI through any corrupt business practice.
6. Without limiting the generality of the foregoing, [the Seller/ Supplier] represents and warrants that it has fully declared the brokerage, commission, fees etc, paid or payable to anyone and not given or agreed to give and shall not give or agree to give to anyone within or

outside Pakistan either directly or indirectly through any natural or juridical person, including its affiliate, agent, associate, broker, consultant, director, promoter, shareholder, sponsor or subsidiary, any commission, gratification, bribe, finder's fee or kickback, whether described as consultation fee or otherwise, with the object of obtaining or including the procurement of a Contract, right interest, privilege or other obligation or benefit in whatsoever form from PESSI, except that which has been expressly declared pursuant hereto.

7. M/s. _____ certifies that has made and shall make full disclosure of all agreements and arrangements with all persons in respect of or related to the transaction with PESSI and has not taken any action or shall not take any action to circumvent the above declaration, representation or warranty.

8. M/s. _____ accepts full responsibility and strict liability for making any false declaration, not making full disclosure, misrepresenting facts or taking any action likely to defeat the purpose of this declaration, representation and warranty. It agrees that any Contract, right, interest, privilege or other obligation or benefit obtained or procured as aforesaid shall, without prejudice to any other right and remedies available to Procuring Agency under any law, Contract or other instrument, be void able at the option of Procuring Agency.

9. Notwithstanding any rights and remedies exercised by Procuring Agency in this regard, M/s. _____ agrees to indemnify Procuring Agency for any loss or damage incurred by it on account of its corrupt business practices and further pay compensation to Procuring Agency in an amount equivalent to ten time the sum of any commission, gratification, bribe, finder's fee or kickback given by M/s. _____ as aforesaid for the purpose of obtaining or inducing the procurement of any Contract, right, interest, privilege or other obligation or benefit in whatsoever form from Procuring Agency.

10 In case of any dispute concerning the interpretation and/or application of this Contract shall be settled through arbitration. Commissioner, PESSI or his nominee shall act as sole arbitrator. The decisions taken and/or award made by the sole arbitrator shall be final and binding on the Parties.

11. This Contract shall be governed by the laws of Pakistan and the courts of Pakistan shall have exclusive jurisdiction.

12. If the firms provide substandard item and fail to provide the item the payment of risk purchase, the price difference shall be paid by the Firm

13. In case of supply of substandard product the destruction cost will be borne by the firm i.e burning, Dumping, Incineration

14. If the price quoted by the firm to the PESSI are more than the T.P prices or charged from any other government institution/hospital in the country for the same financial year, in such

discrepancy the firm shall be bound to refund the prices charged in excess. Affidavit to this effect is also enclosed with the contract by the firm.

IN WITNESS Whereof the Parties hereto have caused this Contract to be executed at PESSI, Head Office and shall enter into force on the day, month and year first above mentioned.

**Signed/ Sealed by the Manufacturer/ Signed/ Sealed by Procuring Agency
authorized Person**

1 _____

DIRECTOR (PURCHASE)
PESSI, HEAD OFFICE

2 _____

BID FORM

Date: _____

No. _____

To:

The Commissioner,
PESSI, Head Office,
3/A, Gulberg-V,
Lahore.

Having examined the Bidding Documents, the receipt of which is hereby duly acknowledged, we, the undersigned, offer the supply and deliver the goods specified in and in conformity with the said Bidding Documents for the sum of *[Total Bid Amount _____], [Bid Amount in words _____]* or such other sums as may be ascertained in accordance with the Schedule of Prices attached herewith and made part of this bid.

We undertake, if our bid is accepted, to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements. If our bid is accepted, we shall submit 7% as performance security (in shape of Bank Guarantee / CDR) of the contract price.

We agree to abide by this bid for a period of **120** days from the date fixed for bid opening under instruction to the bidders, and it shall remain binding upon us and may be accepted at any time before the expiration of that period. Until a formal Framework Contract is prepared and executed, this bid, together with your written acceptance thereof and your notification of award shall constitute a binding Contract between us.

We understand that the Procuring Agency is not bound to accept the lowest or any bid, Procuring Agency may receive.

Name and address of bidder -----

Dated this _____ day of _____ 20_____.

Signature (in the capacity of)

Duly authorized to sign bid for and on behalf of.

=====

DRUG SPECIFICATION PROFORMA

To,

The Commissioner

Punjab Employees Social Security Institution

(Head Office) 3-A, Gulberg-V,

Lahore.

Tender No:

Due on:

Name of Bidder:

Address:

Phone No.

Fax No.

Drug Mfg/Drug Sales Licence No:

Validity of Licence

| Sr # | PESSI # | Name of item as in PESSI Specification List | Specification of the offered item | Brand Name of the offered item | Name and Country of Manufacturer | Drug Registration No | Batch Capacity | Packing Commercial | Page No. / Location of Drug Registration letter | Name of Pharmacy | Name of Pharmacy | Name of Pharmacy | Name of Pharmacy | Name of Pharmacy |
|------|---------|---------------------------------------------|-----------------------------------|--------------------------------|----------------------------------|----------------------|----------------|--------------------|-------------------------------------------------|------------------|------------------|------------------|------------------|------------------|
| 1 | | | | | | | | | | | | | | |
| 2 | | | | | | | | | | | | | | |
| 3 | | | | | | | | | | | | | | |
| 4 | | | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | | | |
| 6 | | | | | | | | | | | | | | |

NOTE

- i) Quoted item should be highlighted with yellow highlighter on drug registration certificate and invoices / bill warranty.
- iii) The firm should provide Two (02) commercial packs as representative of the supplies.

Signature of Authorized Person: _____

Name of Authorized Person: _____

Designation of Authorized Person: _____

Stamp: _____